Anti-acvr2b antibodies and uses thereof
Patent Information
- Application Number
- HK62026125675
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-08-01
- Filing Date
- 2026-07-03
- Publication Date
- 2026-09-11
Smart Images

Figure 00000185_0000 
Figure 00000186_0000 
Figure 00000187_0000
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480061319.7 (22) Application Date 2024.07.31 (66) Domestic Priority Data PCT / CN2023 / 110569 2023.08.01 CN (85) PCT International Application Entering National Phase Date 2026.03.25 (86) PCT International Application Application Data PCT / CN2024 / 108822 2024.07.31 (87) PCT International Application Publication Data WO2025 / 026353 EN 2025.02.06 (71) Applicant Laikai Pharmaceutical Technology (Shanghai) Co., Ltd. Address 201203 5th Floor, No. 987 Cailun Road, Zhangjiang Town, Pudong New Area, Shanghai (72) Inventors: Zhang Ruipeng, Yang Mengxue, Chris Xiangyang, Lu Xiangju, Justin Gu Humeijuan (74) Patent Agency: Beijing Tongli Juncheng Intellectual Property Agency Co., Ltd. 11205 Patent Attorney: Wang Rui (51) Int.Cl. C07K 16 / 28 (2006.01) C12N 15 / 63 (2006.01) A61P 21 / 00 (2006.01) A61P 19 / 00 (2006.01) A61P 35 / 00 (2006.01) (54) Invention Title: Anti-ACVR2B Antibody and Its Use (57) Abstract: Provides an anti-ACVR2B antibody or its antigen-binding fragment and its use in inhibiting or antagonizing ACVR2B. These antibody and antigen-binding fragments can be used in treatments for ACVR2B or ACVR2B ligand-related diseases or conditions that are alleviated or improved by inhibiting ACVR2B. Claims 7 pages, Description 108 pages, Sequence Listing (electronic publication), Drawings 11 pages, CN 121909215 A 2026.04.21 CN 1 21 90 92 15 A 1. An antibody or antigen-binding fragment thereof that binds to ACVR2B, wherein the antibody or antigen-binding fragment has a greater affinity for ACVR2B than for ACVR2A, and wherein optionally the antibody or antigen-binding fragment comprises: (i) HCDR1, HCDR2 and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 1 and LCDR1, LCDR2 and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 2; (ii) HCDR1, HCDR2 and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 3 and LCDR1, LCDR2 and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 4;(iii) HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 5, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 6; (iv) HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 7, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 8; (v) HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 9, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 10; (vi) HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 11, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 12; (vii) as shown in SEQ ID NO: 5, and LCDR1, LCDR2, and LCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 11; (vii) as shown in VH containing the amino acid sequence of SEQ ID NO: 12; (ii) HCDR1, HCDR2, and HCDR3 as shown in VH of the amino acid sequence of SEQ ID NO: 13, and LCDR1, LCDR2, and LCDR3 as shown in VL of the amino acid sequence of SEQ ID NO: 14; (viii) HCDR1, HCDR2, and HCDR3 as shown in VH of the amino acid sequence of SEQ ID NO: 15, and LCDR1, LCDR2, and LCDR3 as shown in VL of the amino acid sequence of SEQ ID NO: 16; (ix) HCDR1, HCDR2, and HCDR3 as shown in VH of the amino acid sequence of SEQ ID NO: 17, and LCDR1, LCDR2, and LCDR3 as shown in VL of the amino acid sequence of SEQ ID NO: 18; (x) HCDR1, HCDR2, and HCDR3 as shown in VH of the amino acid sequence of SEQ ID NO: 19, and LCDR1, LCDR2, and LCDR3 as shown in VL of the amino acid sequence of SEQ ID NO: 20; (xi) as shown in SEQ ID NO: 13; (i) HCDR1, HCDR2, and HCDR3 as shown in VH of the amino acid sequence NO: 21, and LCDR1, LCDR2, and LCDR3 as shown in VL of the amino acid sequence containing SEQ ID NO: 22; (xii) HCDR1, HCDR2, and HCDR3 as shown in VH of the amino acid sequence containing SEQ ID NO: 23, and LCDR1, LCDR2, and LCDR3 as shown in VL of the amino acid sequence containing SEQ ID NO: 22;(xiii) HCDR1, HCDR2, and HCDR3 as shown in VL of the amino acid sequence of SEQ ID NO: 24; (xiv) HCDR1, HCDR2, and HCDR3 as shown in VH of the amino acid sequence of SEQ ID NO: 25 and as shown in VL of the amino acid sequence of SEQ ID NO: 26; (xiv) HCDR1, HCDR2, and HCDR3 as shown in VH of the amino acid sequence of SEQ ID NO: 27 and as shown in VL of the amino acid sequence of SEQ ID NO: 28; (xv) HCDR1, HCDR2, and HCDR3 as shown in VH of the amino acid sequence of SEQ ID NO: 29 and as shown in VL of the amino acid sequence of SEQ ID NO: 30; (xvi) HCDR1, HCDR2, and HCDR3 as shown in VH of the amino acid sequence of SEQ ID NO: 31 and as shown in VL of the amino acid sequence of SEQ ID NO: 25. LCDR1, LCDR2 and LCDR3 as shown in VL of the amino acid sequence NO: 32; or (xvii) HCDR1, HCDR2 and HCDR3 as shown in VH of the amino acid sequence containing SEQ ID NO: 33 and LCDR1, LCDR2 and LCDR3 as shown in VL of the amino acid sequence containing SEQ ID NO: 34. 2. The antibody or antigen-binding fragment according to claim 1, wherein (i) HCDR1 comprises the amino acid sequence of SEQ ID NO: 35, HCDR2 comprises the amino acid sequence of SEQ ID NO: 36, HCDR3 comprises the amino acid sequence of SEQ ID NO: 37, LCDR1 comprises the amino acid sequence of SEQ ID NO: 38, LCDR2 comprises the amino acid sequence of SEQ ID NO: 39, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 40; (ii) HCDR1 comprises the amino acid sequence of SEQ ID NO: 41, HCDR2 comprises the amino acid sequence of SEQ ID NO: 42, HCDR3 comprises the amino acid sequence of SEQ ID NO: 43, LCDR1 comprises the amino acid sequence of SEQ ID NO: 44, LCDR2 comprises the amino acid sequence of SEQ ID NO: 45, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 46; (iii) HCDR1 comprises the amino acid sequence of SEQ ID NO: 37, LCDR1 comprises the amino acid sequence of SEQ ID NO: 38, LCDR2 comprises the amino acid sequence of SEQ ID NO: 39, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 40;(iv) The HCDR1 contains the amino acid sequence of SEQ ID NO: 47, the HCDR2 contains the amino acid sequence of SEQ ID NO: 48, the HCDR3 contains the amino acid sequence of SEQ ID NO: 49, the LCDR1 contains the amino acid sequence of SEQ ID NO: 50, the LCDR2 contains the amino acid sequence of SEQ ID NO: 51, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 52; (iv) The HCDR1 contains the amino acid sequence of SEQ ID NO: 53, the HCDR2 contains the amino acid sequence of SEQ ID NO: 54, the HCDR3 contains the amino acid sequence of SEQ ID NO: 55, the LCDR1 contains the amino acid sequence of SEQ ID NO: 56, the LCDR2 contains the amino acid sequence of SEQ ID NO: 57, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 58; (v) The HCDR1 contains the amino acid sequence of SEQ ID NO: 59, the HCDR2 contains the amino acid sequence of SEQ ID NO: 60, the HCDR3 contains the amino acid sequence of SEQ ID NO: 61, and the LCDR1 contains the amino acid sequence of SEQ ID NO: 52. (vi) The HCDR1 contains the amino acid sequence of SEQ ID NO: 62, the LCDR2 contains the amino acid sequence of SEQ ID NO: 63, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 64; (vi) The HCDR1 contains the amino acid sequence of SEQ ID NO: 65, the HCDR2 contains the amino acid sequence of SEQ ID NO: 66, the HCDR3 contains the amino acid sequence of SEQ ID NO: 67, the LCDR1 contains the amino acid sequence of SEQ ID NO: 68, the LCDR2 contains the amino acid sequence of SEQ ID NO: 69, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 70; (vii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 71, the HCDR2 contains the amino acid sequence of SEQ ID NO: 72, the HCDR3 contains the amino acid sequence of SEQ ID NO: 73, the LCDR1 contains the amino acid sequence of SEQ ID NO: 74, the LCDR2 contains the amino acid sequence of SEQ ID NO: 75, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 76. (viii) HCDR1 contains the amino acid sequence of SEQ ID NO: 77, HCDR2 contains the amino acid sequence of SEQ ID NO: 78, HCDR3 contains the amino acid sequence of SEQ ID NO: 79, and LCDR1 contains the amino acid sequence of SEQ ID NO: 79.(ix) The HCDR1 contains the amino acid sequence of SEQ ID NO: 80, the HCDR2 contains the amino acid sequence of SEQ ID NO: 84, the HCDR3 contains the amino acid sequence of SEQ ID NO: 85, the LCDR1 contains the amino acid sequence of SEQ ID NO: 86, the LCDR2 contains the amino acid sequence of SEQ ID NO: 87, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 88; (x) The HCDR1 contains the amino acid sequence of SEQ ID NO: 89, the HCDR2 contains the amino acid sequence of SEQ ID NO: 90, the HCDR3 contains the amino acid sequence of SEQ ID NO: 91, the LCDR1 contains the amino acid sequence of SEQ ID NO: 92, the LCDR2 contains the amino acid sequence of SEQ ID NO: 93, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 94. (xi) The HCDR1 contains the amino acid sequence of SEQ ID NO: 95, the HCDR2 contains the amino acid sequence of SEQ ID NO: 96, the HCDR3 contains the amino acid sequence of SEQ ID NO: 97, the LCDR1 contains the amino acid sequence of SEQ ID NO: 98, the LCDR2 contains the amino acid sequence of SEQ ID NO: 99, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 100; (xii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 101, the HCDR2 contains the amino acid sequence of SEQ ID NO: 102, the HCDR3 contains the amino acid sequence of SEQ ID NO: 103, the LCDR1 contains the amino acid sequence of SEQ ID NO: 104, the LCDR2 contains the amino acid sequence of SEQ ID NO: 105, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 106; (xiii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 97, the LCDR1 contains the amino acid sequence of SEQ ID NO: 98, the LCDR2 contains the amino acid sequence of SEQ ID NO: 99, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 100; The amino acid sequence of SEQ ID NO: 107, HCDR2 contains the amino acid sequence of SEQ ID NO: 108, HCDR3 contains the amino acid sequence of SEQ ID NO: 109, LCDR1 contains the amino acid sequence of SEQ ID NO: 110, and LCDR2 contains the amino acid sequence of SEQ ID NO: 107.(xiv) The HCDR1 contains the amino acid sequence of SEQ ID NO: 111, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 112; (xiv) The HCDR1 contains the amino acid sequence of SEQ ID NO: 113, the HCDR2 contains the amino acid sequence of SEQ ID NO: 114, the HCDR3 contains the amino acid sequence of SEQ ID NO: 115, the LCDR1 contains the amino acid sequence of SEQ ID NO: 116, the LCDR2 contains the amino acid sequence of SEQ ID NO: 117, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 118; (xv) The HCDR1 contains the amino acid sequence of SEQ ID NO: 119, the HCDR2 contains the amino acid sequence of SEQ ID NO: 120, the HCDR3 contains the amino acid sequence of SEQ ID NO: 121, the LCDR1 contains the amino acid sequence of SEQ ID NO: 122, the LCDR2 contains the amino acid sequence of SEQ ID NO: 123, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 124; (xvi) The HCDR1 contains the amino acid sequence of SEQ ID NO: 125, the HCDR2 contains the amino acid sequence of SEQ ID NO: 126, the HCDR3 contains the amino acid sequence of SEQ ID NO: 127, the LCDR1 contains the amino acid sequence of SEQ ID NO: 128, the LCDR2 contains the amino acid sequence of SEQ ID NO: 129, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 130; or (xvii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 131, the HCDR2 contains the amino acid sequence of SEQ ID NO: 132, the HCDR3 contains the amino acid sequence of SEQ ID NO: 133, the LCDR1 contains the amino acid sequence of SEQ ID NO: 134, the LCDR2 contains the amino acid sequence of SEQ ID NO: 135, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 136. 3. The antibody or antigen-binding fragment according to claim 1, wherein (i) HCDR1 comprises the amino acid sequence of SEQ ID NO: 137, HCDR2 comprises the amino acid sequence of SEQ ID NO: 138, HCDR3 comprises the amino acid sequence of SEQ ID NO: 139, LCDR1 comprises the amino acid sequence of SEQ ID NO: 140, LCDR2 comprises the amino acid sequence of SEQ ID NO: 141, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 149.(ii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 143, the HCDR2 contains the amino acid sequence of SEQ ID NO: 144, the HCDR3 contains the amino acid sequence of SEQ ID NO: 145, the LCDR1 contains the amino acid sequence of SEQ ID NO: 146, the LCDR2 contains the amino acid sequence of SEQ ID NO: 147, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 148; (iii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 149, the HCDR2 contains the amino acid sequence of SEQ ID NO: 150, the HCDR3 contains the amino acid sequence of SEQ ID NO: 151, the LCDR1 contains the amino acid sequence of SEQ ID NO: 152, the LCDR2 contains the amino acid sequence of SEQ ID NO: 153, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 154; (iv) HCDR1 contains the amino acid sequence of SEQ ID NO: 155, HCDR2 contains the amino acid sequence of SEQ ID NO: 156, HCDR3 contains the amino acid sequence of SEQ ID NO: 157, LCDR1 contains the amino acid sequence of SEQ ID NO: 158, LCDR2 contains the amino acid sequence of SEQ ID NO: 159, and LCDR3 contains the amino acid sequence of SEQ ID NO: 160; (v) HCDR1 contains the amino acid sequence of SEQ ID NO: 161, HCDR2 contains the amino acid sequence of SEQ ID NO: 162, HCDR3 contains the amino acid sequence of SEQ ID NO: 163, LCDR1 contains the amino acid sequence of SEQ ID NO: 164, LCDR2 contains the amino acid sequence of SEQ ID NO: 165, and LCDR3 contains the amino acid sequence of SEQ ID NO: 166; (vi) HCDR1 contains the amino acid sequence of SEQ ID NO: 167, HCDR2 contains the amino acid sequence of SEQ ID NO: 168, HCDR2 contains the amino acid sequence of SEQ ID NO: 159, and LCDR3 contains the amino acid sequence of SEQ ID NO: 160. The HCDR3 contains the amino acid sequence of SEQ ID NO: 169, the LCDR1 contains the amino acid sequence of SEQ ID NO: 170, the LCDR2 contains the amino acid sequence of SEQ ID NO: 171, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 172.(vii) HCDR1 contains the amino acid sequence of SEQ ID NO: 173, HCDR2 contains the amino acid sequence of SEQ ID NO: 174, HCDR3 contains the amino acid sequence of SEQ ID NO: 175, LCDR1 contains the amino acid sequence of SEQ ID NO: 176, LCDR2 contains the amino acid sequence of SEQ ID NO: 177, and LCDR3 contains the amino acid sequence of SEQ ID NO: 178; (viii) HCDR1 contains the amino acid sequence of SEQ ID NO: 179, HCDR2 contains the amino acid sequence of SEQ ID NO: 180, HCDR3 contains the amino acid sequence of SEQ ID NO: 181, LCDR1 contains the amino acid sequence of SEQ ID NO: 182, LCDR2 contains the amino acid sequence of SEQ ID NO: 183, and LCDR3 contains the amino acid sequence of SEQ ID NO: 184; (ix) HCDR1 contains the amino acid sequence of SEQ ID NO: 185, HCDR2 contains the amino acid sequence of SEQ ID NO: 176, HCDR2 contains the amino acid sequence of SEQ ID NO: 177, and LCDR3 contains the amino acid sequence of SEQ ID NO: 178. The HCDR1 contains the amino acid sequence SEQ ID NO: 186, the HCDR2 contains the amino acid sequence SEQ ID NO: 187, the LCDR1 contains the amino acid sequence SEQ ID NO: 188, the LCDR2 contains the amino acid sequence SEQ ID NO: 189, and the LCDR3 contains the amino acid sequence SEQ ID NO: 190; (x) the HCDR1 contains the amino acid sequence SEQ ID NO: 191, the HCDR2 contains the amino acid sequence SEQ ID NO: 192, the HCDR3 contains the amino acid sequence SEQ ID NO: 193, the LCDR1 contains the amino acid sequence SEQ ID NO: 194, the LCDR2 contains the amino acid sequence SEQ ID NO: 195, and the LCDR3 contains the amino acid sequence SEQ ID NO: 196; (xi) the HCDR1 contains the amino acid sequence SEQ ID NO: 197, the HCDR2 contains the amino acid sequence SEQ ID NO: 198, the HCDR3 contains the amino acid sequence SEQ ID NO: 199, and the LCDR1 contains the amino acid sequence SEQ ID NO: 190. (xii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 201, and the HCDR3 contains the amino acid sequence of SEQ ID NO: 202; (xii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 203, and the HCDR2 contains the amino acid sequence of SEQ ID NO: 204.The amino acid sequences of the following amino acids are specified: (xiii) HCDR1 contains the amino acid sequence of SEQ ID NO: 205, HCDR2 contains the amino acid sequence of SEQ ID NO: 206, HCDR2 contains the amino acid sequence of SEQ ID NO: 207, and HCDR3 contains the amino acid sequence of SEQ ID NO: 208; (xiii) HCDR1 contains the amino acid sequence of SEQ ID NO: 209, HCDR2 contains the amino acid sequence of SEQ ID NO: 210, HCDR3 contains the amino acid sequence of SEQ ID NO: 211, HCDR1 contains the amino acid sequence of SEQ ID NO: 212, HCDR2 contains the amino acid sequence of SEQ ID NO: 213, and HCDR3 contains the amino acid sequence of SEQ ID NO: 214; (xiv) HCDR1 contains the amino acid sequence of SEQ ID NO: 215, HCDR2 contains the amino acid sequence of SEQ ID NO: 216. The amino acid sequences of the following amino acids are specified: HCDR3 contains the amino acid sequence of SEQ ID NO: 217, LCDR1 contains the amino acid sequence of SEQ ID NO: 218, LCDR2 contains the amino acid sequence of SEQ ID NO: 219, and LCDR3 contains the amino acid sequence of SEQ ID NO: 220; (xv) HCDR1 contains the amino acid sequence of SEQ ID NO: 221, HCDR2 contains the amino acid sequence of SEQ ID NO: 222, HCDR3 contains the amino acid sequence of SEQ ID NO: 223, LCDR1 contains the amino acid sequence of SEQ ID NO: 224, LCDR2 contains the amino acid sequence of SEQ ID NO: 225, and LCDR3 contains the amino acid sequence of SEQ ID NO: 226; (xvi) HCDR1 contains the amino acid sequence of SEQ ID NO: 227, HCDR2 contains the amino acid sequence of SEQ ID NO: 228, HCDR3 contains the amino acid sequence of SEQ ID NO: 229, and LCDR1 contains the amino acid sequence of SEQ ID NO: 220. The amino acid sequence of SEQ ID NO: 230, LCDR2 contains the amino acid sequence of SEQ ID NO: 231, and LCDR3 contains the amino acid sequence of SEQ ID NO: 232; (xvii) HCDR1 contains the amino acid sequence of SEQ ID NO: 233, HCDR2 contains the amino acid sequence of SEQ ID NO: 234, and HCDR3 contains the amino acid sequence of SEQ ID NO: 232.The LCDR1 contains the amino acid sequence of SEQ ID NO: 235, the LCDR2 contains the amino acid sequence of SEQ ID NO: 237, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 238. 4. The antibody or antigen-binding fragment according to any one of claims 1 to 3, wherein the antibody or antigen-binding fragment comprises: (i) a VH comprising the amino acid sequence of SEQ ID NO: 1 and a VL comprising the amino acid sequence of SEQ ID NO: 2; (ii) a VH comprising the amino acid sequence of SEQ ID NO: 3 and a VL comprising the amino acid sequence of SEQ ID NO: 4; (iii) a VH comprising the amino acid sequence of SEQ ID NO: 5 and a VL comprising the amino acid sequence of SEQ ID NO: 6; (iv) a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 8; (v) a VH comprising the amino acid sequence of SEQ ID NO: 9 and a VL comprising the amino acid sequence of SEQ ID NO: 10; (vi) a VH comprising the amino acid sequence of SEQ ID NO: 11 and a VL comprising the amino acid sequence of SEQ ID NO: 12; (vii) a VH comprising the amino acid sequence of SEQ ID NO: 13 and a VL comprising the amino acid sequence of SEQ ID NO: 14. VL containing the amino acid sequence of SEQ ID NO: 14; (viii) VH containing the amino acid sequence of SEQ ID NO: 15 and VL containing the amino acid sequence of SEQ ID NO: 16; (ix) VH containing the amino acid sequence of SEQ ID NO: 17 and VL containing the amino acid sequence of SEQ ID NO: 18; (x) VH containing the amino acid sequence of SEQ ID NO: 19 and VL containing the amino acid sequence of SEQ ID NO: 20; Claims 5 / 7 Page 6 CN 121909215 A (xi) VH containing the amino acid sequence of SEQ ID NO: 21 and VL containing the amino acid sequence of SEQ ID NO: 22; (xii) VH containing the amino acid sequence of SEQ ID NO: 23 and VL containing the amino acid sequence of SEQ ID NO: 24; (xiii) VH containing the amino acid sequence of SEQ ID NO: 25 and VL containing the amino acid sequence of SEQ ID NO: 26; (xiv) containing the amino acid sequence of SEQ ID NO: VH containing the amino acid sequence of SEQ ID NO: 27, and VL containing the amino acid sequence of SEQ ID NO: 28;(xv) a VH comprising the amino acid sequence of SEQ ID NO: 29 and a VL comprising the amino acid sequence of SEQ ID NO: 30; (xvi) a VH comprising the amino acid sequence of SEQ ID NO: 31 and a VL comprising the amino acid sequence of SEQ ID NO: 32; or (xvii) a VH comprising the amino acid sequence of SEQ ID NO: 33 and a VL comprising the amino acid sequence of SEQ ID NO: 34. 5. An antibody or antigen-binding fragment according to any one of claims 1 to 4, wherein the antibody or antigen-binding fragment is IgG. 6. An antibody or antigen-binding fragment according to any one of claims 1 to 5, wherein the antibody or antigen-binding fragment is a human antibody. 7. An antibody or antigen-binding fragment according to any one of claims 1 to 6, wherein the antibody or antigen-binding fragment contains one or more mutations in the Fc region to reduce or eliminate antibody-dependent cell-mediated cytotoxicity (ADCC) and / or complement-dependent cytotoxicity (CDC) effects. 8. An antibody or antigen-binding fragment according to any one of claims 1 to 7, wherein the antibody or antigen-binding fragment comprises: (1) one or both mutations of L239A and L240A; or (2) one or both mutations of L234A and L235A. 9. An antibody or antigen-binding fragment according to any one of claims 1 to 8, wherein the antibody or antigen-binding fragment thereof is genetically fused or chemically conjugated with a pharmaceutical agent. 10. A nucleic acid molecule encoding an antibody or antigen-binding fragment according to any one of claims 1 to 9. 11. A vector comprising the nucleic acid molecule according to claim 10. 12. A host cell transformed with the vector according to claim 11. 13. A composition comprising a therapeutically effective amount of an antibody or antigen-binding fragment according to any one of claims 1 to 9, a nucleic acid molecule according to claim 10, or a vector according to claim 11, and a pharmaceutically acceptable excipient. 14. A method of treating a subject for a disease or condition, the method comprising administering the composition according to claim 13 to the subject. 15. The method according to claim 14, wherein the disease or condition is associated with ACVR2B. 16. The method of claim 14, wherein the disease or condition is associated with the ACVR2B ligand. 17. The method of claim 14, wherein the disease or condition is associated with activator A, activator B, activator AB, GDF8, or GDF11.18. The method of any one of claims 14 to 17, wherein the disease or condition is a musculoskeletal disease or condition. 19. The method of claim 18, wherein the musculoskeletal disease or condition is selected from the group consisting of: muscle atrophy, spinal muscular atrophy, and cancer cachexia. 20. The method of any one of claims 14 to 17, wherein the disease or condition is an age-related symptom selected from the group consisting of: sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, emphysema, osteoporosis, osteoarthritis, immunodeficiency, hypertension, dementia, Huntington's disease, Alzheimer's disease, cataracts, age-related macular degeneration, prostate cancer, stroke, shortened life expectancy, frailty, memory loss, wrinkles, impaired renal function, and age-related hearing loss. 21. The method of any one of claims 14 to 17, wherein the disease or condition is a metabolic disorder selected from the group consisting of: type 2 diabetes, metabolic syndrome, hyperglycemia, NASH, and obesity. 22. The method of any one of claims 14 to 17, wherein the disease or condition is selected from the group consisting of: acute and / or chronic kidney disease or renal failure, liver fibrosis or cirrhosis, pulmonary fibrosis, pulmonary hypertension (PH), pulmonary arterial hypertension (PAH), renal fibrosis, Parkinson's disease, ALS, brain atrophy, dementia cachexia, and cancers that induce bone loss. 23. The method of any one of claims 14 to 17, wherein the disease or condition is cancer selected from the group consisting of: rhabdomyosarcoma, ovarian cancer, breast cancer, esophageal cancer, head and neck cancer, lung cancer, melanoma, multiple myeloma, colorectal cancer, hepatocellular carcinoma, pancreatic cancer, endometrial cancer, and gastrointestinal cancer. 24. The method of any one of claims 14 to 17, wherein the disease or condition is anemia. 25. The method of any one of claims 14 to 17, wherein the method further comprises administering a second agent to the subject. 26. The method of claim 25, wherein the second agent is an ACVR2A antagonist, wherein optionally the ACVR2A antagonist is an ACVR2A antibody. 27. A method for inhibiting or antagonizing ACVR2B activity in cells, the method comprising contacting the cells with the composition of claim 11. 28. A method for inhibiting or blocking the binding of an ACVR2B ligand to ACVR2B expressed on cells, the method comprising contacting the cells with the composition of claim 11, wherein optionally the ACVR2B ligand is activin A, activin B, activin AB, GDF8, or GDF11. 29. A method for inhibiting or blocking signal transduction induced by an ACVR2B ligand in cells via ACVR2B, wherein...The method includes contacting the cells with the composition according to claim 11, wherein optionally the ACVR2B ligand is activin A, activin B, activin AB, GDF8, or GDF11. Claims 7 / 7 Page 8 CN 121909215 A Anti-ACVR2B Antibody and Use Thereof
[0001] Cross-Reference to Related Applications
[0002] This application claims priority to International Patent Application No. PCT / CN2023 / 110569, filed August 1, 2023, the disclosure of which is incorporated herein by reference in its entirety.
[0003] Sequence Listing
[0004] This application includes an electronic sequence listing submitted together with this application in XML file format, the entire contents of which are incorporated herein by reference in their entirety. The sequence listing XML file submitted with this application is named "14668-031-228_SEQ_LISTING.xml", created on July 29, 2024, and is 242,113 bytes in size. 1. Technical Field
[0005] This document provides molecules capable of binding to ACVR2B, pharmaceutical compositions containing such molecules, and uses thereof. 2. Background Art
[0006] Type 2B activin receptors (ACVR2B) are receptors that mediate the function and other biological activities of activins. Activins are dimeric growth and differentiation factors belonging to the transforming growth factor-β (TGF-β) superfamily of structure-associated signaling proteins, playing important roles in multiple processes during embryonic development, organogenesis, and adult homeostasis. Activins signal through heteromeric complexes of receptor serine kinases, including type I and type II receptors, and these receptors are transmembrane proteins composed of a ligand-binding extracellular domain with a cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with serine / threonine specificity. Type I receptors are essential for signal transduction; and type II receptors are required for ligand binding and phosphorylation of type I receptors. Although type II receptors (including ACVR2A and ACVR2B) have been shown to be involved in various disease symptoms, and we have developed ACVR2A-specific antibodies (see WO 2023 / 030503), there is a need in the art for improved antibody therapies targeting ACVR2B. 3. Summary of the Invention
[0007] In one aspect, antibodies or antigen-binding fragments thereof that selectively bind ACVR2B are provided herein. In some embodiments, the antibodies provided herein bind ACVR2B more than ACVR2A. In some embodiments, the antibodies or antigen-binding fragments provided herein bind ACVR2B with a higher affinity than for ACVR2A. This disclosure provides methods for using ACVR2B binding proteins. In some embodiments, the anti-ACVR2B antibodies or antigen-binding fragments provided herein are capable of inhibiting or blockingACVR2B binds to ACVR2B ligands such as activin A, activin B, activin AB, GDF8, and GDF11. In some embodiments, the antibody or antigen-binding fragments provided herein do not inhibit or block the binding of ACVR2A to ACVR2A ligands such as activin A, activin B, activin AB, GDF8, and GDF11. In some embodiments, the antibody or antigen-binding fragments provided herein have a greater inhibitory or blocking effect on the binding of ACVR2B to ACVR2B ligands than on the binding of ACVR2A to ACVR2A ligands.
[0008] In some embodiments, the antibody or antigen-binding fragments provided herein comprise:
[0009] (i) HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO: 1, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 2;
[0010] (ii) HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO: 3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 4;
[0011] (iii) HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO: 5, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 6;
[0012] (iv) HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO: 7, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 8;
[0013] (v) HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO: 9, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 10; (vi) HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO: 11, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 12; (vii) HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO: 13, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 14;
[0014] (viii) HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO: 15, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 16;
[0015] (ix) HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO: 17, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 18LCDR1, LCDR2, and LCDR3;
[0016] (x) HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO: 19, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 20;
[0017] (xi) HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO: 21, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 22;
[0018] (xii) HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO: 23, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 24;
[0019] (xiii) HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO: 25, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 26;
[0020] (xiv) as shown in SEQ ID NO: HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 27, and LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 28;
[0021] (xv) HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 29, and LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 30;
[0022] (xvi) HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 31, and LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 32; or
[0023] (xvii) HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 33, and LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 34.
[0024] In some embodiments, the antibody or antigen-binding fragments provided herein comprise:
[0025] (i) HCDR1 comprises the amino acid sequence of SEQ ID NO: 35, HCDR2 comprises the amino acid sequence of SEQ ID NO: 36, HCDR3 comprises the amino acid sequence of SEQ ID NO: 37, LCDR1 comprises the amino acid sequence of SEQ ID NO: 38, LCDR2 comprises the amino acid sequence of SEQ ID NO: 39, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 40;
[0026] (ii) HCDR1 comprises the amino acid sequence of SEQ ID NO: 41, HCDR2 comprises the amino acid sequence of SEQ ID NO: 42, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 43.The amino acid sequence of SEQ ID NO: 43, LCDR1 contains the amino acid sequence of SEQ ID NO: 44, LCDR2 contains the amino acid sequence of SEQ ID NO: 45, and LCDR3 contains the amino acid sequence of SEQ ID NO: 46;
[0027] (iii) HCDR1 contains the amino acid sequence of SEQ ID NO: 47, HCDR2 contains the amino acid sequence of SEQ ID NO: 48, HCDR3 contains the amino acid sequence of SEQ ID NO: 49, LCDR1 contains the amino acid sequence of SEQ ID NO: 50, LCDR2 contains the amino acid sequence of SEQ ID NO: 51, and LCDR3 contains the amino acid sequence of SEQ ID NO: 52; Specification 2 / 108 pages 10 CN 121909215 A
[0028] (iv) HCDR1 contains the amino acid sequence of SEQ ID NO: 53, HCDR2 contains the amino acid sequence of SEQ ID NO: 54, HCDR3 contains the amino acid sequence of SEQ ID NO: 55, and LCDR1 contains the amino acid sequence of SEQ ID NO: 56, LCDR2 contains the amino acid sequence of SEQ ID NO: 57, and LCDR3 contains the amino acid sequence of SEQ ID NO: 58;
[0029] (v) HCDR1 contains the amino acid sequence of SEQ ID NO: 59, HCDR2 contains the amino acid sequence of SEQ ID NO: 60, HCDR3 contains the amino acid sequence of SEQ ID NO: 61, LCDR1 contains the amino acid sequence of SEQ ID NO: 62, LCDR2 contains the amino acid sequence of SEQ ID NO: 63, and LCDR3 contains the amino acid sequence of SEQ ID NO: 64;
[0030] (vi) HCDR1 contains the amino acid sequence of SEQ ID NO: 65, HCDR2 contains the amino acid sequence of SEQ ID NO: 66, HCDR3 contains the amino acid sequence of SEQ ID NO: 67, LCDR1 contains the amino acid sequence of SEQ ID NO: 68, LCDR2 contains the amino acid sequence of SEQ ID NO: 69, and LCDR3 contains the amino acid sequence of SEQ ID NO: 70;
[0031] (vii) HCDR1 contains the amino acid sequence of SEQ ID NO: 59, HCDR2 contains the amino acid sequence of SEQ ID NO: 60, HCDR3 contains the amino acid sequence of SEQ ID NO: 61, LCDR1 contains the amino acid sequence of SEQ ID NO: 62, LCDR2 contains the amino acid sequence of SEQ ID NO: 63, and LCDR3 contains the amino acid sequence of SEQ ID NO: 70; The amino acid sequence of SEQ ID NO: 71, HCDR2 contains the amino acid sequence of SEQ ID NO: 72, HCDR3 contains the amino acid sequence of SEQ ID NO: 73, LCDR1 contains the amino acid sequence of SEQ ID NO: 74, LCDR2 contains the amino acid sequence of SEQ ID NO: 75, and LCDR3 contains the amino acid sequence of SEQ ID NO: 75.
[0032] (viii) HCDR1 contains the amino acid sequence of SEQ ID NO: 77, HCDR2 contains the amino acid sequence of SEQ ID NO: 78, HCDR3 contains the amino acid sequence of SEQ ID NO: 79, LCDR1 contains the amino acid sequence of SEQ ID NO: 80, LCDR2 contains the amino acid sequence of SEQ ID NO: 81, and LCDR3 contains the amino acid sequence of SEQ ID NO: 82;
[0033] (ix) HCDR1 contains the amino acid sequence of SEQ ID NO: 83, HCDR2 contains the amino acid sequence of SEQ ID NO: 84, HCDR3 contains the amino acid sequence of SEQ ID NO: 85, LCDR1 contains the amino acid sequence of SEQ ID NO: 86, LCDR2 contains the amino acid sequence of SEQ ID NO: 87, and LCDR3 contains the amino acid sequence of SEQ ID NO: 88;
[0034] (x) HCDR1 contains the amino acid sequence of SEQ ID NO: 89, HCDR2 ... The amino acid sequence of SEQ ID NO: 90, HCDR3 contains the amino acid sequence of SEQ ID NO: 91, LCDR1 contains the amino acid sequence of SEQ ID NO: 92, LCDR2 contains the amino acid sequence of SEQ ID NO: 93, and LCDR3 contains the amino acid sequence of SEQ ID NO: 94;
[0035] (xi) HCDR1 contains the amino acid sequence of SEQ ID NO: 95, HCDR2 contains the amino acid sequence of SEQ ID NO: 96, HCDR3 contains the amino acid sequence of SEQ ID NO: 97, LCDR1 contains the amino acid sequence of SEQ ID NO: 98, LCDR2 contains the amino acid sequence of SEQ ID NO: 99, and LCDR3 contains the amino acid sequence of SEQ ID NO: 100;
[0036] (xii) HCDR1 contains the amino acid sequence of SEQ ID NO: 101, HCDR2 contains the amino acid sequence of SEQ ID NO: 102, HCDR3 contains the amino acid sequence of SEQ ID NO: 103, and LCDR1 contains the amino acid sequence of SEQ ID NO: 94; The amino acid sequence of SEQ ID NO: 104, LCDR2 contains the amino acid sequence of SEQ ID NO: 105, and LCDR3 contains the amino acid sequence of SEQ ID NO: 106;
[0037] (xiii) HCDR1 contains the amino acid sequence of SEQ ID NO: 107, HCDR2 contains the amino acid sequence of SEQ ID NO: 108, and HCDR3 contains the amino acid sequence of SEQ ID NO: 106;The amino acid sequence NO: 109, LCDR1 contains the amino acid sequence of SEQ ID NO: 110, LCDR2 contains the amino acid sequence of SEQ ID NO: 111, and LCDR3 contains the amino acid sequence of SEQ ID NO: 112;
[0038] (xiv) HCDR1 contains the amino acid sequence of SEQ ID NO: 113, HCDR2 contains the amino acid sequence of SEQ ID NO: 114, HCDR3 contains the amino acid sequence of SEQ ID NO: 115, LCDR1 contains the amino acid sequence of SEQ ID NO: 116, LCDR2 contains the amino acid sequence of SEQ ID NO: 117, and LCDR3 contains the amino acid sequence of SEQ ID NO: 118;
[0039] (xv) HCDR1 contains the amino acid sequence of SEQ ID NO: 119, HCDR2 contains the amino acid sequence of SEQ ID NO: 120, HCDR3 contains the amino acid sequence of SEQ ID NO: 121, LCDR1 contains the amino acid sequence of SEQ ID NO: 122, and LCDR2 contains the amino acid sequence of SEQ ID NO: 113; The amino acid sequence of SEQ ID NO: 123, and LCDR3 contains the amino acid sequence of SEQ ID NO: 124. (See specification 3 / 108, page 11, CN 121909215, column A);
[0040] (xvi) HCDR1 contains the amino acid sequence of SEQ ID NO: 125, HCDR2 contains the amino acid sequence of SEQ ID NO: 126, HCDR3 contains the amino acid sequence of SEQ ID NO: 127, LCDR1 contains the amino acid sequence of SEQ ID NO: 128, LCDR2 contains the amino acid sequence of SEQ ID NO: 129, and LCDR3 contains the amino acid sequence of SEQ ID NO: 130; or
[0041] (xvii) HCDR1 contains the amino acid sequence of SEQ ID NO: 131, HCDR2 contains the amino acid sequence of SEQ ID NO: 132, HCDR3 contains the amino acid sequence of SEQ ID NO: 133, LCDR1 contains the amino acid sequence of SEQ ID NO: 134, LCDR2 contains the amino acid sequence of SEQ ID NO: 129, and LCDR3 contains the amino acid sequence of SEQ ID NO: 129. The amino acid sequence is SEQ ID NO: 135, and LCDR3 contains the amino acid sequence of SEQ ID NO: 136.
[0042] In some embodiments, the antibody or antigen binding fragment provided herein comprises:
[0043] (i) HCDR1 contains the amino acid sequence of SEQ ID NO: 137, HCDR2 contains the amino acid sequence of SEQ ID NO: 138, and HCDR3 contains the amino acid sequence of SEQ ID NO: 135.The amino acid sequence of SEQ ID NO: 139, LCDR1 contains the amino acid sequence of SEQ ID NO: 140, LCDR2 contains the amino acid sequence of SEQ ID NO: 141, and LCDR3 contains the amino acid sequence of SEQ ID NO: 142;
[0044] (ii) HCDR1 contains the amino acid sequence of SEQ ID NO: 143, HCDR2 contains the amino acid sequence of SEQ ID NO: 144, HCDR3 contains the amino acid sequence of SEQ ID NO: 145, LCDR1 contains the amino acid sequence of SEQ ID NO: 146, LCDR2 contains the amino acid sequence of SEQ ID NO: 147, and LCDR3 contains the amino acid sequence of SEQ ID NO: 148;
[0045] (iii) HCDR1 contains the amino acid sequence of SEQ ID NO: 149, HCDR2 contains the amino acid sequence of SEQ ID NO: 150, HCDR3 contains the amino acid sequence of SEQ ID NO: 151, LCDR1 contains the amino acid sequence of SEQ ID NO: 152, LCDR2 contains the amino acid sequence of SEQ ID NO: 143, HCDR2 contains the amino acid sequence of SEQ ID NO: 144, HCDR3 contains the amino acid sequence of SEQ ID NO: 145, LCDR1 contains the amino acid sequence of SEQ ID NO: 146, LCDR2 contains the amino acid sequence of SEQ ID NO: 147, and LCDR3 contains the amino acid sequence of SEQ ID NO: 148; (iv) HCDR1 contains the amino acid sequence of SEQ ID NO: 155, HCDR2 contains the amino acid sequence of SEQ ID NO: 156, HCDR3 contains the amino acid sequence of SEQ ID NO: 157, LCDR1 contains the amino acid sequence of SEQ ID NO: 158, LCDR2 contains the amino acid sequence of SEQ ID NO: 159, and LCDR3 contains the amino acid sequence of SEQ ID NO: 160;
[0047] (v) HCDR1 contains the amino acid sequence of SEQ ID NO: 161, HCDR2 contains the amino acid sequence of SEQ ID NO: 162, HCDR3 contains the amino acid sequence of SEQ ID NO: 163, LCDR1 contains the amino acid sequence of SEQ ID NO: 164, LCDR2 contains the amino acid sequence of SEQ ID NO: 165, and LCDR3 contains the amino acid sequence of SEQ ID NO: 166;
[0048] (vi) HCDR1 contains the amino acid sequence of SEQ ID NO: 167, HCDR2 contains the amino acid sequence of SEQ ID NO: 168, HCDR3 contains the amino acid sequence of SEQ ID NO: 169, LCDR1 contains the amino acid sequence of SEQ ID NO: 170, and LCDR2 contains the amino acid sequence of SEQ ID NO: 169.The amino acid sequence of SEQ ID NO: 171, and LCDR3 contains the amino acid sequence of SEQ ID NO: 172;
[0049] (vii) HCDR1 contains the amino acid sequence of SEQ ID NO: 173, HCDR2 contains the amino acid sequence of SEQ ID NO: 174, HCDR3 contains the amino acid sequence of SEQ ID NO: 175, LCDR1 contains the amino acid sequence of SEQ ID NO: 176, LCDR2 contains the amino acid sequence of SEQ ID NO: 177, and LCDR3 contains the amino acid sequence of SEQ ID NO: 178;
[0050] (viii) HCDR1 contains the amino acid sequence of SEQ ID NO: 179, HCDR2 contains the amino acid sequence of SEQ ID NO: 180, HCDR3 contains the amino acid sequence of SEQ ID NO: 181, LCDR1 contains the amino acid sequence of SEQ ID NO: 182, and LCDR2 contains the amino acid sequence of SEQ ID NO: 173; The amino acid sequence of SEQ ID NO: 183 is included, and LCDR3 includes the amino acid sequence of SEQ ID NO: 184;
[0051] (ix) HCDR1 includes the amino acid sequence of SEQ ID NO: 185, HCDR2 includes the amino acid sequence of SEQ ID NO: 186, HCDR3 includes the amino acid sequence of SEQ ID NO: 187, LCDR1 includes the amino acid sequence of SEQ ID NO: 188, LCDR2 includes the amino acid sequence of SEQ ID NO: 189, and LCDR3 includes the amino acid sequence of SEQ ID NO: 190;
[0052] (x) HCDR1 includes the amino acid sequence of SEQ ID NO: 191, HCDR2 includes the amino acid sequence of SEQ ID NO: 192, HCDR3 includes the amino acid sequence of SEQ ID NO: 193, LCDR1 includes the amino acid sequence of SEQ ID NO: 194, LCDR2 includes the amino acid sequence of SEQ ID NO: 195, and LCDR3 includes the amino acid sequence of SEQ ID NO: 196;
[0053] (xi)HCDR1 contains the amino acid sequence of SEQ ID NO: 197, HCDR2 contains the amino acid sequence of SEQ ID NO: 198, HCDR3 contains the amino acid sequence of SEQ ID NO: 199, LCDR1 contains the amino acid sequence of SEQ ID NO: 200, LCDR2 contains the amino acid sequence of SEQ ID NO: 201, and LCDR3 contains the amino acid sequence of SEQ ID NO: 202;
[0054] (xii) HCDR1 contains the amino acid sequence of SEQ ID NO: 203, HCDR2 contains the amino acid sequence of SEQ ID NO: 204, HCDR3 contains the amino acid sequence of SEQ ID NO: 205, LCDR1 contains the amino acid sequence of SEQ ID NO: 206, LCDR2 contains the amino acid sequence of SEQ ID NO: 207, and LCDR3 contains the amino acid sequence of SEQ ID NO: 208;
[0055] (xiii) HCDR1 contains the amino acid sequence of SEQ ID NO: 209, HCDR2 contains the amino acid sequence of SEQ ID NO: 210, HCDR3 contains the amino acid sequence of SEQ ID NO: 211, LCDR1 contains the amino acid sequence of SEQ ID NO: 212, LCDR2 contains the amino acid sequence of SEQ ID NO: 213, and LCDR3 contains the amino acid sequence of SEQ ID NO: 214;
[0056] (xiv) HCDR1 contains the amino acid sequence of SEQ ID NO: 215, HCDR2 contains the amino acid sequence of SEQ ID NO: 207, and LCDR3 contains the amino acid sequence of SEQ ID NO: 208; The amino acid sequence NO: 216, HCDR3 contains the amino acid sequence of SEQ ID NO: 217, LCDR1 contains the amino acid sequence of SEQ ID NO: 218, LCDR2 contains the amino acid sequence of SEQ ID NO: 219, and LCDR3 contains the amino acid sequence of SEQ ID NO: 220;
[0057] (xv) HCDR1 contains the amino acid sequence of SEQ ID NO: 221, HCDR2 contains the amino acid sequence of SEQ ID NO: 222, HCDR3 contains the amino acid sequence of SEQ ID NO: 223, LCDR1 contains the amino acid sequence of SEQ ID NO: 224, LCDR2 contains the amino acid sequence of SEQ ID NO: 225, and LCDR3 contains the amino acid sequence of SEQ ID NO: 226;
[0058] (xvi) HCDR1 contains the amino acid sequence of SEQ ID NO: 227, HCDR2 contains the amino acid sequence of SEQ ID NO: 228, HCDR3 contains the amino acid sequence of SEQ ID NO: 229, and LCDR1 contains the amino acid sequence of SEQ ID NO: 220. The amino acid sequence of NO: 230, LCDR2 contains the amino acid sequence of SEQ ID NO: 231, and LCDR3 contains the amino acid sequence of SEQ ID NO: 232;
[0059] (xvii) HCDR1 contains the amino acid sequence of SEQ ID NO: 233, and HCDR2 contains the amino acid sequence of SEQ ID NO: 234.The amino acid sequences are as follows: HCDR3 contains the amino acid sequence of SEQ ID NO: 235, LCDR1 contains the amino acid sequence of SEQ ID NO: 236, LCDR2 contains the amino acid sequence of SEQ ID NO: 237, and LCDR3 contains the amino acid sequence of SEQ ID NO: 238. Specification 5 / 108 pages 13 CN 121909215 A
[0060] In some embodiments, the antibody or antigen binding fragment provided herein comprises:
[0061] (i) a VH comprising the amino acid sequence of SEQ ID NO: 1 and a VL comprising the amino acid sequence of SEQ ID NO: 2;
[0062] (ii) a VH comprising the amino acid sequence of SEQ ID NO: 3 and a VL comprising the amino acid sequence of SEQ ID NO: 4;
[0063] (iii) a VH comprising the amino acid sequence of SEQ ID NO: 5 and a VL comprising the amino acid sequence of SEQ ID NO: 6;
[0064] (iv) a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 8;
[0065] (v) a VH comprising the amino acid sequence of SEQ ID NO: 9 and a VL comprising the amino acid sequence of SEQ ID NO: 10;
[0066] (vi) a VH comprising the amino acid sequence of SEQ ID NO: 10; VH containing the amino acid sequence of SEQ ID NO: 11, and VL containing the amino acid sequence of SEQ ID NO: 12;
[0067] (vii) VH containing the amino acid sequence of SEQ ID NO: 13, and VL containing the amino acid sequence of SEQ ID NO: 14;
[0068] (viii) VH containing the amino acid sequence of SEQ ID NO: 15, and VL containing the amino acid sequence of SEQ ID NO: 16;
[0069] (ix) VH containing the amino acid sequence of SEQ ID NO: 17, and VL containing the amino acid sequence of SEQ ID NO: 18;
[0070] (x) VH containing the amino acid sequence of SEQ ID NO: 19, and VL containing the amino acid sequence of SEQ ID NO: 20;
[0071] (xi) VH containing the amino acid sequence of SEQ ID NO: 21, and VL containing the amino acid sequence of SEQ ID NO: 22;
[0072] (xii) VH containing the amino acid sequence of SEQ ID NO: 11, and VL containing the amino acid sequence of SEQ ID NO: 22; VH containing the amino acid sequence of SEQ ID NO: 23, and VL containing the amino acid sequence of SEQ ID NO: 24;
[0073] (xiii) containing SEQ ID NO:VH containing the amino acid sequence of SEQ ID NO: 25, and VL containing the amino acid sequence of SEQ ID NO: 26;
[0074] (xiv) VH containing the amino acid sequence of SEQ ID NO: 27, and VL containing the amino acid sequence of SEQ ID NO: 28;
[0075] (xv) VH containing the amino acid sequence of SEQ ID NO: 29, and VL containing the amino acid sequence of SEQ ID NO: 30;
[0076] (xvi) VH containing the amino acid sequence of SEQ ID NO: 31, and VL containing the amino acid sequence of SEQ ID NO: 32; or
[0077] (xvii) VH containing the amino acid sequence of SEQ ID NO: 33, and VL containing the amino acid sequence of SEQ ID NO: 34.
[0078] In some embodiments, the antibody or antigen-binding fragment provided herein is IgG. In some embodiments, the antibody or antigen-binding fragment provided herein is IgG1. In some embodiments, the antibody is a human antibody. In some embodiments, the antibody or antigen-binding fragments provided herein contain one or more mutations in the Fc region to reduce or eliminate antibody-dependent cell-mediated cytotoxicity (ADCC) and / or complement-dependent cytotoxicity (CDC) effects. In some embodiments, as described on page 6 / 108 of CN 121909215 A, the antibody or antigen-binding fragments provided herein contain one or both mutations of L239A and L240A in the Fc region. In some embodiments, the antibody or antigen-binding fragments provided herein contain one or both mutations of L234A and L235A in the Fc region (Lund J et al., J Immunol. 147: 2657–2662 (1991)).
[0079] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragments provided herein comprise a heavy chain containing the amino acid sequence of SEQ ID NO: 239. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragments provided herein comprise a light chain containing the amino acid sequence of SEQ ID NO: 240. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 239 and a light chain containing the amino acid sequence of SEQ ID NO: 240.
[0080] In some embodiments, the antibody or antigen-binding fragment thereof is genetically fused or chemically conjugated with a pharmaceutical agent.
[0081] In another aspect, this document provides a nucleic acid molecule encoding the antibody or antigen-binding fragment provided herein.
[0082] In another aspect, this document provides a nucleic acid molecule comprising encoding the antibody or antigen-binding fragment provided herein.Acid molecule carrier.
[0083] In another aspect, this document provides a host cell transformed with a carrier encoding an antibody or antigen-binding fragment provided herein.
[0084] In yet another aspect, this document provides a composition comprising a therapeutically effective amount of an antibody or antigen-binding fragment, a nucleic acid molecule or carrier encoding an antibody or antigen-binding fragment provided herein, and a pharmaceutically acceptable excipient.
[0085] In yet another aspect, this document provides a method of treating a disease or condition in a subject, the method comprising administering the composition provided herein to the subject. In some embodiments, the method further comprises administering a second agent to the subject. In some embodiments, the disease or condition is associated with ACVR2B. In some embodiments, the disease or condition is associated with an ACVR2B ligand, which includes activins (such as activin A, activin B, activin AB, activin C, activin AC, and activin E), growth / differentiation factors (GDFs, such as GDF1, GDF3, GDF5, GDF6, GDF7, GDF8, GDF10, and GDF11), and bone morphogenetic proteins (BMPs, such as BMP2, BMP4, BMP6, BMP7, BMP8a, BMP8b, BMP9, and BMP10).
[0086] In some embodiments of the methods for treating a disease or condition provided herein, the disease or condition is associated with ACVR2B.
[0087] In some embodiments, the disease or condition is a musculoskeletal disease or condition. In some embodiments, the musculoskeletal disease or condition is selected from the group consisting of anemia, muscle atrophy, spinal muscular atrophy, and cancer cachexia. In some implementations, the disease or condition is an age-related symptom selected from the group consisting of: sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, emphysema, osteoporosis, osteoarthritis, immunodeficiency, hypertension, dementia, Huntington's disease, Alzheimer's disease, cataracts, age-related macular degeneration, prostate cancer, stroke, shortened life expectancy, frailty, memory loss, wrinkles, impaired kidney function, and age-related hearing loss. In some implementations, the disease or condition is a metabolic disorder selected from the group consisting of: type II diabetes, metabolic syndrome, hyperglycemia, non-alcoholic steatohepatitis (NASH), and obesity. In some implementations, the disease or condition is selected from the group consisting of: acute and / or chronic kidney disease or kidney failure, liver fibrosis or cirrhosis, pulmonary fibrosis, pulmonary hypertension (PH), pulmonary arterial hypertension (PAH), cancer, renal fibrosis, Parkinson's disease, amyotrophic lateral sclerosis (ALS), brain atrophy, dementia and anemia, cachexia, rhabdomyosarcoma, and bone loss. In some implementations, the disease or condition is cancer, including ovarian cancer and breast cancer.Cancer, breast cancer, esophageal cancer, head and neck cancer, lung cancer, melanoma, multiple myeloma, colorectal cancer, hepatocellular carcinoma, pancreatic cancer, endometrial cancer, and gastrointestinal cancer.
[0088] In another aspect, this document provides a method for inhibiting or antagonizing ACVR2B activity in cells, the method comprising contacting the cells with a composition provided herein. In another aspect, this document provides a method for inhibiting or blocking the binding of an ACVR2B ligand to ACVR2B expressed on cells, the method comprising contacting the cells with a composition provided herein. In yet another aspect, this document provides a method for inhibiting or blocking ACVR2B ligand-induced signal transduction in cells via ACVR2B, the method comprising contacting the cells with a composition provided herein. The ACVR2B ligands include, but are not limited to, activins (such as activin A, activin B, activin AB, activin C, activin AC, and activin E), growth / differentiation factors (GDFs, such as GDF1, GDF3, GDF5, GDF6, GDF7, GDF8, GDF10, and GDF11), and bone morphogenetic proteins (BMPs, such as BMP2, BMP4, BMP6, BMP7, BMP8a, BMP8b, BMP9, and BMP10). 4. Figure Descriptions
[0089] Figures 1A to 1C. Binding kinetics of the equilibrium dissociation constant (KD) of ACVR2B hits. The binding kinetics of three representative hit antibodies to human ACVR2B protein were analyzed using an anti-human Fc capture format on a CM5 sensor chip at 25°C using a Biacore 3000. The sensor map was fitted using a 1:1 Langmuir binding model via nonlinear least squares regression. Figure 1A: Binding kinetics of T334 antibody with ACVR2B. Figure 1B: Binding kinetics of T363 antibody with ACVR2B. Figure 1C: Binding kinetics of T377 antibody with ACVR2B.
[0090] Figures 2A to 2E. Competitive ELISA assay of activin A in ACVR2B hits. Figures 2A-2D: 23 anti-ACVR2B phages from the κ-chain shuffle phage display library hits and binds to ACVR2B, blocking the interaction between activin A and ACVR2B. Figure 2E: Competitive ELISA assay of activin A in representative anti-ACVR2B IgG from the κ-chain shuffle library.
[0091] Figure 3. Assay of phosphorylated Smad-dependent reporter gene in ACVR2B hits from the κ-chain shuffle library. The ACVR2A knockout stable cell line HEK293T-A1-6 was transfected with CAGA-12 luciferase reporter plasmid, and the luciferase signal transduction...The signal was tested after incubation overnight with IgG hits and activator A. Hits at C62, T18, T27, T11, and parental hits at T334 and T363 inhibited activator A-induced phosphorylation-dependent Smad signaling.
[0092] Figures 4A to 4C. Determination of phosphorylation-dependent reporter genes for ACVR2B hits from CDRH1 and CDRH2 randomized libraries. The ACVR2A knockout stable cell line HEK293T-A1-6 was transfected with the CAGA-12 luciferase reporter plasmid, and luciferase signaling was tested after incubation overnight with IgG hits and ACVR2B ligands. Hit T16076 (LAE103), C16062, T16059, T24117, and T24166 inhibited phosphorylated Smad-dependent signaling induced by activin A (Fig. 4A), GDF8 (Fig. 4B), and GDF11 (Fig. 4C), respectively.
[0093] Figs. 5A to 5B. ACVR2B Ab LAE103 binds to ACVR2B protein and ACVR2B overexpressing cells with high affinity. LAE103 is a human IgG1 with the L239A / L240A mutation, which has the same variable region sequence of the heavy and light chains that effectively hit T16076 from CDRH1 and CDRH2 randomized libraries. This variable region sequence has been shown to inhibit phosphorylated Smad-dependent signaling induced by activin A, GDF8, and GDF11, as shown in Figs. 4A to 4C. LAE103 binds to ACVR2B protein at EC50 0.377 nM (Fig. 5A) and to ACVR2B-overexpressing 293T cells at EC50 0.752 nM (Fig. 5B).
[0094] Figs. 6A to 6B. ACVR2B Ab. LAE103 loses its activity in ACVR2B knockout cells. ACVR2B knockout stable cell line HEK293T-B1-12 was transfected with CAGA-12 luciferase reporter plasmid, and luciferase signaling was tested after overnight incubation with LAE103 and ACVR2B ligands. LAE103 loses its inhibitory activity against phosphorylated Smad-dependent signaling induced by activin A (Fig. 6A) and GDF11 (Fig. 6B) in ACVR2B knockout 293T cells, indicating that it cannot inhibit signaling transduced by ACVR2A. LAE102 is an ACVR2A-specific antagonistic Ab used as a positive control, which blocks phosphorylated Smad-dependent signaling induced by activin A (Fig. 6A) and GDF11 (Fig. 6B). Specification 8 / 108 pages 16 CN 121909215 A
[0095] Fig. 7. ACVR2B Ab LAE103 vs. ACVR2A Ab LAE102 (also referred to as LA01 in WO 2023 / 030503)Combined inhibition of phosphorylated Smad-dependent signaling. Wild-type HEK293T cells express both ACVR2B and ACVR2A, both of which contribute to ACVR2 ligand-induced signaling. Blocking ACVR2B alone with Ab LAE103 slightly inhibits phosphorylated Smad-dependent signaling; however, when combined with ACVR2A Ab LAE102, it completely blocks this signaling.
[0096] Figure 8. Phosphorylated Smad3 HTRF assay in human primary skeletal muscle (SkMC) cells. Human primary SkMC cells express both ACVR2A and ACVR2B. The combination of ACVR2B Ab LAE103 and ACVR2A Ab LAE102 inhibits activin A-induced phosphorylated Smad3 levels. , P < 0.05 relative to isotype control; , P < 0.01 relative to control; , P < 0.001 relative to control (one-way ANOVA test). 5. Detailed Description
[0097] This disclosure is based in part on novel antibodies bound to ACVR2B and their superior properties.
[0098] 5.1. Definitions
[0099] The techniques and procedures described or referenced herein include those techniques and procedures commonly understood by those skilled in the art and / or employed using conventional methodologies, such as those widely used, for example, as described in the following literature: Sambrook et al., Molecular Cloning: A Laboratory Manual (3rd edition, 2001); Current Protocols in Molecular Biology (edited by Ausubel et al., 2003); Therapeutic Monoclonal Antibodies: From Bench to Clinic (edited by An, 2009); Monoclonal Antibodies: Methods and Protocols (edited by Albitar, 2010); and Antibody Engineering, Volumes 1 and 2 (edited by Kontermann and Dübel, 2nd edition, 2010). Unless otherwise defined herein, the technical and scientific terms used in this specification have the meanings commonly understood by those skilled in the art. For the purposes of interpreting this specification, the following description of the terminology will apply, and whenever appropriate, terms used in the singular will also include the plural form, and vice versa. In the event of any conflict between any description of the terminology set forth and any reference incorporated herein by reference, the description of the terminology set forth below shall prevail.
[0100] As used herein, the term “binding agent” or its grammatical equivalent refers to an antigen having one or more binding antigens.A molecule that binds to a binding site (e.g., an antibody). In some embodiments, the ACVR2B binder as described herein is an antibody (including antibody fragments, such as antigen-binding fragments or epitope-binding fragments) that binds to ACVR2B (such as human ACVR2B) or other peptide-based molecules, as well as conjugates of antibodies, antibody fragments, or peptide-based molecules (e.g., antibody-drug conjugates).
[0101] The terms “antibody,” “immunoglobulin,” or “Ig” are used interchangeably herein and in the broadest sense, and specifically cover, for example, monoclonal antibodies (including agonists, antagonists, neutralizing antibodies, full-length or intact monoclonal antibodies), antibody compositions having multi-epitope or single-epitope specificity, polyclonal or monovalent antibodies, multivalent antibodies, multispecific antibodies formed from at least two intact antibodies (e.g., bispecific antibodies, provided they exhibit the desired biological activity), single-chain antibodies, and fragments thereof (e.g., domain antibodies), as described below. Antibodies can be human, humanized, chimeric, and / or affinity-mature, as well as antibodies from other species (e.g., mice, rabbits, llamas, etc.). The term "antibody" is intended to include B-cell polypeptide products within the immunoglobulin class that are capable of binding specific molecular antigens and consist of two pairs of identical polypeptide chains, each pair having a heavy chain (approximately 50 kDa–70 kDa) and a light chain (approximately 25 kDa). Each amino-terminal portion of each chain includes a variable region of approximately 100 to approximately 130 or more amino acids, and each carboxyl-terminal portion of each chain includes a constant region. See, for example, Antibody Engineering (Borrebaeck, ed., 2nd ed., 1995); and Kuby, Immunology (3rd ed., 1997). Antibodies also include, but are not limited to, synthetic antibodies, recombinant antibodies, antibodies from Camelidae species (e.g., llamas or alpacas) or their humanized variants, intracellular antibodies, anti-idiotypic (anti-Id) antibodies, and functional fragments (e.g., antigen-binding fragments) of any of the antibodies described above, whereby the functional portion refers to a portion of an antibody heavy or light chain polypeptide that retains some or all of the binding activity of the antibody from which the fragment is derived. Non-limiting examples of functional fragments (e.g., antigen-binding fragments) include single-chain Fv (scFv) (e.g., including monospecific, bispecific, etc.), Fab fragments, F(ab') fragments, F(ab)2 fragments, F(ab')2 fragments, disulfide-linked Fv (dsFv), Fd fragments, Fv fragments, biantibodies, triantibodies, tetraantibodies, and microantibodies. In particular, antibodies provided herein include immunoglobulin molecules and immunoglobulin molecules containing, for example, immunoglobulin molecules containing,An antigen-binding domain or molecule (e.g., one or more CDRs of an antibody) that binds to an antigen-binding site. Such antibody fragments can be found, for example, in Harlow and Lane, *Antibodies: A Laboratory Manual* (1989); Mol. *Biology and Biotechnology: A Comprehensive Desk Reference* (edited by Myers, 1995); Huston et al., 1993, *Cell Biophysics* 22: 189–224; Plückthun and Skerra, 1989, *Meth. Enzymol.* 178: 497–515; and Day, *Advanced Immunochemistry* (2nd edition, 1990). The antibodies described herein can be any class of immunoglobulin molecules (e.g., IgG, IgE, IgM, IgD, and IgA) or any subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2). Antibodies can be agonist or antagonist. Antibodies may be neither agonist nor antagonist.
[0102] When used to refer to a conjugate (e.g., an antibody) as used herein, the term “single-specific” means a conjugate having one or more binding sites, each binding to the same epitope of the same antigen.
[0103] When used to refer to a conjugate (e.g., an antibody), the term “multi-specific” means that the conjugate is capable of specifically binding to at least two different epitopes, such as two binding sites, each formed by a pair of antibody heavy chain variable domains (VH) and antibody light chain variable domains (VL), or each formed by a pair of VHH domains that bind to different antigens or different epitopes on the same antigen. Such bispecific conjugates (e.g., antibodies) may have a 1+1 form (comprising a binding site for a first antigen or epitope and a binding site for a second antigen or epitope). Other bispecific binders (e.g., antibodies) may be in a 2+1 or 1+2 form (containing two binding sites against a first antigen or epitope and one binding site against a second antigen or epitope) or a 2+2 form (containing two binding sites against a first antigen or epitope and two binding sites against a second antigen or epitope). When a bispecific binder (e.g., an antibody) contains two antigen binding sites, each antigen binding site may bind to a different epitope. Such bispecific binders (e.g., antibodies) may bind to two different epitopes on the same antigen (e.g., an epitope on ACVR2B).
[0104] In the context of two or more nucleic acids or peptides, the term "identical" or "identity" percentage refers to when compared toWhen comparing and aligning (introducing gaps if necessary) for maximum correspondence, any conserved amino acid substitutions are not considered as part of sequence identity, and two or more sequences or subsequences are identical or have a specified percentage of identical nucleotide or amino acid residues. The percentage of identity can be measured using sequence comparison software or algorithms or by visual inspection. Various algorithms and software available for obtaining amino acid or nucleotide sequence alignments are well known in the art. These include, but are not limited to, BLAST, ALIGN, Megalign, BestFit, the GCG Wisconsin package, and variants thereof. In some embodiments, the two nucleic acids or peptides are substantially identical, meaning that when comparing and aligning for maximum correspondence, they have at least 70%, at least 75%, at least 80%, at least 85%, or at least 90%, and in some embodiments at least 95%, 96%, 97%, 98%, or 99% nucleotide or amino acid residue identity, as measured using sequence comparison algorithms or by visual inspection. In some embodiments, identity exists in regions of amino acid sequences of at least about 10 residues, at least about 20 residues, at least about 40-60 residues, at least about 60-80 residues, or any integer value therebetween. In some embodiments, identity exists in regions longer than 60-80 residues (e.g., at least about 80-100 residues), and in some embodiments, the sequences are substantially identical along the full length of the compared sequences (e.g., the coding region of a target protein or antibody). In some embodiments, identity exists in regions of nucleotide sequences of at least about 10 bases, at least about 20 bases, at least about 40-60 bases, at least about 60-80 bases, or any integer value therebetween. In some embodiments, identity exists in regions longer than 60-80 bases (such as at least about 80-1000 bases or more), and in some embodiments, the sequences are substantially identical along the full length of the sequences being compared (such as nucleotide sequences encoding proteins of interest).
[0105] "Conservative amino acid substitution" refers to the substitution in which one amino acid residue is replaced by another amino acid residue having a similar chemical signature side chain. Families of amino acid residues with similar side chains are generally defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), β-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).(Acid). For example, phenylalanine replacing tyrosine is a conserved substitution. Generally, conserved substitutions in the sequences of polypeptides, soluble proteins, and / or antibodies of this disclosure do not eliminate the binding of the polypeptide, soluble protein, or antibody containing the amino acid sequence to the target binding site. Methods for identifying conserved substitutions of amino acids that do not eliminate binding are well known in the art.
[0106] The term “polypeptide” refers to a polymer of amino acids of any length. The polymer may be linear or branched, may contain modified amino acids, and may contain non-amino acids (e.g., interrupted by non-amino acids). The term also covers amino acid polymers that have been naturally modified or modified by intervention; for example, disulfide bond formation, glycosylation, esterification, acetylation, phosphorylation, or any other operation or modification, such as direct or indirect linking or conjugation to a portion such as a labeled component or a drug (e.g., a toxin). The definition also includes, for example, polypeptides containing one or more amino acid analogs (including, for example, non-natural amino acids) and other modifications known in the art. It should be understood that because the polypeptides of this disclosure can be based on antibodies or other members of the immunoglobulin superfamily, in some embodiments, the polypeptides can exist as a single chain or as a single-chain dimer.
[0107] An “antigen” is a structure that an antibody can selectively bind to. A target antigen can be a polypeptide, carbohydrate, nucleic acid, lipid, hapten, or other naturally occurring or synthetic compound. In some embodiments, the target antigen is a polypeptide. In some embodiments, the antigen is cell-associated, for example, present on or within a cell.
[0108] An “intact” antibody is an antibody that includes an antigen-binding site as well as CL and at least heavy chain constant regions CH1, CH2, and CH3. The constant regions can include human constant regions or amino acid sequence variants thereof. In some embodiments, an intact antibody has one or more effector functions.
[0109] The terms “binds” or “binding” refer to interactions between molecules, including, for example, forming a complex. Interactions can be, for example, non-covalent interactions, including hydrogen bonds, ionic bonds, hydrophobic interactions, and / or van der Waals interactions. Complexes can also comprise the binding of two or more molecules held together by covalent or non-covalent bonds, interactions, or forces. The strength of the total non-covalent interaction between a single antigen-binding site on an antibody and a single epitope of a target molecule (such as an antigen) is the affinity of the antibody or functional fragment for that epitope. The ratio (koff / kon) of the dissociation rate of a binding molecule (e.g., an antibody) to the association rate of a monovalent antigen is the dissociation constant KD, which is negatively correlated with affinity. The lower the KD value, the higher the affinity of the antibody. The value of KD varies for different antibody and antigen complexes and depends on both kon and koff. The dissociation constant KD of antibodies provided herein can be obtained using any of the methods provided herein or this document.Any other method known to those skilled in the art can be used to determine it. Affinity at a binding site does not always reflect the true strength of the interaction between the antibody and the antigen. When a complex antigen containing multiple repeating antigenic determinants (such as a multivalent antigen) comes into contact with an antibody containing multiple binding sites, the interaction between the antibody and the antigen at one site will increase the likelihood of a reaction at a second site. The strength of such multiple interactions between a multivalent antibody and an antigen is called affinity.
[0110] Regarding the binding molecules described herein, terms such as “bind to,” “specifically bind to,” and similar terms are used interchangeably herein and refer to a binding molecule or antigen-binding domain that specifically binds to an antigen (such as a polypeptide). A binding molecule or antigen-binding domain that binds to or specifically binds to an antigen can be identified, for example, by immunoassay, Octet®, Biacore®, or other techniques known to those skilled in the art. In some embodiments, when a binding molecule or antigen-binding domain binds to an antigen with a higher affinity than binding to any cross-reactive antigen, the binding molecule or antigen-binding domain binds or specifically binds to the antigen, as determined using experimental techniques such as enzyme-linked immunosorbent assay (ELISA). Typically, the specific or selective reaction will be at least twice the background signal or noise, and can be more than 10 times the background. For a discussion of binding specificity, see, for example, Fundamental Immunology 332-36 (Paul, ed., 2nd ed., 1989). In some embodiments, the degree to which the binding molecule or antigen-binding domain binds to a “non-target” protein is less than about 10% of the binding of the binding molecule or antigen-binding domain to its specific target antigen, for example, as determined by fluorescence activated cell sorting (FACS) analysis. Binding molecules or antigen-binding domains that bind to antigens include those that bind to antigens with sufficient affinity such that the binding molecule can be used as, for example, a therapeutic agent and / or diagnostic agent targeting the antigen. In some embodiments, the binding molecule or antigen-binding domain that binds to the antigen has a dissociation constant (KD) less than or equal to 1 µM, 800 nM, 600 nM, 550 nM, 500 nM, 300 nM, 250 nM, 100 nM, 50 nM, 10 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, or 0.1 nM. In some embodiments, the binding molecule or antigen-binding domain binds to a conserved epitope of an antigen from antigens from different species.
[0111] "Binding affinity" generally refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., a binder, such as an antibody) and its binding partner (e.g., an antigen, such as ACVR2B). Unless otherwise specified, as used herein, "binding affinity" refers to the inherent binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a binding molecule X for its binding partner Y is generally expressed by a dissociation constant (KD). Affinity can be measured by conventional methods known in the art, including those described herein. Low-affinity antibodies typically bind antigens slowly and tend to dissociate readily, while high-affinity antibodies typically bind antigens more quickly and tend to remain bound for longer periods. A variety of methods for measuring binding affinity are known in the art, any of which can be used for the purposes of this disclosure. In one embodiment, "KD" or "KD value" can be measured by biological layer interferometry (BLI) using, for example, an OctetQK384 system (ForteBio, Menlo Park, CA). Alternatively, KD can also be measured in radiolabeled antigen binding assays (RIA), for example, with the Fab form of the antibody of interest and its antigen (Chen et al., (1999) J. Mol Biol 293: 865-881) or using surface plasmon resonance (SPR) assays via Biacore™ using, for example, Biacore™-2000 or Biacore™-3000 (Biacore™, Inc., Piscataway, NJ). “On-rate” or “rate of association” or “association rate” or “kon” and “off-rate” or “rate of dissociation” or “dissociation rate” or “koff” can also be determined using the same SPR or BLI techniques described above, for example using the Octet QK384 system (ForteBio, Menlo Park, CA) or the Biacore™-2000 or Biacore™-3000 (Biacore™, Inc., Piscataway, NJ).
[0112] When used in the context of ACVR2B binders (e.g., antibodies), the term “competition” or any grammatical variation thereof means binders competing for the same epitope or binding site on a target, including competition between such binders as determined by assay, wherein the binder under study prevents or inhibits the binding of a reference molecule (e.g., a reference ligand or reference antigen).The specific binding of a protein (such as a reference antibody) to a common antigen (e.g., ACVR2B). Numerous types of competitive binding assays can be used to determine whether a test binder competes with a reference molecule for binding to ACVR2B (e.g., human ACVR2B). Examples of assays that may be used include solid-phase direct or indirect radioimmunoassays (RIA); solid-phase direct or indirect enzyme immunoassays (EIA); sandwich competitive assays (see, for example, Stahli et al., (1983) Methods in Enzymology 9: 242–253); solid-phase direct biotin-avidin EIA (see, for example, Kirkland et al., (1986) J. Immunol. 137: 3614–3619 or Cheung et al., (1990) Virology 176: 546–552); solid-phase direct labeling assays; solid-phase direct labeling sandwich assays (see, for example, Harlow and Lane, (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Pres); solid-phase direct labeling RIAs using I-125 labeling (see, for example, Morel et al., (1988) Molec. Immunol. 25: 7–15); and directly labeled RIAs (Moldenhauer et al., (1990) Scand. J. Immunol. 32: 77–82). Typically, such assays involve using a purified antigen (e.g., ACVR2B, such as human ACVR2B) bound to a solid surface or cell carrying an unlabeled test antigen-binding protein (e.g., a test ACVR2B antibody) or a labeled reference antigen-binding protein (e.g., a reference ACVR2B antibody). Competitive inhibition can be measured by determining the amount of label bound to the solid surface or cell in the presence of the test antigen-binding protein. Typically, an excess of the test antigen-binding protein is present. Antibodies identified by competitive assays (competitive antibodies) include antibodies that bind to the same epitope as the reference antibody and / or antibodies that bind to an adjacent epitope sufficiently close to the epitope bound by the reference antibody to cause antibody steric hindrance (e.g., similar epitopes or overlapping epitopes). Typically, when an excess of competing antibody is present, it will inhibit the specific binding of the reference antibody to the common antigen by at least 20%, such as at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75%. In some cases, binding is inhibited by at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more.
[0113] In some embodiments, the binding molecule or antigen-binding domain may include a “chimeric” sequence in which a portion of the heavy and / or light chain is identical or homologous to a corresponding sequence in an antibody derived from a specific species or belonging to a specific antibody class or subclass, while the remainder of the chain is identical or homologous to a corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, provided they exhibit the desired biological activity (see U.S. Patent No. 4,816,567; and Morrison et al., 1984, Proc. Natl. Acad. Sci. USA 81: 6851–55). The chimeric sequence may include a humanized sequence.
[0114] In some embodiments, the binding molecule or antigen-binding domain may comprise a portion of a “humanized” form of a non-human (e.g., camel, murine, or non-human primate) antibody, which comprises a sequence from a human immunoglobulin (e.g., a recipient antibody) wherein native CDR residues are replaced by residues of the corresponding CDR from a non-human species (e.g., a donor antibody) having the desired specificity, affinity, and capability. In some cases, one or more FR region residues of a human immunoglobulin sequence are replaced by corresponding non-human residues. Furthermore, the humanized antibody may contain residues not found in the recipient antibody or in the donor antibody. These modifications are made to further optimize antibody performance. The heavy or light chain of the humanized antibody may comprise substantially all of at least one or more variable regions, wherein all or substantially all of the CDRs correspond to those CDRs of the non-human immunoglobulin, and all or substantially all of the FRs are those FRs of the human immunoglobulin sequence. In some implementations, the humanized antibody will contain at least a portion of the immunoglobulin constant region (Fc), typically the constant region of human immunoglobulins. For further details, see Jones et al., Nature 321: 522–25 (1986); Riechmann et al., Nature 332: 323–29 (1988); Presta, Curr. Op. Struct. Biol. 2: 593–96 (1992); Carter et al., Proc. Natl. Acad. Sci. USA 89: 4285–89 (1992); U.S. Patents 6,800,738, 6,719,971, 6,639,055, 6,407,213, and 6,054,297.
[0115] In some embodiments, the binding molecule or antigen-binding domain may comprise a "fully human antibody" or a "human antibody". (Specification 13 / 108 pages, 21 CN 121909215 A)The term is used interchangeably herein and refers to an antibody containing a human variable region and, for example, a human constant region. The binding molecule may contain an antibody sequence. In a particular embodiment, the term refers to an antibody containing a human-derived variable region and a constant region. In some embodiments, a “fully human” antibody may also encompass an antibody that binds a polypeptide and is encoded by a nucleic acid sequence that is a naturally occurring somatic variant of a human immunoglobulin nucleic acid sequence. The term “fully human antibody” includes antibodies having variable and constant regions corresponding to human immunoglobulin sequences as described by Kabat et al. (see Kabat et al. (1991) Sequences of Proteins of Immunological Interest, 5th ed., US Department of Health and Human Services, NIH Publication No. 91-3242). A “human antibody” is an antibody having an amino acid sequence corresponding to that of an antibody produced by humans and / or an amino acid sequence produced using any technology for producing human antibodies. This definition of a human antibody specifically excludes humanized antibodies containing non-human antigen-binding residues. Human antibodies can be produced using a variety of techniques known in the art, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol. 227: 381 (1991); Marks et al., J. Mol. Biol. 222: 581 (1991)) and yeast display libraries (Chao et al., Nature Protocols 1: 755–68 (2006)). Methods for preparing human monoclonal antibodies are also described in Cole et al., Monoclonal Antibodies and Cancer Therapy 77 (1985); Boerner et al., J. Immunol. 147 (1): 86–95 (1991); and van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5: 368–74 (2001). Human antibodies can be prepared by administering antigens to transgenic animals that have been modified to produce such antibodies in response to antigen stimulation but whose endogenous loci have been disabled, such as mice (for XENOMOUSE™ technology, see, for example, Jakobovits, Curr. Opin. Biotechnol. 6(5): 561–66 (1995); Brüggemann and Taussing, Curr. Opin. Biotechnol. 8(4):455-58 (1997); and U.S. Patent Nos. 6,075,181 and 6,150,584. For information on human antibodies produced via human B-cell hybridoma technology, see also, for example, Li et al., Proc. Natl. Acad. Sci. USA 103: 3557-62 (2006).
[0116] In some embodiments, the binding molecule or antigen-binding domain may include the term “recombinant human antibody,” wherein the phrase includes human antibodies prepared, expressed, generated, or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into host cells, antibodies isolated from a recombinant combined human antibody library, antibodies isolated from transgenic and / or transchromosomally transgenic animals (e.g., mice or cattle) for which the human immunoglobulin gene is transgenic (see, for example, Taylor, LD et al., Nucl. Acids Res. 20: 6287–6295 (1992)), or antibodies prepared, expressed, generated, or isolated by any other means involving splicing a human immunoglobulin gene sequence into another DNA sequence. Such recombinant human antibodies may have variable and constant regions derived from human germline immunoglobulin sequences (see Kabat, E.A. et al. (1991) Sequences of Proteins of Immunological Interest, 5th ed., US Department of Health and Human Services, NIH Publication No. 91–3242). However, in some embodiments, such recombinant human antibodies are mutagenized in vitro (or, when using animals that are transgenic for human Ig sequences, in vivo somatic cell mutagenesis), so that the amino acid sequences of the VH and VL regions of the recombinant antibody are sequences that, while derived from and associated with human germline VH and VL sequences, may not be naturally present in a human antibody germline library in vivo.
[0117] In some embodiments, the binding molecule or antigen-binding domain may comprise a portion of a “monoclonal antibody,” wherein the term as used herein refers to an antibody obtained from a substantially homogeneous group of antibodies, for example, the individual antibodies constituting the group are identical except that, in small amounts, possibly naturally occurring mutations or well-known post-translational modifications, such as amino acid isomerization or deamidation, methionine oxidation or asparagine or glutamine deamidation, each monoclonal antibody will typically recognize a single epitope on the antigen. In specific embodiments, a “monoclonal antibody” as used herein is an antibody produced from a single hybridoma or other cell. The term “monoclonal” is not limited to any particular method used to prepare the antibody. Example instruction manual, page 14 / 108, 22 CN 121909215 AFor example, monoclonal antibodies that can be used in this disclosure can be prepared by the hybridoma methodology first described by Kohler et al., Nature 256: 495 (1975), or can be prepared using recombinant DNA methods in bacterial cells, eukaryotic animal cells, or eukaryotic plant cells (see, for example, U.S. Patent No. 4,816,567). For example, “monoclonal antibodies” can also be isolated from phage antibody libraries using techniques described in Clackson et al., Nature 352: 624-28 (1991) and Marks et al., J. Mol. Biol. 222: 581-97 (1991). Other methods for preparing clonal cell lines and monoclonal antibodies expressed therefrom are well known in the art. See, for example, Short Protocols in Molecular Biology (edited by Ausubel et al., 5th edition, 2002).
[0118] A typical 4-chain antibody unit is a heterotetrameric glycoprotein consisting of two identical light (L) chains and two identical heavy (H) chains. In the case of IgG, this 4-chain unit is typically about 150,000 Daltons. Each L chain is linked to the H chain by a covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds depending on the H chain isoform. Each H and L chain also has regularly spaced intrachain disulfide bridges. Each H chain has a variable domain (VH) at its N-terminus, followed by three constant domains (CH) for each α and γ chain, and four CH domains for the μ and ε isoforms. Each L chain has a variable domain (VL) at its N-terminus, followed by a constant domain (CL) at its other end. The VL is aligned with the VH, and the CL is aligned with the first constant domain (CH1) of the heavy chain. Specific amino acid residues are believed to form an interface between the variable domains of the light and heavy chains. The pairing of VH and VL together forms a single antigen-binding site. For the structure and properties of different classes of antibodies, see, for example, Basic and Clinical Immunology 71 (edited by Stites et al., 8th edition, 1994); and Immunobiology (edited by Janeway et al., 5th edition, 2001).
[0119] The term “Fab” or “Fab region” refers to the antibody region that binds to the antigen. Conventional IgG typically contains two Fab regions, each located on one of the two arms of the Y-shaped IgG structure. Each Fab region typically consists of a variable region and a constant region for each heavy chain and light chain. More specifically, the variable and constant regions of the heavy chain in the Fab region are the VH and CH1 regions, and the variable and constant regions of the light chain in the Fab region are the VL and CL regions. The VH, CH1, VL, and CL regions in the Fab region can beVarious arrangements are made to impart antigen-binding capability according to this disclosure. For example, the VH and CH1 regions may be on one polypeptide, and the VL and CL regions may be on separate polypeptides, similar to the Fab region of conventional IgG. Alternatively, the VH, CH1, VL, and CL regions may all be on the same polypeptide and oriented in different orders, as described in more detail below.
[0120] The terms “variable region,” “variable domain,” “V region,” or “V domain” refer to a portion of the light or heavy chain of an antibody that is typically located at the amino terminus of the light or heavy chain and has a length of about 120 to 130 amino acids in the heavy chain and about 100 to 110 amino acids in the light chain, and are used for the binding and specificity of each particular antibody to its particular antigen. The variable region of the heavy chain may be referred to as “VH.” The variable region of the light chain may be referred to as “VL.” The term “variable” refers to the fact that certain segments of the variable region differ widely in sequence between antibodies. The V region mediates antigen binding and defines the specificity of a particular antibody to its particular antigen. However, the variability is not uniformly distributed across the 110 amino acid span of the variable region. Instead, the V region consists of less variable (e.g., relatively constant) extensions of about 15 to 30 amino acids called framework regions (FRs), which are separated by shorter, more variable (e.g., extremely variable) regions, each about 9 to 12 amino acids long, called “hypervariates.” The variable regions of both the heavy and light chains each contain four FRs, predominantly in a β-sheet configuration, connected by three hypervariates that form loops connecting the β-sheet structure and, in some cases, form part of the β-sheet structure. The hypervariates in each chain are held together closely by the FRs and, together with hypervariates from the other chain, contribute to the formation of the antigen-binding site of the antibody (see, for example, Kabat et al., Sequences of Proteins of Immunological Interest (5th ed., 1991)). Constant regions do not directly participate in antibody-antigen binding but exhibit various effector functions, such as antibody involvement in antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Variable regions vary widely in sequence between different antibodies. In a specific embodiment, the variable region is the human variable region described on page 15 / 108 of the specification, CN 121909215 A.
[0121] The terms “variable region residue numbering according to Kabat” or “amino acid position numbering as in Kabat” and their variations refer to the numbering system of heavy chain or light chain variable regions used in antibody compilation by Kabat et al., see above. Using this numbering system, the actual linear amino acid sequence may contain fewer or additional shortenings of the FR or CDR of the variable domain.The amino acid corresponding to the FR or CDR inserted into the variable domain. For example, the heavy chain variable domain may include a single amino acid insertion after residue 52 (according to Kabat residue 52a) and three inserted residues after residue 82 (e.g., according to Kabat residues 82a, 82b, and 82c, etc.). For a given antibody, the Kabat number of the residues can be determined by aligning the sequence of the homology region of the antibody sequence with the sequence of the “standard” Kabat number. When referring to residues in the variable domain, the Kabat numbering system (approximately residues 1-107 of the light chain and residues 1-113 of the heavy chain) is generally used (e.g., Kabat et al., see above). When referring to residues in the constant region of the immunoglobulin heavy chain, the “EU numbering system” or “EU index” is generally used (e.g., the EU index reported in Kabat et al., see above). “EU index as in Kabat” refers to the residue number of the human IgG 1 EU antibody. Other numbering systems have been described, such as AbM, Chothia, Contact, IMGT, and AHon.
[0122] When used to refer to antibodies, the term "heavy chain" refers to a polypeptide chain of approximately 50 kDa–70 kDa, wherein the amino-terminal portion comprises a variable region of approximately 120 to 130 or more amino acids, and the carboxyl-terminal portion comprises a constant region. Based on the amino acid sequence of the heavy chain's constant region, the constant region can be one of five different types (e.g., isotypes) known as alpha (α), delta (δ), epsilon (ε), gamma (γ), and muon (μ). The different heavy chains are of different sizes: α, δ, and γ contain approximately 450 amino acids, while μ and ε contain approximately 550 amino acids. When combined with light chains, these different types of heavy chains respectively produce five well-known classes (e.g., isotypes) of antibodies: IgA, IgD, IgE, IgG, and IgM, including four IgG subclasses, namely IgG1, IgG2, IgG3, and IgG4.
[0123] When used to refer to antibodies, the term "light chain" refers to a polypeptide chain of about 25 kDa, wherein the amino-terminal portion includes a variable region of about 100 to about 110 or more amino acids, and the carboxyl-terminal portion includes a constant region. The light chain is approximately 211 to 217 amino acids in length. There are two different types, based on the amino acid sequence of the constant domain, called Kappa (κ) or Lambda (λ).
[0124] As used herein, the terms "hypervariate region," "HVR," "complementarity-determining region," and "CDR" are used interchangeably. "CDR" refers to one of the three hypervariate regions (H1, H2, or H3) within the non-framework region of the VH β-sheet framework of an immunoglobulin (Ig or antibody), or one of the three hypervariate regions (L1, L2, or L3) within the non-framework region of the VL β-sheet framework of an antibody. CDR1, CDR2 in the VH domainCDR1, CDR2, and CDR3 are also referred to as HCDR1, HCDR2, and HCDR3, respectively. CDR1, CDR2, and CDR3 in the VL domain are also referred to as LCDR1, LCDR2, and LCDR3, respectively. Therefore, CDR is a sequence of variable regions scattered within the frame region sequence.
[0125] CDR regions are well known to those skilled in the art and have been defined by well-known numbering systems. For example, the Kabat complementarity determination region (CDR) is based on sequence variability and is the most commonly used (see, for example, Kabat et al., above; Nick Deschacht et al., J Immunol 2010; 184: 5696–5704). Chothia, on the other hand, refers to the location of the structural loop (see, for example, Chothia and Lesk, J. Mol. Biol. 196: 901–17 (1987)). When using the Kabat numbering rules, the end of the Chothia CDR-H1 loop varies between H32 and H34, depending on the loop length (this is because the Kabat numbering scheme places the insertions at H35A and H35B; if neither 35A nor 35B exists, the loop ends at 32; if only 35A exists, the loop ends at 33; if both 35A and 35B exist, the loop ends at 34). The AbM hypervariable region represents a compromise between the Kabat CDR and the Chothia structural loop and is used by the AbM antibody modeling software of Oxford Molecular (see, for example, Antibody Engineering, Vol. 2 (edited by Kontermann and Dübel, 2nd edition, 2010)). The “contact” hypervariable region is based on the analysis of available complex crystal structures. Another universal numbering system that has been developed and widely adopted is the ImMunoGeneTics (IMGT) Information System® (Lafranc et al., Dev. Comp. Immunol. 27(1): 55-77, manual 16 / 108 pages, 24 CN 121909215 A (2003)). IMGT is an integrated information system dedicated to immunoglobulins (IG), T-cell receptors (TCR), and major histocompatibility complex (MHC) in humans and other vertebrates. In this paper, CDR refers to both the amino acid sequence and its position within the light or heavy chain. Since the “position” of CDR within the structure of the variable domain of immunoglobulins is conserved across species and exists in structures called loops, CDRs and framework residues can be easily identified by using a numbering system that aligns the variable domain sequence according to structural features. This information can be used to transplant CDR residues of immunoglobulins from a species.And replaced into the acceptor frame typically derived from human antibodies. An additional numbering system (AHon) has been developed by Honegger and Plückthun, J. Mol. Biol. 309: 657-70 (2001). Correspondences between numbering systems (including, for example, the Kabat numbering and the IMGT unique numbering system) are well known to those skilled in the art (see, for example, Kabat, see above; Chothia and Lesk, see above; Martin, see above; Lefranc et al., see above). Residues from each of these hypervariable regions or CDRs are illustrated in Table 1 below.
[0126]
[0127] The boundaries of a given CDR can vary depending on the scheme used for identification. Therefore, unless otherwise stated, the terms “CDR” and “complementarity-determining region” for a given antibody or its regions (such as variable regions), and individual CDRs (e.g., CDR-H1, CDR-H2) of an antibody or its regions, should be understood to encompass complementarity-determining regions as defined above by any known scheme described herein. In some cases, a scheme for identifying a specific CDR or multiple CDRs (such as CDRs defined by the IMGT, Kabat, Chothia, or Contact methods) is described. In other cases, the specific amino acid sequence of the CDR is given. It should be noted that CDR areas can also be defined by combinations of various numbering systems (e.g., a combination of the Kabat and Chothia numbering systems or a combination of the Kabat and IMGT numbering systems). Therefore, terms such as “CDR1 as shown in a particular VH” include, but are not limited to, any CDR1 as defined by the exemplary CDR numbering systems described above. Once a variable area (e.g., VH or VL) is given, those skilled in the art will understand that CDRs within that area can be defined by different numbering systems or combinations thereof.
[0128] High-variable areas may include “extended high-variable areas” as follows: 24-36 or 24-34 (L1), 46-56 or 50-56 (L2) and 89-97 or 89-96 (L3) in VL, and 26-35 or 26-35A (H1), 50-65 or 49-65 (H2) and 93-102, 94-102 or 95-102 (H3) in VH.
[0129] The term "constant region" or "constant domain" refers to the carboxyl-terminal portion of the light and heavy chains, which does not directly participate in antibody-antigen binding but exhibits various effector functions, such as interaction with Fc receptors. This term refers to a portion of an immunoglobulin molecule with a more conserved amino acid sequence compared to other portions (i.e., variable regions) containing antigen-binding sites. Constant regions can contain the CH1, CH2, and CH3 regions of the heavy chain and the CL region of the light chain. (Specification 17 / 108 pages, 25 CN)121909215 A
[0130] The term “frame” or “FR” refers to those variable region residues flanking the CDR. FR residues are present in, for example, chimeric antibodies, humanized antibodies, human antibodies, domain antibodies, biantibodies, linear antibodies, and bispecific antibodies. FR residues are those variable domain residues other than hypervariable region residues or CDR residues.
[0131] The term “Fc region” is used herein to define the C-terminal region of the immunoglobulin heavy chain, including, for example, the native sequence Fc region, the recombinant Fc region, and the variant Fc region. Although the boundaries of the Fc region of the immunoglobulin heavy chain may vary, the human IgG heavy chain Fc region is generally defined as extending from an amino acid residue at position Cys226 or from Pro230 to its carboxyl terminus. The C-terminal lysine of the Fc region (residue 447 according to the EU numbering system) may be removed, for example, during antibody production or purification or by recombinantly engineering the nucleic acid encoding the antibody heavy chain. Therefore, a composition of a complete antibody can comprise an antibody population with all K447 residues removed, an antibody population without K447 residues removed, and an antibody population having a mixture of antibodies containing and not containing K447 residues. The “functional Fc region” has the “effective function” of the native sequence Fc region. Exemplary “effective functions” include C1q binding; CDC; Fc receptor binding; ADCC; phagocytosis; downregulation of cell surface receptors (e.g., B cell receptors), etc. Such effector functions typically require the Fc region to be combined with a binding region or binding domain (e.g., antibody variable region or domain) and can be evaluated using various assays known to those skilled in the art. The “native sequence Fc region” contains the same amino acid sequence as the naturally occurring Fc region and has not been manipulated, modified, and / or altered (e.g., isolated, purified, selected, including or combined with other sequences such as variable region sequences). The native sequence human Fc region includes the native sequence human IgG1 Fc region (non-A and A allotypes); the native sequence human IgG2 Fc region; the native sequence human IgG3 Fc region; and the native sequence human IgG4 Fc region and its naturally occurring variants. A “variant Fc region” comprises an amino acid sequence that differs from the amino acid sequence of the native sequence Fc region due to at least one amino acid modification (e.g., substitution, addition, or deletion). In some embodiments, the variant Fc region has at least one amino acid substitution compared to the native sequence Fc region or the Fc region of the parent peptide, for example, about one to about ten amino acid substitutions, or about one to about five amino acid substitutions, in the native sequence Fc region or the Fc region of the parent peptide. The variant Fc region herein may have at least about 80% homology with the native sequence Fc region and / or the Fc region of the parent peptide, or at least about 90% homology with it, for example, at least about 95% homology with it.
[0132] The terms “antigen-binding fragment,” “antigen-binding domain,” “antigen-binding region,” and similar terms refer to a portion of an antibody that contains amino acid residues (e.g., CDRs) that interact with an antigen and confer specificity and affinity to the antigen on the binding fragment, domain, or region. As used herein, “antigen-binding fragment” includes “antibody fragment” that contains a portion of an antibody, including one or more CDRs, such as an antigen-binding region or variable region of an antibody.
[0133] Antibodies described herein include, but are not limited to, synthetic antibodies, monoclonal antibodies, recombinant antibodies, multispecific antibodies (e.g., bispecific antibodies), human antibodies, humanized antibodies, chimeric antibodies, intracellular antibodies, single-chain Fv (scFv) (e.g., including monospecific, bispecific, etc.), camelified antibodies, Fab fragments, F(ab') fragments, disulfide-linked Fv (sdFv), anti-idiotype (anti-Id) antibodies, and epitope-binding fragments of any of the above.
[0134] In some embodiments, antibodies described herein include immunoglobulin molecules and immunoactive portions of immunoglobulin molecules, including molecules containing one or more antigen-binding sites that bind to the ACVR2B antigen.
[0135] The antibody can be any type (e.g., IgG, IgE, IgM, IgD, IgA, or IgY), any class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, or IgA2), or any subclass (e.g., IgG2a or IgG2b) of an immunoglobulin molecule. In some embodiments, the antibody described herein is an IgG antibody (e.g., human IgG) or its class (e.g., human IgG1, IgG2, IgG3, or IgG4) or subclass.
[0136] In some embodiments, the antibody is a 4-chain antibody unit comprising two heavy (H) chain / light (L) chain pairs. In another embodiment, the amino acid sequences of the H chains are identical, and the amino acid sequences of the L chains are identical. In other embodiments, the amino acid sequences of the H chains are different from each other. Additionally or alternatively, the amino acid sequences of the L chains are different from each other. In some embodiments, as described on page 18 / 108 of CN 121909215 A, the antibody comprises a first H / L chain pair and a second H / L chain pair, wherein the first H / L chain pair binds to an ACVR2B antigen, and the second H / L chain pair binds to another ACVR2B antigen or a non-ACVR2B antigen. In some embodiments, the antibody is a 2-chain antibody unit comprising a VHH-VHH pair. In other embodiments, the amino acid sequences of the VHHs are identical. In other embodiments, the amino acid sequences of the VHHs are different from each other. For example, the antibody comprises a first VHH and a second VHH, wherein the first VHH binds to an ACVR2B antigen, and the second VHH binds to another ACVR2B antigen or a non-ACVR2B antigen. In some embodiments...In this embodiment, the H and / or L chains contain constant regions, such as human constant regions. In some embodiments, the L chain constant region of such antibodies is a κ or λ light chain constant region, such as human κ or λ light chain constant regions. In some embodiments, the H chain constant region of such antibodies contains a γ heavy chain constant region, such as human γ heavy chain constant regions. In some embodiments, such antibodies contain IgG constant regions, such as human IgG constant regions (e.g., IgG1, IgG2, IgG3, and / or IgG4 constant regions).
[0137] Antibodies or fragments thereof may preferentially bind to ACVR2B (such as human ACVR2B), meaning that antibodies or fragments thereof bind to ACVR2B with a greater affinity than they bind to control proteins (e.g., unrelated control proteins, such as egg white lysozyme or ACVR2A), and / or bind to human ACVR2B with a greater affinity than they bind to unrelated control proteins. For example, antibodies or fragments thereof may specifically recognize and bind to ACVR2B or a portion thereof. "Specific binding" means that an antibody or fragment thereof binds to ACVR2B with an affinity of at least 5, 10, 15, 20, 25, 50, 100, 250, 500, 1000, or 10,000 times that of an unrelated control protein (e.g., egg white lysozyme). In some embodiments, the antibody or fragment thereof may bind to ACVR2B substantially exclusively (e.g., capable of distinguishing ACVR2B from other known peptides, for example, by measurable differences in binding affinity). In some embodiments, the ACVR2B binder (e.g., antibody) may react with ACVR2B sequences other than the human ACVR2B sequence (e.g., cynomolgus monkey ACVR2B sequence). In other embodiments, the ACVR2B binder (e.g., antibody) does not react with non-human sequences (such as cynomolgus monkey ACVR2B sequences).
[0138] As used herein, "epitope" is a term in the art and refers to a localized region of an antigen to which a binding molecule (e.g., antibody) may specifically bind. Epitopes can be linear epitopes or conformational, nonlinear, or discontinuous epitopes. In the case of peptide antigens, for example, an epitope can be a continuous amino acid of the peptide (“linear” epitope), or an epitope can comprise amino acids from two or more discontinuous regions of the peptide (“conformational,” “nonlinear,” or “discontinuous” epitopes). Those skilled in the art will understand that, in general, linear epitopes may or may not depend on secondary, tertiary, or quaternary structures. For example, in some embodiments, a binding molecule binds a set of amino acids regardless of whether they are folded in the native three-dimensional protein structure. In other embodiments, the binding molecule requires the amino acid residues constituting the epitope to exhibit a specific conformation (e.g., bending, twisting, flipping, or folding) in order to recognize and bind to the epitope.
[0139] When two antibodies recognize the same, overlapping, or adjacent epitopes in three-dimensional space, the antibody binds to the reference antibody “epitope”."Epitope" or "substantially identical epitope" or "identical epitope". The most widely used and rapid method for determining whether two antibodies bind to the same, overlapping or adjacent epitopes in three-dimensional space is a competitive assay, which can be configured in a variety of different forms, for example, using labeled antigens or labeled antibodies. In some assays, the antigen is immobilized on a 96-well plate or expressed on a cell surface, and radioactive, fluorescent or enzyme labeling is used to measure the ability of the unlabeled antibody to block the binding of the labeled antibody.
[0140] "Epitope binning" is the process of grouping antibodies based on the epitopes they recognize. More specifically, epitope binning includes methods and systems for distinguishing the epitope recognition characteristics of different antibodies, which use a competitive assay combined with a computational process to cluster antibodies based on their epitope recognition characteristics and identify antibodies with different binding specificities.
[0141] The "percentage of amino acid sequence identity (%)" and "homology" for peptide, polypeptide, or antibody sequences are defined as the percentage of amino acid residues in a candidate sequence that are identical to amino acid residues in a specific peptide or polypeptide sequence after sequence alignment, introducing gaps where necessary to achieve the maximum percentage of sequence identity, and without considering any conserved substitutions as part of sequence identity. Alignment for the purpose of determining the percentage of amino acid sequence identity can be performed in various ways within the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or MEGALIGN™ (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms required to achieve maximum alignment across the full length of the compared sequences.
[0142] The term "specificity" refers to the selective recognition of a specific epitope of an antigen by an antigen-binding protein. For example, natural antibodies are monospecific. The term "multispecific" as used herein means that an antigen-binding protein has two or more antigen-binding sites, wherein at least two antigen-binding sites bind different antigens. The term "bispecific" as used herein means that an antigen-binding protein has two different antigen-binding specificities. The term "monospecific" as used herein means that an antigen-binding protein has one or more binding sites, each binding the same antigen.
[0143] The term "valence" as used herein means that a specific number of binding sites are present in an antigen-binding protein. For example, a natural antibody or a full-length antibody has two binding sites and is divalent. Therefore, the terms "trivalent," "tetravalent," "pentavalent," and "hexavalent" mean that two, three, four, five, and six binding sites are present in an antigen-binding protein, respectively.
[0144] The terms “polypeptide” and “protein” are used interchangeably herein and refer to a polymer of amino acids of any length. The polymer may be linear or branched, may contain modified amino acids, and may be interrupted by non-amino acid components. The term also covers amino acid polymers that have been naturally modified or modified by intervention; for example, disulfide bond formation, glycosylation, esterification, acetylation, phosphorylation, or any other operation or modification. The definition also includes polypeptides containing, for example, one or more amino acid analogs (including, but not limited to, non-natural amino acids) and other modifications known in the art. It should be understood that because the polypeptides of this disclosure may be based on antibodies or other members of the immunoglobulin superfamily, in some embodiments, “polypeptide” may exist as a single chain or as two or more associated chains.
[0145] The terms “polynucleotide” or “nucleic acid” are used interchangeably herein and refer to a nucleotide polymer of any length and include DNA and RNA. Nucleotides may be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases and / or analogs thereof, or any substrate that may be incorporated into the polymer by DNA or RNA polymerase or by a synthetic reaction. Polynucleotides can contain modified nucleotides, such as methylated nucleotides and their analogues. As used herein, “oligonucleotide” refers to a short, usually single-stranded, synthetic polynucleotide whose length is typically, but not necessarily, less than about 200 nucleotides. The terms “oligonucleotide” and “polynucleotide” are mutually exclusive. The above description of polynucleotides also applies fully to oligonucleotides. Cells that produce the binding molecules of this disclosure can include parental hybridoma cells, as well as bacterial and eukaryotic host cells in which nucleic acids encoding antibodies have been introduced. Unless otherwise stated, the left-hand end of any single-stranded polynucleotide sequence disclosed herein is the 5' end; the left-hand direction of a double-stranded polynucleotide sequence is referred to as the 5' direction. The direction of 5' to 3' addition of the nascent RNA transcript is referred to as the transcription direction; a sequence region on the DNA strand having the same sequence as the RNA transcript, with the 5' end of the RNA transcript located at 5', is referred to as the “upstream sequence”; a sequence region on the DNA strand having the same sequence as the RNA transcript, with the 3' end of the RNA transcript located at 3', is referred to as the “downstream sequence”.
[0146] "Isolated nucleic acid" is a nucleic acid (e.g., RNA, DNA, or a mixture of nucleic acids) that is substantially isolated from other genomic DNA sequences and proteins or complexes (such as ribosomes and polymerases) that naturally accompany the natural sequence. An "isolated" nucleic acid molecule is a nucleic acid molecule that is isolated from other nucleic acid molecules present in the natural source of that nucleic acid molecule. Furthermore, "isolated" nucleic acid molecules (such as cDNA molecules) may be substantially free of other cellular material or culture medium when produced by recombinant technology.Alternatively, when chemically synthesized, it may be substantially free of chemical precursors or other chemicals. In a specific embodiment, one or more nucleic acid molecules encoding antibodies as described herein are isolated or purified. This term includes nucleic acid sequences that have been removed from their natural environment and includes recombinant or cloned DNA isolates and chemically synthesized analogs or analogs biosynthesized by heterologous systems specification 20 / 108 pages 28 CN 121909215 A. A substantially pure molecule may include the isolated form of the molecule. Specifically, an “isolated” nucleic acid molecule encoding an antibody as described herein is a nucleic acid molecule identified and isolated from at least one contaminating nucleic acid molecule that is normally associated with it in the environment in which it is produced.
[0147] Unless otherwise stated, a “nucleotide sequence encoding an amino acid sequence” includes all nucleotide sequences that are degenerate to each other and encode the same amino acid sequence. A nucleotide sequence encoding a protein or RNA phrase may also include introns to such an extent that a nucleotide sequence encoding a protein may contain introns in some forms.
[0148] The term “control sequence” refers to a DNA sequence necessary for the expression of an operablely linked coding sequence in a particular host organism. For example, control sequences suitable for use in prokaryotes include promoters, optionally operon sequences, and ribosome binding sites. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
[0149] As used herein, the term “operably linked” and similar phrases (e.g., gene fusion), when used to refer to nucleic acids or amino acids, refer to the operably linked nucleic acid sequences or amino acid sequences that are in a functional relationship with each other. For example, an operably linked promoter, enhancer element, open reading frame, 5' and 3' UTR, and terminator sequence results in the accurate production of a nucleic acid molecule (e.g., RNA). In some embodiments, an operably linked nucleic acid element results in the transcription of an open reading frame and ultimately the production of a polypeptide (i.e., expression of an open reading frame). As another example, an operably linked peptide is a peptide in which functional domains are positioned at appropriate distances from each other to confer the intended function of each domain.
[0150] The term “vector” refers to a substance used to carry or include a nucleic acid sequence (including, for example, a nucleic acid sequence encoding a binding molecule (e.g., an antibody) as described herein) for the purpose of introducing the nucleic acid sequence into a host cell. Suitable vectors include, for example, expression vectors, plasmids, phage vectors, viral vectors, episomes, and artificial chromosomes, which may include selectable sequences or markers operable for stable integration into the host cell chromosome. Additionally, the vector may include one or more selectable marker genes and appropriate expression control sequences. Selectable marker genes may include, for example, providing resistance to antibiotics or toxins, supplementing auxotrophic deficiencies, or supplying critical nutrients not present in the culture medium. Expression control sequences may include components...Inducible and inducible promoters, transcription enhancers, transcription terminators, etc., are well known in the art. When two or more nucleic acid molecules are to be co-expressed (e.g., both the heavy and light chains of an antibody or both VH and VL of an antibody), the two nucleic acid molecules can be inserted, for example, into a single expression vector or separate expression vectors. For single vector expression, the encoding nucleic acid can be operatively ligated to a common expression control sequence or to different expression control sequences, such as an inducible promoter and a constitutive promoter. The introduction of the nucleic acid molecule into the host cell can be confirmed using methods well known in the art. Such methods include, for example, nucleic acid analysis (such as Northern blotting or polymerase chain reaction (PCR) amplification of mRNA), immunoblotting of gene product expression, or other suitable analytical methods for testing the expression of the introduced nucleic acid sequence or its corresponding gene product. Those skilled in the art will understand that nucleic acid molecules are expressed in an amount sufficient to produce the desired product, and will also understand that expression levels can be optimized using methods well known in the art to obtain sufficient expression.
[0151] As used herein, the term “host” refers to an animal, such as a mammal (e.g., a human).
[0152] As used herein, the term “host cell” refers to a specific test cell that can be transfected with a nucleic acid molecule, as well as the progeny or potential progeny of such cells. The progeny of such cells may differ from the parent cells transfected with the nucleic acid molecule due to mutations or environmental influences that may occur in subsequent generations or during the integration of the nucleic acid molecule into the host cell genome.
[0153] As used herein, the terms “transfected,” “transformed,” or “transduced” refer to the process of transferring or introducing exogenous nucleic acids into a host cell. “Transfected,” “transformed,” or “transduced” cells are cells that have been transfected, transformed, or transduced with exogenous nucleic acids. These cells include primary test cells and their progeny.
[0154] As used herein, the term “pharmaceutical acceptable” means approved by a federal or state regulatory agency, or listed in the United States Pharmacopeia, the European Pharmacopeia, or other generally recognized pharmacopoeias for use in animals and more specifically in humans.
[0155] “Excipient” means a pharmaceutically acceptable material, composition, or medium, such as a liquid or solid filler, diluent, solvent, or encapsulating material. Excipients include, for example, encapsulating materials or additives, such as absorption enhancers, antioxidants, binders, buffers, carriers, coatings, colorants, diluents, disintegrants, emulsifiers, swelling agents, fillers, flavorings, humectants, lubricants, fragrances, preservatives, propellants, release agents, bactericides, sweeteners, solubilizers, wetting agents, and mixtures thereof.The term “excipient” can also refer to a diluent, adjuvant (e.g., Freund’s adjuvant (complete or incomplete)) or mediator.
[0156] In some embodiments, the excipient is a pharmaceutically acceptable excipient. Examples of pharmaceutically acceptable excipients include buffers such as phosphates, citrates and other organic acids; antioxidants, including ascorbic acid; low molecular weight (e.g., fewer than about 10 amino acid residues) peptides; proteins such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates, including glucose, mannose or dextrin; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or nonionic surfactants such as TWEEN™, polyethylene glycol (PEG) and PLURONICS™. Other examples of pharmaceutically acceptable excipients are described in Remington and Gennaro, Remington's Pharmaceutical Sciences (18th edition, 1990).
[0157] In one embodiment, each component is "pharmaceutically acceptable" in the sense of compatibility with other components of the pharmaceutical formulation and is suitable for contact with human or animal tissues or organs without excessive toxicity, irritation, allergic reactions, immunogenicity or other problems or complications, in proportion to a reasonable benefit / risk ratio. See, for example, Lippincott Williams & Wilkins: Philadelphia, PA, 2005; Handbook of Pharmaceutical Excipients, 6th edition; edited by Rowe et al.; The Pharmaceutical Press and the American Pharmaceutical Association: 2009; Handbook of Pharmaceutical Additives, 3rd edition; edited by Ash and Ash; Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, 2nd edition; edited by Gibson; CRC Publishing Ltd: Boca Raton, FL, 2009. In some embodiments, the pharmaceutically acceptable excipient is non-toxic to cells or mammals exposed to it at the doses and concentrations used. In some embodiments, the pharmaceutically acceptable excipient is a pH-buffered aqueous solution.
[0158] In some embodiments, the excipients are sterile liquids, such as water and oils, including oils of petroleum, animal, plant, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Water is an exemplary excipient when the composition (e.g., a pharmaceutical composition) is administered intravenously. Saline solutions and aqueous solutions of glucose and glycerol can also be used as liquid excipients, particularly for injectable solutions. Excipients may also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, skim milk powder, glycerol, propylene, ethylene glycol, water, ethanol, etc. If desired, the composition may also contain small amounts of wetting agents or emulsifiers, or pH buffers. The composition may be in the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations, etc. Oral compositions (including formulations) may include standard excipients such as pharmaceutical-grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, etc.
[0159] Compositions (including pharmaceutical compounds) may contain, for example, a conjugated molecule (e.g., an antibody) in isolated or purified form, and an appropriate amount of excipient.
[0160] The terms “effective amount” or “therapeutic effective amount” as used herein refer to an amount of antibody, or a therapeutic molecule comprising an agent and an antibody, or a pharmaceutical composition provided herein sufficient to produce the desired results.
[0161] The terms “subject” and “patient” are used interchangeably. As used herein, in some embodiments, a subject is a mammal, such as a non-primate or primate (e.g., a human). In a particular embodiment, a subject is a human. In one embodiment, a subject is a mammal diagnosed with a disease or condition (e.g., a human). In another embodiment, a subject is a mammal at risk of developing a disease or condition (e.g., a human).
[0162] "Administer" or "administration" means the act of injecting or otherwise physically delivering a substance present outside the body into a patient, such as by means of mucosal, intradermal, intravenous, intramuscular delivery and / or any other physical delivery method described herein or known in the art.
[0163] The term "treatment" or any grammatical variation thereof means reducing and / or improving the severity and / or duration of a given disease, condition or symptom and / or associated symptoms, such as (i) reducing, delaying or improving the progression or course of a given disease, condition or symptom, (ii) reducing, delaying or improving the recurrence, development or onset of a given disease, condition or symptom, and / or (iii) improving or enhancing the preventive or therapeutic effect of another therapy (e.g., a therapy other than the administration of the agent described herein).
[0164] "Effective preventive dose" is an amount of pharmaceutical composition that, when administered to a subject, will have the expected preventive effect (e.g., prevent or delay the onset (or recurrence) of a disease, condition, or symptom, or reduce the likelihood of the onset (or recurrence) of a disease, condition, or symptom or associated symptoms).
[0165] A complete therapeutic or preventive effect does not necessarily occur by administering a single dose and may occur only after a series of doses have been administered. Therefore, an effective preventive dose may be administered once or multiple times.
[0166] The terms "prevent," "preventing," and "prevention" refer to reducing the likelihood of the onset (or recurrence) of a disease, condition, symptom, or associated symptoms (e.g., diabetes or cancer).
[0167] As used herein, “delaying” cancer development means postponing, hindering, slowing, delaying, stabilizing, and / or postponing the development of the disease. This delay can be of varying lengths, depending on the history of the disease and / or the individual being treated. As will be apparent to those skilled in the art, a sufficient or significant delay can effectively cover prevention, as the individual does not develop the disease. Methods of “delaying” cancer development include reducing the likelihood of disease development and / or reducing the severity of the disease within a given timeframe compared to not using such methods. Such comparisons are typically based on clinical studies using a statistically significant number of individuals. Cancer development can be detected using standard methods, including but not limited to computed axial computed tomography (CAT scan), magnetic resonance imaging (MRI), abdominal ultrasound, coagulation tests, arteriography, or biopsy. Development can also refer to cancer progression that may initially be undetectable and includes occurrence, recurrence, and onset.
[0168] As used herein, “ACVR2B-associated disease or condition” refers to a disease or condition containing cells or tissues in which ACVR2B is expressed or overexpressed. In some embodiments, ACVR2B-associated disease or condition contains ACVR2B. Cells on which ACVR2B is abnormally expressed. In other embodiments, the ACVR2B-associated disease or condition comprises cells in which ACVR2B lacks at least one of its activities.
[0169] As used herein, “ACVR2B ligand-associated disease or condition” refers to a disease or condition comprising cells or tissues in which one or more ACVR2B ligands are expressed or overexpressed, the ACVR2B ligands including activins (such as activin A, activin B, activin AB, activin C, activin AC, and activin E), growth / differentiation factors (GDFs, such as GDF1, GDF3, GDF5, GDF6, GDF7, GDF8, GDF10, and GDF11), bone morphogenetic proteins (BMPs, such as BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8, BMP10, BMP11, BMP11, BMP12, BMP13, BMP14, BMP15, BMP16, BMP17, BMP18, BMP11, BMP10 ...1, BMP12, BMP13, BMP14, BMP15, BMP16, BMP17, BMP18, BMP10, BMP11, BMP12, BMP13, BMP14, BMP15, BMP16, BMP17, BMP18, BMP11, BMP12, BMP13, BMP14, BMP15, BMP16, BMP17, BMP18, BMP11, BMP(BMP4, BMP6, BMP7, BMP8a, BMP8b, BMP9, and BMP10). In some embodiments, ACVR2B ligand-associated diseases or conditions comprise cells in which one or more ACVR2B ligands are aberrantly expressed. In other embodiments, ACVR2B ligand-associated diseases or conditions comprise cells in which one or more ACVR2B ligands lack at least one of their activities. In other embodiments, ACVR2B ligand-associated diseases or conditions include abnormal levels of one or more ACVR2B ligand proteins in serum, plasma, or blood.
[0170] The terms “about” and “approximately” mean within 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less of a given value or range.
[0171] As used herein, comparative terms such as reduction, decrease, increase, or any grammatical variation thereof may refer to certain variations of the reference. In some embodiments, such a change may refer to a value approximately 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% higher than the reference, or approximately 1, 2, 3, 4, 5, 10, 20, 30, 40, or 100 times higher than the reference. In some embodiments, such a change may refer to approximately 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% higher than the reference.
[0172] As used in this disclosure and claims, the singular forms “a,” “an,” and “the / said” include the plural forms unless the context clearly indicates otherwise.
[0173] In some embodiments, the terms “first,” “second,” “third,” “fourth,” and similar terms in component names are used to distinguish and identify more than one component that shares a particular identity in its name. For example, “first antibody” and “second antibody” are used to distinguish two antibodies.
[0174] It should be understood that wherever the term “comprising” is used to describe an embodiment herein, other similar embodiments described as “consisting of” and / or “substantially consisting of” are also provided. It should also be understood that wherever the phrase “substantially consisting of” is used to describe an embodiment herein, other similar embodiments described as “consisting of” are also provided.
[0175] The term “between” as used in phrases such as “between A and B” or “between A and B” refers to a range including both A and B.
[0176] The term “and / or” as used herein in phrases such as “A and / or B” is intended to include both A and B; A or B; A (alone); and B (alone). Similarly, the term “and / or” as used in phrases such as “A, B and / or C” is intended to cover each of the following embodiments: A, B and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0177] The terms “optional” or “optionally” mean that the situation described below may or may not occur, and therefore the description includes the case in which the situation occurs and the case in which the situation does not occur.
[0178] 5.2. ACVR2B Binding Molecules
[0179] 5.2.1. Antibodies Binding to ACVR2B
[0180] In one aspect, this document provides antibodies capable of binding to ACVR2B. ACVR2B is a receptor that mediates the function of activins, which are members of the transforming growth factor-β (TGF-β) superfamily involved in a variety of biological processes. ACVR2B is a transmembrane serine-threonine kinase receptor that mediates signal transduction by forming heterodimeric complexes with various combinations of type I and type II receptors and ligands in a cell-specific manner. Type II receptors are primarily involved in ligand binding and include an extracellular ligand-binding domain, a transmembrane domain, and a cytoplasmic serine-threonine kinase domain. The nucleic acid and amino acid sequences of ACVR2B are known (see GCID: GC03P038453, HGNC: 174, NCBI Entrez Gene: 93, Ensembl: ENSG00000114739, OMIM®: 602730, and UniProtKB / Swiss-Prot: Q13705).
[0181] In some embodiments, this disclosure provides ACVR2B antibodies or antigen-binding fragments that can be used herein as reagents for therapeutic purposes. Exemplary antibodies include polyclonal antibodies, monoclonal antibodies, humanized antibodies, human antibodies, bispecific antibodies, and heteroconjugated antibodies, as well as variants of them having increased or decreased affinity or other properties.
[0182] In some embodiments, this document describes anti-ACVR2B antibodies or antigen-binding fragments that bind to ACVR2B, including ACVR2B polypeptides, ACVR2B polypeptide fragments, ACVR2B peptides, or ACVR2B epitopes. In some implementations, the anti-ACVR2B specification is 24 / 108 pages, 32 CN 121909215 A.An antibody is a human or humanized antibody (e.g., containing a human constant region) that binds to ACVR2B (including ACVR2B polypeptide, ACVR2B polypeptide fragment, ACVR2B peptide, or ACVR2B epitope). In some embodiments, an anti-ACVR2B antibody, such as a human ACVR2B antibody, may bind to ACVR2B expressed on the surface of mammalian (e.g., human) cells (including cells expressing ACVR2B). In some embodiments, an anti-ACVR2B antibody binds to ACVR2B extracellular epitopes exposed on cells. In some embodiments, an ACVR2B antibody that binds to ACVR2B (such as human ACVR2B or a portion thereof) is described herein. In some embodiments, ACVR2B is human ACVR2B. In some embodiments, an anti-ACVR2B antibody is a human ACVR2B antibody (e.g., an antibody that binds to human ACVR2B). In some embodiments, an ACVR2B antibody binds to both human and cynomolgus monkey ACVR2B. In other embodiments, an anti-ACVR2B antibody binds to human ACVR2B but not to cynomolgus monkey ACVR2B.
[0183] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein modulates one or more ACVR2B activities. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein is an antagonist antibody. In one embodiment, the antibody or antigen-binding fragment according to this disclosure is an ACVR2B antagonist that has no agonist activity or low agonist activity. In another embodiment, the antibody or functional fragment comprising the antigen-binding portion binds to the target protein ACVR2B and reduces the binding of ACVR2B ligands (including activin A and GDF) to ACVR2B to basal levels. In one aspect of this embodiment, the antibody or functional fragment reduces the amount of ACVR2B ligands (including activin A and GDF) bound to ACVR2B. In another aspect of this embodiment, the antibody or functional fragment completely prevents ACVR2B ligands (including activin A and GDF) from binding to ACVR2B. In another embodiment, the antibody or functional fragment inhibits Smad activation or phosphorylation. As determined according to the methods known in the art and described herein, an antibody that inhibits one or more of the functional properties of ACVR2B (e.g., biochemical, immunochemical, cellular, physiological, or other biological activities) will be understood to be associated with a statistically significant reduction in a specific activity observed in the absence of an antibody (e.g., or when a control antibody of unrelated specificity is present). In some embodiments, the antibody inhibiting ACVR2B activity achieves such a statistically significant reduction of at least 10%, at least 50%, 80%, or 90% of the measured parameter, and in some embodiments, the antibody of this disclosure can inhibit large...The antibodies exhibit 95%, 98%, or 99% ACVR2B functional activity.
[0184] In one embodiment, the antibodies or antigen-binding fragments of this disclosure do not cross-react with ACVR2B-related proteins, and more specifically, do not cross-react with human ACVR2A (UniProtKB / Swiss-Prot: P27037). In one embodiment, the antibodies of this disclosure bind to ACVR2B instead of ACVR2A. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to ACVR2B with a higher affinity than to ACVR2A. In one embodiment, the antibodies of this disclosure bind to ACVR2B with 2 times the affinity they bind to ACVR2A. In one embodiment, the antibodies of this disclosure bind to ACVR2B with 3 times the affinity they bind to ACVR2A. In one embodiment, the antibodies of this disclosure bind to ACVR2B with 4 times the affinity they bind to ACVR2A. In one embodiment, the antibodies of this disclosure bind to ACVR2B with 5 times the affinity they bind to ACVR2A. In one embodiment, the antibodies of this disclosure bind to ACVR2B with an affinity 6 times that of ACVR2A. In one embodiment, the antibodies of this disclosure bind to ACVR2B with an affinity 7 times that of ACVR2A. In one embodiment, the antibodies of this disclosure bind to ACVR2B with an affinity 8 times that of ACVR2A. In one embodiment, the antibodies of this disclosure bind to ACVR2B with an affinity 9 times that of ACVR2A. In one embodiment, the antibodies of this disclosure bind to ACVR2B with an affinity 10 times that of ACVR2A. In one embodiment, the antibodies of this disclosure bind to ACVR2B with an affinity 20 times that of ACVR2A. In one embodiment, the antibodies of this disclosure bind to ACVR2B with an affinity 30 times that of ACVR2A. In one embodiment, the antibodies of this disclosure bind to ACVR2B with an affinity 40 times that of ACVR2A. In one embodiment, the antibodies of this disclosure bind to ACVR2B with 50 times the affinity they bind to ACVR2A. In one embodiment, the antibodies of this disclosure bind to ACVR2B with 60 times the affinity they bind to ACVR2B. In one embodiment, the antibodies of this disclosure bind to ACVR2B with 70 times the affinity they bind to ACVR2A. In one embodiment, the antibodies of this disclosure bind to ACVR2B with 80 times the affinity they bind to ACVR2A. In one embodiment, the antibodies of this disclosure bind to ACVR2B with 90 times the affinity they bind to ACVR2A.ACVR2B. In one embodiment, the antibodies of this disclosure bind to ACVR2B with an affinity 100 times that they bind to ACVR2A. In one embodiment, the antibodies of this disclosure bind to ACVR2B with an affinity greater than 100 times (such as 500 times or 1000 times) that they bind to ACVR2A.
[0185] In some embodiments, the anti-ACVR2B antibodies or antigen-binding fragments provided herein bind to ACVR2B (e.g., human ACVR2B) with a dissociation constant (KD) of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM or ≤0.001 nM (e.g., 10⁻⁸ M or less, e.g., 10⁻⁸ M to 10⁻¹³ M, e.g., 10⁻⁹ M to 10⁻¹³ M). Various methods for measuring binding affinity are known in the art, any of which can be used for the purposes of this disclosure, including by RIA, for example with the Fab form of the antibody of interest and its antigen (Chen et al., 1999, J. Mol Biol 293: 865-81); by biolayer interferometry (BLI) or surface plasmon resonance (SPR), using Octet® (using, for example, the Octet® Red96 system) or Biacore® (using, for example, the Biacore®™-3000 or Biacore®™-8000). The “on-rate” or “rate of association” or “association rate” or “kon” can also be determined using the same biolayer interferometry (BLI) or surface plasmon resonance (SPR) techniques described above, using, for example, the Octet® Red96, Biacore®™-3000, or Biacore®™-8000 system.
[0186] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein is capable of inhibiting or blocking the binding of ACVR2B to ACVR2B ligands, which include activins (such as activin A, activin B, activin AB, activin C, activin AC, and activin E), growth / differentiation factors (GDFs, such as GDF1, GDF3, GDF5, GDF6, GDF7, GDF8, GDF10, and GDF11), and bone morphogenetic proteins (BMPs, such as BMP2, BMP4, BMP6, BMP7, BMP8a, BMP8b, BMP9, and BMP10). In some embodiments, the antibody or antigen-binding fragment provided herein does not inhibit or block the binding of ACVR2A to ACVR2A ligands, which include activins (such as activin A, activin B, activin AB, activin C, activin AC, and activin E), and activin ligands activating the ACVR2B ...The antibodies and antigen-binding fragments provided herein exhibit greater inhibitory or blocking activity against ACVR2B and its ligand than against ACVR2A and its ligand. In some embodiments, the antibody or antigen-binding fragments provided herein exhibit twice the inhibitory or blocking activity against ACVR2B and its ligand compared to the inhibitory or blocking activity against ACVR2A and its ligand. In some embodiments, the antibody or antigen-binding fragments provided herein exhibit three times the inhibitory or blocking activity against ACVR2B and its ligand compared to the inhibitory or blocking activity against ACVR2A and its ligand. In some embodiments, the antibody or antigen-binding fragments provided herein exhibit a 4-fold greater inhibitory or blocking effect on the binding of ACVR2B to the ACVR2B ligand than on the binding of ACVR2A to the ACVR2A ligand. In some embodiments, the antibody or antigen-binding fragments provided herein exhibit a 5-fold greater inhibitory or blocking effect on the binding of ACVR2B to the ACVR2B ligand than on the binding of ACVR2A to the ACVR2A ligand. In some embodiments, the antibody or antigen-binding fragments provided herein exhibit a 6-fold greater inhibitory or blocking effect on the binding of ACVR2B to the ACVR2B ligand than on the binding of ACVR2A to the ACVR2A ligand. In some embodiments, the antibody or antigen-binding fragments provided herein exhibit a 7-fold greater inhibitory or blocking effect on the binding of ACVR2B to the ACVR2B ligand than on the binding of ACVR2A to the ACVR2A ligand. In some embodiments, the antibody or antigen-binding fragments provided herein exhibit an inhibitory or blocking effect on the binding of ACVR2B to the ACVR2B ligand that is 8 times more potent than the inhibitory or blocking effect on the binding of ACVR2A to the ACVR2A ligand. In some embodiments, the antibody or antigen-binding fragments provided herein exhibit an inhibitory or blocking effect on the binding of ACVR2B to the ACVR2B ligand that is 9 times more potent than the inhibitory or blocking effect on the binding of ACVR2A to the ACVR2A ligand. In some embodiments, the antibody or antigen-binding fragments provided herein exhibit an inhibitory or blocking effect on the binding of ACVR2B to the ACVR2B ligand that is 10 times more potent than the inhibitory or blocking effect on the binding of ACVR2A to the ACVR2A ligand. In some embodiments...In this protocol, the antibody or antigen-binding fragment provided herein exhibits an inhibitory or blocking effect on the binding of ACVR2B to the ACVR2B ligand that is 20 times greater than the inhibitory or blocking effect on the binding of ACVR2A to the ACVR2A ligand. In some embodiments, the antibody or antigen-binding fragment provided herein exhibits an inhibitory or blocking effect on the binding of ACVR2B to the ACVR2B ligand that is 30 times greater than the inhibitory or blocking effect on the binding of ACVR2A to the ACVR2A ligand. In some embodiments, the antibody or antigen-binding fragment provided herein exhibits an inhibitory or blocking effect on the binding of ACVR2B to the ACVR2B ligand that is 40 times greater than the inhibitory or blocking effect on the binding of ACVR2A to the ACVR2A ligand. In some embodiments, the antibody or antigen-binding fragment provided herein exhibits an inhibitory or blocking effect on the binding of ACVR2B to the ACVR2B ligand that is 50 times greater than the inhibitory or blocking effect on the binding of ACVR2A to the ACVR2A ligand. In some embodiments, the antibody or antigen-binding fragments provided herein exhibit 60-fold greater inhibition or blocking effect on the binding of ACVR2B to the ACVR2B ligand than on the binding of ACVR2A to the ACVR2A ligand. In some embodiments, the antibody or antigen-binding fragments provided herein exhibit 70-fold greater inhibition or blocking effect on the binding of ACVR2B to the ACVR2B ligand than on the binding of ACVR2A to the ACVR2A ligand. In some embodiments, the antibody or antigen-binding fragments provided herein exhibit 80-fold greater inhibition or blocking effect on the binding of ACVR2B to the ACVR2B ligand than on the binding of ACVR2A to the ACVR2A ligand. In some embodiments, the antibody or antigen-binding fragments provided herein exhibit 90-fold greater inhibition or blocking effect on the binding of ACVR2B to the ACVR2B ligand than on the binding of ACVR2A to the ACVR2A ligand. In some embodiments, the antibody or antigen-binding fragments provided herein exhibit an inhibitory or blocking effect on the binding of ACVR2B to the ACVR2B ligand that is 100 times greater than the inhibitory or blocking effect on the binding of ACVR2A to the ACVR2A ligand. In some embodiments, the antibody or antigen-binding fragments provided herein exhibit an inhibitory or blocking effect on the binding of ACVR2B to the ACVR2B ligand that is more than 100 times greater than the inhibitory or blocking effect on the binding of ACVR2A to the ACVR2A ligand, such as 500 times or 1000 times.
[0187] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragments provided herein are those described in Section 7 below. Thus, in some embodiments, the antibody or antigen-binding fragments provided herein comprise one or more CDR sequences of any of SEQ ID NO: 1 to 34. The CDR sequences can be determined according to well-known numbering systems.In some embodiments, the CDR is based on the IMGT number. In some embodiments, the CDR is based on the Kabat number. In some embodiments, the CDR is based on the AbM number. In other embodiments, the CDR is based on the Chothia number. In other embodiments, the CDR is based on the Contact number. In some embodiments, the anti-ACVR2B antibody is a human monoclonal antibody or a humanized antibody. In some embodiments, the anti-ACVR2B antibody comprises a recipient human framework, such as a human immunoglobulin framework or a human common framework.
[0188] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment described herein comprises the VH region, VL region, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and / or LCDR3 of any of the antibodies described herein, such as the amino acid sequence of the VH region, VL region, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and / or LCDR3 depicted in Tables 7 to 9. Therefore, in some embodiments, the anti-ACVR2B antibody or antigen-binding fragment described herein comprises any, any two, and / or all three heavy chain CDRs and / or any, any two, and / or all three light chain CDRs from any of the following antibodies: (a) an antibody named T334; (b) an antibody named T363; (c) an antibody named T377; (d) an antibody named C62; (e) an antibody named T11; (f) an antibody named T18; (g) an antibody named T27; (h) an antibody named C14163; (i) an antibody named C16062; (j) an antibody named T16059; (k) an antibody named T16067; (l) an antibody named T16075; (m) an antibody named T16076 (LAE103); (n) an antibody named T16123; (o) an antibody named […]. (See page 27 / 108 of the specification, 35 CN] 121909215 A Antibody named T24106; (p) Antibody named T24117, and (q) Antibody named T24166, as shown in Tables 7 to 9. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment described herein comprises any, any two, and / or all three heavy chain CDRs and any, any two, and / or all three light chain CDRs from any of the following antibodies: (a) Antibody named T334; (b) Antibody named T363; (c) Antibody named T377; (d) Antibody named C62; (e) Antibody named T11; (f) Antibody named T18; (g) Antibody named T27; (h) Antibody named C14163;(i) an antibody named C16062; (j) an antibody named T16059; (k) an antibody named T16067; (l) an antibody named T16075; (m) an antibody named T16076 (LAE103); (n) an antibody named T16123; (o) an antibody named T24106; (p) an antibody named T24117; and (q) an antibody named T24166, as shown in Tables 7 through 9. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment comprises the VH region and / or VL region of any of the antibodies described herein, wherein the VH region comprises HCDR1, HCDR2, and / or HCDR3, and the VL region comprises LCDR1, LCDR2, and / or LCDR3 (see, for example, any of Tables 7 through 9).
[0189] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 1. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 3. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 5. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 7. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 9. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 11. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 13. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 15.The anti-ACVR2B antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 as shown in the VH of the amino acid sequence of SEQ ID NO: 17. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 as shown in the VH of the amino acid sequence of SEQ ID NO: 21. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 as shown in the VH of the amino acid sequence of SEQ ID NO: 23. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 as shown in the VH of the amino acid sequence of SEQ ID NO: 25. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 27. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 29. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 31. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 33. The CDR sequence can be determined according to a well-known numbering system or a combination thereof. In some embodiments, the CDR is based on an IMGT number. In some embodiments, the CDR is based on a Kabat number (see page 36 of specification 28 / 108, CN 121909215 A). In some embodiments, the CDR is numbered according to AbM. In other embodiments, the CDR is numbered according to Chothia. In other embodiments, the CDR is numbered according to Contact.
[0190] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 2. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises as shown in VL containing the amino acid sequence of SEQ ID NO: 2.The anti-ACVR2B antibody or antigen-binding fragment provided herein comprises LCDR1, LCDR2, and LCDR3 as shown in the VL containing the amino acid sequence of SEQ ID NO: 6. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises LCDR1, LCDR2, and LCDR3 as shown in the VL containing the amino acid sequence of SEQ ID NO: 8. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises LCDR1, LCDR2, and LCDR3 as shown in the VL containing the amino acid sequence of SEQ ID NO: 10. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises LCDR1, LCDR2, and LCDR3 as shown in the VL containing the amino acid sequence of SEQ ID NO: 12. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises LCDR1, LCDR2, and LCDR3 as shown in the VL containing the amino acid sequence of SEQ ID NO: 14. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises LCDR1, LCDR2, and LCDR3 as shown in the VL containing the amino acid sequence of SEQ ID NO: 16. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises LCDR1, LCDR2, and LCDR3 as shown in the VL containing the amino acid sequence of SEQ ID NO: 18. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises LCDR1, LCDR2, and LCDR3 as shown in the VL containing the amino acid sequence of SEQ ID NO: 20. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises LCDR1, LCDR2, and LCDR3 as shown in the VL containing the amino acid sequence of SEQ ID NO: 22. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 24. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 26. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 28.In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises LCDR1, LCDR2, and LCDR3 as shown in the VL containing the amino acid sequence of SEQ ID NO: 30. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises LCDR1, LCDR2, and LCDR3 as shown in the VL containing the amino acid sequence of SEQ ID NO: 32. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises LCDR1, LCDR2, and LCDR3 as shown in the VL containing the amino acid sequence of SEQ ID NO: 34. The CDR sequence can be determined according to a well-known numbering system or a combination thereof. In some embodiments, the CDR is numbered according to IMGT. In some embodiments, the CDR is numbered according to Kabat. In some embodiments, the CDR is numbered according to AbM. In other embodiments, the CDR is numbered according to Chothia. In other embodiments, the CDR is numbered according to Contact.
[0191] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises (i) HCDR1, HCDR2, and HCDR3 as shown in VH of the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, or SEQ ID NO: 33, and / or (ii) HCDR1, HCDR2, and HCDR3 as shown in VH of the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, or SEQ ID NO: 33, and / or (ii) HCDR1, HCDR2, and HCDR3 as shown in VH of the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32 or SEQ ID NO: 34 in the VL of the amino acid sequence. (See specification 29 / 108, page 37, CN 121909215 A)LCDR1, LCDR2, and LCDR3 are shown.
[0192] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and / or HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 1, and / or LCDR1, LCDR2, and / or LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 2. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 1, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 2.
[0193] In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and / or HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 3, and / or LCDR1, LCDR2, and / or LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 4. In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 3, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 4.
[0194] In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and / or HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 5, and / or LCDR1, LCDR2, and / or LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 6. In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 5, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 6.
[0195] In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and / or HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 7, and / or LCDR1, LCDR2, and / or LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 8. In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and / or HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 7.The amino acid sequence of SEQ ID NO: 7 contains HCDR1, HCDR2, and HCDR3 as shown in VH, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 8.
[0196] In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and / or HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 9, and / or LCDR1, LCDR2, and / or LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 10. In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 9, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 10.
[0197] In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and / or HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 11, and / or LCDR1, LCDR2, and / or LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 12. In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 11, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 12.
[0198] In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and / or HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 13, and / or LCDR1, LCDR2, and / or LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 14. In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 13, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 14.
[0199] In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and / or HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 15 (page 30 / 108 of specification, CN 121909215 A), and / or as shown in VL containing the amino acid sequence of SEQ ID NO: 16.The amino acid sequence VL contains LCDR1, LCDR2, and / or LCDR3. In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 15, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 16.
[0200] In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and / or HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 17, and / or LCDR1, LCDR2, and / or LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 18. In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 17, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 18.
[0201] In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and / or HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 19, and / or LCDR1, LCDR2, and / or LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 20. In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 19, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 20.
[0202] In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and / or HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 21, and / or LCDR1, LCDR2, and / or LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 22. In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 21, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 22.
[0203] In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 23.The amino acid sequence VH contains HCDR1, HCDR2, and / or HCDR3, and / or LCDR1, LCDR2, and / or LCDR3 as shown in the amino acid sequence VL containing SEQ ID NO: 24. In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 as shown in the amino acid sequence VH containing SEQ ID NO: 23, and LCDR1, LCDR2, and LCDR3 as shown in the amino acid sequence VL containing SEQ ID NO: 24.
[0204] In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and / or HCDR3 as shown in the amino acid sequence VH containing SEQ ID NO: 25, and / or LCDR1, LCDR2, and / or LCDR3 as shown in the amino acid sequence VL containing SEQ ID NO: 26. In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 25, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 26.
[0205] In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and / or HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 27, and / or LCDR1, LCDR2, and / or LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 28. In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 27, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 28.
[0206] In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and / or HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 29, and / or LCDR1, LCDR2, and / or LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 30. In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 29, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 30. (Description)Page 31 / 108, page 39, CN 121909215 A
[0207] In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and / or HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 31, and / or LCDR1, LCDR2, and / or LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 32. In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 31, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 32.
[0208] In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and / or HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 33, and / or LCDR1, LCDR2, and / or LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 34. In some embodiments, the antibody or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 33, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 34.
[0209] The CDR sequence can be determined according to a well-known numbering system or a combination thereof. In some embodiments, the CDR is numbered according to IMGT. In some embodiments, the CDR is numbered according to Kabat. In some embodiments, the CDR is numbered according to AbM. In other embodiments, the CDR is numbered according to Chothia. In other embodiments, the CDR is numbered according to Contact.
[0210] In other embodiments, this document provides an antibody or antigen-binding fragment binding to ACVR2B, the antibody or antigen-binding fragment comprising HCDR1 having an amino acid sequence having at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of SEQ ID NO: 35, 41, 47, 53, 59, 65, 71, 77, 83, 89, 95, 101, 107, 113, 119, 125, and 131; (ii) containing an amino acid sequence having ...HCDR2 containing an amino acid sequence having at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of SEQ ID NO: 37, 43, 49, 55, 61, 67, 73, 79, 85, 91, 97, 103, 109, 115, 121, 127, and 133. (iv) HCDR3 containing an amino acid sequence that is 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identical to any of SEQ ID NOs: 38, 44, 50, 56, 62, 68, 74, 80, 86, 92, 98, 104, 110, 116, 122, 128, and 134 having at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identical to any of SEQ ID NOs: 39, 45, 51, 57, LCDR2 containing an amino acid sequence of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of SEQ ID NO: 40, 46, 52, 58, 64, 70, 76, 82, 88, 94, 100, 106, 112, 118, 124, 130, and 136, having an amino acid sequence of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, or 90% sequence identity; and / or (vi) containing an amino acid sequence of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, or 90% sequence identity with any one of SEQ ID NO: 40, 46, 52, 58, 64, 70, 76, 82, 88, 94, 100, 106, 112, 118, 124, 130, and 136. LCDR3 with amino acid sequences exhibiting 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, and 100% sequence identity. In some embodiments, the CDR is based on an IMGT number. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment is a human antibody or a humanized antibody. In some embodiments, the anti-ACVR2B antibody comprises a recipient human frame, such as a human immunoglobulin frame or a human common frame.
[0211] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 contains the amino acid sequence of SEQ ID NO: 35, HCDR2 contains the amino acid sequence of SEQ ID NO: 36, HCDR3 contains the amino acid sequence of SEQ ID NO: 37, LCDR1 contains the amino acid sequence of SEQ ID NO: 38, LCDR2 contains the amino acid sequence of SEQ ID NO: 39, and LCDR3 contains the amino acid sequence of SEQ ID NO: 40.
[0212] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 contains the amino acid sequence of SEQ ID NO: 41, HCDR2 contains the amino acid sequence of SEQ ID NO: 42, HCDR3 contains the amino acid sequence of SEQ ID NO: 43, LCDR1 contains the amino acid sequence of SEQ ID NO: 44, LCDR2 contains the amino acid sequence of SEQ ID NO: 45, and LCDR3 contains the amino acid sequence of SEQ ID NO: 46.
[0213] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 comprises the amino acid sequence of SEQ ID NO: 47, HCDR2 comprises the amino acid sequence of SEQ ID NO: 48, HCDR3 comprises the amino acid sequence of SEQ ID NO: 49, LCDR1 comprises the amino acid sequence of SEQ ID NO: 50, LCDR2 comprises the amino acid sequence of SEQ ID NO: 51, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 52.
[0214] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 comprises the amino acid sequence of SEQ ID NO: 53, HCDR2 comprises the amino acid sequence of SEQ ID NO: 54, HCDR3 comprises the amino acid sequence of SEQ ID NO: 55, LCDR1 comprises the amino acid sequence of SEQ ID NO: 56, LCDR2 comprises the amino acid sequence of SEQ ID NO: 57, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 58.
[0215] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 comprises the amino acid sequence of SEQ ID NO: 59, HCDR2 comprises the amino acid sequence of SEQ ID NO: 60, HCDR3 comprises the amino acid sequence of SEQ ID NO: 61, LCDR1 comprises the amino acid sequence of SEQ ID NO: 62, and LCDR2 comprises the amino acid sequence of SEQ ID NO: 63.The amino acid sequence of SEQ ID NO: 63, and LCDR3 contains the amino acid sequence of SEQ ID NO: 64.
[0216] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 contains the amino acid sequence of SEQ ID NO: 65, HCDR2 contains the amino acid sequence of SEQ ID NO: 66, HCDR3 contains the amino acid sequence of SEQ ID NO: 67, LCDR1 contains the amino acid sequence of SEQ ID NO: 68, LCDR2 contains the amino acid sequence of SEQ ID NO: 69, and LCDR3 contains the amino acid sequence of SEQ ID NO: 70.
[0217] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 comprises the amino acid sequence of SEQ ID NO: 71, HCDR2 comprises the amino acid sequence of SEQ ID NO: 72, HCDR3 comprises the amino acid sequence of SEQ ID NO: 73, LCDR1 comprises the amino acid sequence of SEQ ID NO: 74, LCDR2 comprises the amino acid sequence of SEQ ID NO: 75, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 76.
[0218] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 comprises the amino acid sequence of SEQ ID NO: 77, HCDR2 comprises the amino acid sequence of SEQ ID NO: 78, HCDR3 comprises the amino acid sequence of SEQ ID NO: 79, LCDR1 comprises the amino acid sequence of SEQ ID NO: 80, LCDR2 comprises the amino acid sequence of SEQ ID NO: 81, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 82.
[0219] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 comprises the amino acid sequence of SEQ ID NO: 83, HCDR2 comprises the amino acid sequence of SEQ ID NO: 84, HCDR3 comprises the amino acid sequence of SEQ ID NO: 85, LCDR1 comprises the amino acid sequence of SEQ ID NO: 86, LCDR2 comprises the amino acid sequence of SEQ ID NO: 87, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 88.
[0220] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 comprises the amino acid sequence of SEQ ID NO: 89, HCDR2 comprises the amino acid sequence of SEQ ID NO: 90, HCDR3 comprises the amino acid sequence of SEQ ID NO: 91, and LCDR1 comprises the amino acid sequence of SEQ ID NO: 88.The amino acid sequence of SEQ ID NO: 92, LCDR2 contains the amino acid sequence of SEQ ID NO: 93, and LCDR3 contains the amino acid sequence of SEQ ID NO: 94.
[0221] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 contains the amino acid sequence of SEQ ID NO: 95, HCDR2 contains the amino acid sequence of SEQ ID NO: 96, HCDR3 contains the amino acid sequence of SEQ ID NO: 97, LCDR1 contains the amino acid sequence of SEQ ID NO: 98, LCDR2 contains the amino acid sequence of SEQ ID NO: 99, and LCDR3 contains the amino acid sequence of SEQ ID NO: 100. Specification 33 / 108 pages 41 CN 121909215 A
[0222] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 contains the amino acid sequence of SEQ ID NO: 101, HCDR2 contains the amino acid sequence of SEQ ID NO: 102, HCDR3 contains the amino acid sequence of SEQ ID NO: 103, LCDR1 contains the amino acid sequence of SEQ ID NO: 104, LCDR2 contains the amino acid sequence of SEQ ID NO: 105, and LCDR3 contains the amino acid sequence of SEQ ID NO: 106.
[0223] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 comprises the amino acid sequence of SEQ ID NO: 107, HCDR2 comprises the amino acid sequence of SEQ ID NO: 108, HCDR3 comprises the amino acid sequence of SEQ ID NO: 109, LCDR1 comprises the amino acid sequence of SEQ ID NO: 110, LCDR2 comprises the amino acid sequence of SEQ ID NO: 111, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 112.
[0224] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 comprises the amino acid sequence of SEQ ID NO: 113, HCDR2 comprises the amino acid sequence of SEQ ID NO: 114, HCDR3 comprises the amino acid sequence of SEQ ID NO: 115, LCDR1 comprises the amino acid sequence of SEQ ID NO: 116, LCDR2 comprises the amino acid sequence of SEQ ID NO: 117, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 118.
[0225] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 comprises the amino acid sequence of SEQ ID NO: 119, and HCDR2 comprises the amino acid sequence of SEQ ID NO: 119.The amino acid sequence NO: 120, HCDR3 contains the amino acid sequence of SEQ ID NO: 121, LCDR1 contains the amino acid sequence of SEQ ID NO: 122, LCDR2 contains the amino acid sequence of SEQ ID NO: 123, and LCDR3 contains the amino acid sequence of SEQ ID NO: 124.
[0226] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 contains the amino acid sequence of SEQ ID NO: 125, HCDR2 contains the amino acid sequence of SEQ ID NO: 126, HCDR3 contains the amino acid sequence of SEQ ID NO: 127, LCDR1 contains the amino acid sequence of SEQ ID NO: 128, LCDR2 contains the amino acid sequence of SEQ ID NO: 129, and LCDR3 contains the amino acid sequence of SEQ ID NO: 130.
[0227] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 contains the amino acid sequence of SEQ ID NO: 131, HCDR2 contains the amino acid sequence of SEQ ID NO: 132, HCDR3 contains the amino acid sequence of SEQ ID NO: 133, LCDR1 contains the amino acid sequence of SEQ ID NO: 134, LCDR2 contains the amino acid sequence of SEQ ID NO: 135, and LCDR3 contains the amino acid sequence of SEQ ID NO: 136.
[0228] In other embodiments, this document provides an antibody or antigen-binding fragment binding to ACVR2B, the antibody or antigen-binding fragment comprising HCDR1 having an amino acid sequence having at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of SEQ ID NO: 137, 143, 149, 155, 161, 167, 173, 179, 185, 191, 197, 203, 209, 215, 221, 227, and 233; (ii) containing an amino acid sequence having ... HCDR2 containing an amino acid sequence of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of SEQ ID NO:HCDR3 containing amino acid sequences of SEQ ID NO: 139, 145, 151, 157, 163, 169, 175, 181, 187, 193, 199, 205, 211, 217, 223, 229, and 235 having at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity; (iv) HCDR3 containing an amino acid sequence of at least 75%, 80%, 85%, or 86% identity to any one of SEQ ID NO: 140, 146, 152, 158, 164, 170, 176, 182, 188, 194, 200, 206, 212, 218, 224, 230, and 236. LCDR1 containing an amino acid sequence that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identical to the amino acid sequence of SEQ ID NO: 141, 147, 153, 159, 165, 171, 177, 183, 189, 195, 201, 207, 213, 219, 225, 231, and 237 having at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identical to the amino acid sequence of SEQ ID NO: 141, 147, 153, 159, 165, 171, 177, 183, 189, 195, 201, 207, 213, 219, 225, 231, and 237; and / or LCDR2 containing an amino acid sequence that is 87%, 88%, 89%, 96%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identical to the amino acid sequence of SEQ ID NO: 141, 147, 153, 159, 165, 171, 177, 183, 189, 195, 201, 207, 213, 219 LCDR3 comprises any one of the amino acid sequences 142, 148, 154, 160, 166, 172, 178, 184, 190, 196, 202, 208, 214, 220, 226, 232, and 238 having at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity. In some embodiments, the CDR is based on a Kabat number. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment is a human antibody or a humanized antibody. In some embodiments, the anti-ACVR2B antibody comprises a recipient human frame, such as a human immunoglobulin frame or a human common frame.
[0229] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 contains the amino acid sequence of SEQ ID NO: 137, HCDR2 contains the amino acid sequence of SEQ ID NO: 138, HCDR3 contains the amino acid sequence of SEQ ID NO: 139, and LCDR1 contains the amino acid sequence of SEQ ID NO: 139.The amino acid sequence NO: 140, LCDR2 contains the amino acid sequence SEQ ID NO: 141, and LCDR3 contains the amino acid sequence SEQ ID NO: 142.
[0230] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 contains the amino acid sequence SEQ ID NO: 143, HCDR2 contains the amino acid sequence SEQ ID NO: 144, HCDR3 contains the amino acid sequence SEQ ID NO: 145, LCDR1 contains the amino acid sequence SEQ ID NO: 146, LCDR2 contains the amino acid sequence SEQ ID NO: 147, and LCDR3 contains the amino acid sequence SEQ ID NO: 148.
[0231] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 comprises the amino acid sequence of SEQ ID NO: 149, HCDR2 comprises the amino acid sequence of SEQ ID NO: 150, HCDR3 comprises the amino acid sequence of SEQ ID NO: 151, LCDR1 comprises the amino acid sequence of SEQ ID NO: 152, LCDR2 comprises the amino acid sequence of SEQ ID NO: 153, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 154.
[0232] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 comprises the amino acid sequence of SEQ ID NO: 155, HCDR2 comprises the amino acid sequence of SEQ ID NO: 156, HCDR3 comprises the amino acid sequence of SEQ ID NO: 157, LCDR1 comprises the amino acid sequence of SEQ ID NO: 158, LCDR2 comprises the amino acid sequence of SEQ ID NO: 159, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 160.
[0233] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 comprises the amino acid sequence of SEQ ID NO: 161, HCDR2 comprises the amino acid sequence of SEQ ID NO: 162, HCDR3 comprises the amino acid sequence of SEQ ID NO: 163, LCDR1 comprises the amino acid sequence of SEQ ID NO: 164, LCDR2 comprises the amino acid sequence of SEQ ID NO: 165, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 166.
[0234] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 comprises the amino acid sequence of SEQ ID NO: 167, HCDR2 comprises the amino acid sequence of SEQ ID NO: 167, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 164.The amino acid sequence of SEQ ID NO: 168, HCDR3 contains the amino acid sequence of SEQ ID NO: 169, LCDR1 contains the amino acid sequence of SEQ ID NO: 170, LCDR2 contains the amino acid sequence of SEQ ID NO: 171, and LCDR3 contains the amino acid sequence of SEQ ID NO: 172.
[0235] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 contains the amino acid sequence of SEQ ID NO: 173, HCDR2 contains the amino acid sequence of SEQ ID NO: 174, HCDR3 contains the amino acid sequence of SEQ ID NO: 175, LCDR1 contains the amino acid sequence of SEQ ID NO: 176, LCDR2 contains the amino acid sequence of SEQ ID NO: 177, and LCDR3 contains the amino acid sequence of SEQ ID NO: 178.
[0236] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 contains the amino acid sequence of SEQ ID NO: 179, HCDR2 contains the amino acid sequence of SEQ ID NO: 180, HCDR3 contains the amino acid sequence of SEQ ID NO: 181, LCDR1 contains the amino acid sequence of SEQ ID NO: 182, LCDR2 contains the amino acid sequence of SEQ ID NO: 183, and LCDR3 contains the amino acid sequence of SEQ ID NO: 184.
[0237] In some specific embodiments, in the antibody or antigen binding fragments provided herein, HCDR1 contains the amino acid sequence of SEQ ID NO: 185, HCDR2 contains the amino acid sequence of SEQ ID NO: 186, HCDR3 contains the amino acid sequence of SEQ ID NO: 187, LCDR1 contains the amino acid sequence of SEQ ID NO: 188, LCDR2 contains the amino acid sequence of SEQ ID NO: 189, and LCDR3 contains the amino acid sequence of SEQ ID NO: 190.
[0238] In some specific embodiments, in the antibody or antigen-binding fragments provided herein, HCDR1 comprises the amino acid sequence of SEQ ID NO: 191, HCDR2 comprises the amino acid sequence of SEQ ID NO: 192, HCDR3 comprises the amino acid sequence of SEQ ID NO: 193, LCDR1 comprises the amino acid sequence of SEQ ID NO: 194, LCDR2 comprises the amino acid sequence of SEQ ID NO: 195, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 196.
[0239] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 contains the amino acid sequence of SEQ ID NO: 197, HCDR2 contains the amino acid sequence of SEQ ID NO: 198, HCDR3 contains the amino acid sequence of SEQ ID NO: 199, LCDR1 contains the amino acid sequence of SEQ ID NO: 200, LCDR2 contains the amino acid sequence of SEQ ID NO: 201, and LCDR3 contains the amino acid sequence of SEQ ID NO: 202.
[0240] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 contains the amino acid sequence of SEQ ID NO: 203, HCDR2 contains the amino acid sequence of SEQ ID NO: 204, HCDR3 contains the amino acid sequence of SEQ ID NO: 205, LCDR1 contains the amino acid sequence of SEQ ID NO: 206, LCDR2 contains the amino acid sequence of SEQ ID NO: 207, and LCDR3 contains the amino acid sequence of SEQ ID NO: 208.
[0241] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 comprises the amino acid sequence of SEQ ID NO: 209, HCDR2 comprises the amino acid sequence of SEQ ID NO: 210, HCDR3 comprises the amino acid sequence of SEQ ID NO: 211, LCDR1 comprises the amino acid sequence of SEQ ID NO: 212, LCDR2 comprises the amino acid sequence of SEQ ID NO: 213, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 214.
[0242] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 comprises the amino acid sequence of SEQ ID NO: 215, HCDR2 comprises the amino acid sequence of SEQ ID NO: 216, HCDR3 comprises the amino acid sequence of SEQ ID NO: 217, LCDR1 comprises the amino acid sequence of SEQ ID NO: 218, LCDR2 comprises the amino acid sequence of SEQ ID NO: 219, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 220.
[0243] In some specific embodiments, in the antibody or antigen-binding fragments provided herein, HCDR1 comprises the amino acid sequence of SEQ ID NO: 221, HCDR2 comprises the amino acid sequence of SEQ ID NO: 222, HCDR3 comprises the amino acid sequence of SEQ ID NO: 223, LCDR1 comprises the amino acid sequence of SEQ ID NO: 224, and LCDR2 comprises the amino acid sequence of SEQ ID NO: 225.The amino acid sequence, and LCDR3 contains the amino acid sequence of SEQ ID NO: 226.
[0244] In some specific embodiments, in the antibody or antigen binding fragment provided herein, HCDR1 contains the amino acid sequence of SEQ ID NO: 227, HCDR2 contains the amino acid sequence of SEQ ID NO: 228, HCDR3 contains the amino acid sequence of SEQ ID NO: 229, LCDR1 contains the amino acid sequence of SEQ ID NO: 230, LCDR2 contains the amino acid sequence of SEQ ID NO: 231, and LCDR3 contains the amino acid sequence of SEQ ID NO: 232.
[0245] In some specific embodiments, in the antibody or antigen-binding fragment provided herein, HCDR1 comprises the amino acid sequence of SEQ ID NO: 233, HCDR2 comprises the amino acid sequence of SEQ ID NO: 234, HCDR3 comprises the amino acid sequence of SEQ ID NO: 235, LCDR1 comprises the amino acid sequence of SEQ ID NO: 236, LCDR2 comprises the amino acid sequence of SEQ ID NO: 237, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 238.
[0246] In some embodiments, the antibody or antigen-binding fragment further comprises one or more frame regions of SEQ ID NO: 1 to 34. In some embodiments, the antibody provided herein is a humanized antibody. The frame regions described herein are defined based on the boundaries of the CDR numbering system. In other words, if the CDR is determined by, for example, Kabat, IMGT, or Chothia, then the frame region is the amino acid residue surrounding the CDR in a variable region in the format FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 from the N-terminus to the C-terminus. (See page 44 of CN 121909215, 36 / 108 of the specification). For example, FR1 is defined as the amino acid residue located at the N-terminus of the CDR1 amino acid residue as defined by, for example, the Kabat numbering system, the IMGT numbering system, or the Chothia numbering system; FR2 is defined as the amino acid residue between the CDR1 amino acid residue and the CDR2 amino acid residue as defined by, for example, the Kabat numbering system, the IMGT numbering system, or the Chothia numbering system; FR3 is defined as the amino acid residue between the CDR2 amino acid residue and the CDR3 amino acid residue as defined by, for example, the Kabat numbering system, the IMGT numbering system, or the Chothia numbering system; and FR4 is defined as the amino acid residue located at the C-terminus of the CDR3 amino acid residue as defined by, for example, the Kabat numbering system, the IMGT numbering system, or the Chothia numbering system.
[0247] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment (e.g., antibody, such as a monospecific or bispecific antibody) (including human ACVR2B antibody) provided herein contains a VH region or VH domain. Additionally or alternatively, the anti-ACVR2B antibody or antigen-binding fragment (e.g., antibody, such as a monospecific or bispecific antibody) (including human ACVR2B antibody) provided herein contains a VL region or VL domain. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment (e.g., antibody, such as a monospecific or bispecific antibody) (including human ACVR2B antibody) provided herein has a combination of: (i) a VH domain or VH region; and (ii) a VL domain or VL region.
[0248] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein contains a VH containing the amino acid sequence of SEQ ID NO: 1. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein contains a VL containing the amino acid sequence of SEQ ID NO: 2. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 1 and a VL containing the amino acid sequence of SEQ ID NO: 2.
[0249] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 3. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VL containing the amino acid sequence of SEQ ID NO: 4. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 3 and a VL containing the amino acid sequence of SEQ ID NO: 4.
[0250] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 5. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VL containing the amino acid sequence of SEQ ID NO: 6. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 5 and a VL containing the amino acid sequence of SEQ ID NO: 6.
[0251] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 7. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 7.The VL containing the amino acid sequence of SEQ ID NO: 7. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 7 and a VL containing the amino acid sequence of SEQ ID NO: 8.
[0252] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 9. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VL containing the amino acid sequence of SEQ ID NO: 10. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 9 and a VL containing the amino acid sequence of SEQ ID NO: 10.
[0253] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 11. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VL containing the amino acid sequence of SEQ ID NO: 12. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 11 and a VL containing the amino acid sequence of SEQ ID NO: 12.
[0254] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 13. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VL containing the amino acid sequence of SEQ ID NO: 14. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 13 and a VL containing the amino acid sequence of SEQ ID NO: 14.
[0255] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VL containing the amino acid sequence of SEQ ID NO: 16. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 15 and a VL containing the amino acid sequence of SEQ ID NO: 16.
[0256] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 15 and a VL containing the amino acid sequence of SEQ ID NO: 16.VH containing the amino acid sequence of SEQ ID NO: 17. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises VL containing the amino acid sequence of SEQ ID NO: 18. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises VH containing the amino acid sequence of SEQ ID NO: 17 and VL containing the amino acid sequence of SEQ ID NO: 18.
[0257] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises VH containing the amino acid sequence of SEQ ID NO: 19. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises VL containing the amino acid sequence of SEQ ID NO: 20. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises VH containing the amino acid sequence of SEQ ID NO: 19 and VL containing the amino acid sequence of SEQ ID NO: 20.
[0258] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises VH containing the amino acid sequence of SEQ ID NO: 21. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VL containing the amino acid sequence of SEQ ID NO: 22. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 21 and a VL containing the amino acid sequence of SEQ ID NO: 22.
[0259] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 23. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VL containing the amino acid sequence of SEQ ID NO: 24. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 23 and a VL containing the amino acid sequence of SEQ ID NO: 24.
[0260] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 25. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VL containing the amino acid sequence of SEQ ID NO: 26. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 25 and a VL containing the amino acid sequence of SEQ ID NO: 26. Specification 38 / 108Page 46 CN 121909215 A
[0261] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 27. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VL containing the amino acid sequence of SEQ ID NO: 28. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 27 and a VL containing the amino acid sequence of SEQ ID NO: 28.
[0262] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 29. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VL containing the amino acid sequence of SEQ ID NO: 30. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 29 and a VL containing the amino acid sequence of SEQ ID NO: 30.
[0263] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 31. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VL containing the amino acid sequence of SEQ ID NO: 32. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 31 and a VL containing the amino acid sequence of SEQ ID NO: 32.
[0264] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 33. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VL containing the amino acid sequence of SEQ ID NO: 34. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a VH containing the amino acid sequence of SEQ ID NO: 33 and a VL containing the amino acid sequence of SEQ ID NO: 34.
[0265] In some embodiments, the antibody or antigen-binding fragment described herein comprises an amino acid sequence having a certain percentage of identity with any antibody provided herein (e.g., those described in Section 7 below).
[0266] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises an amino acid sequence having a certain percentage of identity with any antibody provided herein (e.g., those described in Section 7 below).Any antibody or fragment thereof provided herein (e.g., CDR, VH, or VL in Tables 7 through 9) or any full-length antibody chain as disclosed herein has an amino acid sequence having a certain percentage of identity (such as at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or higher). In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises the CDR of any antibody or fragment thereof provided herein (e.g., in Tables 8 and 9). In other embodiments, the ACVR2B antibody or antigen-binding fragment provided herein comprises an amino acid sequence having a certain percentage of identity (such as at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or higher) relative to any antibody or fragment thereof provided herein (e.g., VH or VL in Table 7) or any full-length antibody chain as disclosed herein.
[0267] The determination of the percentage of identity between two sequences (e.g., amino acid sequences or nucleic acid sequences) can be accomplished using mathematical algorithms. A non-limiting example of a mathematical algorithm for comparing two sequences is the algorithm in Karlin and Altschul, Proc. Natl. Acad. Sci. U.S.A. 87: 2264 2268 (1990), as improved in Karlin and Altschul, Proc. Natl. Acad. Sci. USA 90: 5873 5877 (1993). This algorithm is described on page 39 / 108 of CN 121909215 A in Altschul et al., J. Mol. Biol. 215: 403 (1990) using the NBLAST and XBLAST procedures. BLAST nucleotide searches can be performed using NBLAST nucleotide program parameters set, for example, score=100 and word length=12, to obtain nucleotide sequences homologous to the nucleic acid molecules described herein. BLAST protein searches can be performed using parameters set, for example, score=50 and word length=3.The XBLAST procedure parameters are used to obtain amino acid sequences homologous to the protein molecule described herein. To obtain gap alignments for comparative purposes, gap BLAST can be used as described in Altschul et al., Nucleic Acids Res. 25: 3389 3402 (1997). In some embodiments, the percentage of identity between two sequences is calculated by dividing the number of residues that vary between the two sequences in the alignment (excluding or including conserved amino acid substitutions or degenerate nucleotide substitutions) by the number of residues in either of the following: (i) the full length of the shorter sequence, (ii) the full length of the longer sequence, (iii) the average length of the two sequences, (iv) the total length of the non-gap portion of the alignment, (v) the length of the alignment excluding protrusions, or (vi) the length of the alignment including protrusions. As used herein, a protrusion in sequence alignment refers to either end or both ends of the alignment, where residues in one sequence are considered to be aligned with residues-free (i.e., gaps) in the other sequence. Alternatively, PSI BLAST can be used for iterative searches to detect long-distance relationships between molecules (as above). When using BLAST, nick BLAST, and PSI BLAST programs, the default parameters of the respective programs can be used (e.g., default parameters for XBLAST and NBLAST) (see, for example, the National Center for Biotechnology Information (NCBI), World Wide Web: ncbi.nlm.nih.gov). Another non-limiting example of a mathematical algorithm for sequence comparison is the algorithm of Myers and Miller, CABIOS 4: 11–17 (1998). This algorithm is incorporated into the ALIGN program (version 2.0), which is part of the GCG sequence alignment software package. When comparing amino acid sequences using the ALIGN program, the PAM120 weight residue table, nick length penalty 12, and nick penalty 4 can be used. The percentage of identity between two sequences can be determined using techniques similar to those described above, with or without nicks. In calculating the percentage of identity, typically only exact matches are counted.
[0268] In some embodiments, the antibody or antigen-binding fragments provided herein contain substitutions (e.g., conserved substitutions), insertions, or deletions relative to a reference sequence, but the antibody containing that sequence retains its ability to bind to ACVR2B. In some embodiments, a total of 1 to 10 amino acids in the reference amino acid sequence have been substituted, inserted, and / or deleted. In some embodiments, the substitutions, insertions, or deletions occur in regions outside the CDR (e.g., in the FR and / or constant regions).
[0269] In some embodiments, the ACVR2B antibody or antigen-binding fragments described herein (including human ACVR2B antibody)The position of one or more CDRs in the VH (e.g., CDR1, CDR2, or CDR3) and / or VL (e.g., CDR1, CDR2, or CDR3) regions of the antigen-binding fragment can vary by one, two, three, four, five, or six amino acid positions, provided that they remain (e.g., substantially remain, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) bound to ACVR2B (e.g., human ACVR2B). For example, in some embodiments, the position of a CDR defined in either Table 8 or Table 9 can be varied by shifting the N-terminal and / or C-terminal boundary of the CDR relative to the current CDR position by one, two, three, four, five, or six amino acids, provided that they remain (e.g., substantially remain, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) bound to ACVR2B (e.g., human ACVR2B). Additionally or alternatively, in some embodiments, the length of one or more CDRs along the VH (e.g., CDR1, CDR2, or CDR3) and / or VL (e.g., CDR1, CDR2, or CDR3) regions of the ACVR2B antibody or antigen-binding fragment (including the human ACVR2B antibody or antigen-binding fragment) described herein may vary by one, two, three, four, five, or more amino acids (e.g., shorter or longer), as long as binding to ACVR2B (e.g., human ACVR2B) is maintained (e.g., substantially maintained, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%). For example, in some embodiments, the VH and / or VL CDR1, CDR2 and / or CDR3 described herein may be one, two, three, four, five or more amino acids shorter than one or more of the CDRs described by SEQ ID NO: 35-238, provided that they remain (e.g., substantially remain, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95%) bound to ACVR2B (e.g., human ACVR2B). In other embodiments, the VH and / or VL described herein (page 40 / 108, CN 121909215 A) CDR1, CDR2, and / or CDR3 may be one, two, three, four, five, or more amino acids longer than one or more of the CDRs described by SEQ ID NO: 35-238, provided that they are retained (e.g., substantially retained, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) to bind to ACVR2B (e.g., human ACVR2B). In some embodiments, the amino terminus of the VH and / or VL CDR1, CDR2, and / or CDR3 described herein is bound to the amino terminus described by SEQ ID NO: 35-238.Compared to one or more of the CDRs described in SEQ ID NO: 35-238, the CDRs may be extended or shortened by one, two, three, four, five, or more amino acids, provided that they remain (e.g., substantially maintained, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) bound to ACVR2B (e.g., human ACVR2B). Additionally or alternatively, in some embodiments, the carboxyl termini of the VH and / or VL CDR1, CDR2, and / or CDR3 described herein may be extended or shortened by one, two, three, four, five, or more amino acids compared to one or more of the CDRs described in SEQ ID NO: 35-238, provided that they remain (e.g., substantially maintained, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) bound to ACVR2B (e.g., human ACVR2B). Any method known in the art can be used to determine whether binding to ACVR2B (e.g., human ACVR2B) is maintained, such as the binding assays and conditions described in the "Examples" section herein.
[0270] In other embodiments, the anti-ACVR2B antibody or antigen-binding fragment (including human ACVR2B antibody or antigen-binding fragment) presented herein that binds to ACVR2B also contains conserved sequence modifications. For peptides that are ACVR2B antibody or antigen-binding fragments, such as human ACVR2B antibody or antigen-binding fragments, the conserved sequence modifications include conserved amino acid substitutions, which include conserved amino acid substitutions in which amino acid residues are replaced by amino acid residues having similar side chains. Families of amino acid residues having similar side chains have been defined in the art. Thus, in some embodiments, non-essential amino acid residues predicted in ACVR2B are replaced by another amino acid residue from the same side chain family. Methods for identifying conserved amino acid substitutions that do not eliminate antigen binding and their encoding nucleotides are well known in the art (see, for example, Brummell et al., Biochem. 32:1180–1187 (1993); Kobayashi et al., Protein Eng. 12(10):879–884 (1999); and Burks et al., Proc. Natl. Acad. Sci. USA 94: 412–417 (1997)). In some embodiments, the conserved sequence modifications described herein modify the amino acid sequence of ACVR2B binders (e.g., antibodies) (including human ACVR2B binders) by 50%, or 55%, or 60%, or 65%, or 70%, or 75%, or 80%, or 85%, or 90%, or 95%, or 98%, or 99%. In some embodiments, the amino acid sequence modification refers to the substitution of up to 1, 2, 3, 4, 5, or 6 amino acids of the CDR, as shown in Tables 8 and 9.Those described in any of the above. Thus, for example, each such CDR may contain up to 5 conserved amino acid substitutions, for example up to (no more than) 4 conserved amino acid substitutions, for example up to (no more than) 3 conserved amino acid substitutions, for example up to (no more than) 2 conserved amino acid substitutions, or no more than 1 conserved amino acid substitution. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment (including human ACVR2B antibody) contains one or more (including six) CDRs having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with the CDRs in Tables 8 and 9.
[0271] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment (including human ACVR2B antibody) contains VH and VL comprising the same CDRs as those in Tables 8 and 9. In some embodiments, the amino acid sequence modification does not include any modification within the SDR. In some embodiments, the amino acid sequence modification does not include any modification within the CDR (such as CDR1, CDR2, CDR3, or any combination thereof). Additionally or alternatively, amino acid sequences are modified in the framework, constant region, and / or fragment crystallizable region (Fc).
[0272] In some embodiments, the antibody or fragment provided herein comprises a VH domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 1 and / or a VL domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 2, and retains (e.g., substantially retains, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) the binding of the antibody or fragment thereof to ACVR2B (e.g., human ACVR2B).
[0273] In some embodiments, the antibody or fragment provided herein comprises a VH domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 3 and / or with the amino acid sequence of SEQ ID NO: 4.The sequence has a VL domain with at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and retains (e.g., substantially retains, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) the binding of the antibody or a fragment thereof to ACVR2B (e.g., human ACVR2B).
[0274] In some embodiments, the antibody or fragment provided herein comprises a VH domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 5 and / or a VL domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 6, and retains (e.g., substantially retains, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) the binding of the antibody or fragment thereof to ACVR2B (e.g., human ACVR2B).
[0275] In some embodiments, the antibody or fragment provided herein comprises a VH domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 7 and / or a VL domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 8, and retains (e.g., substantially retains, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) the binding of the antibody or fragment thereof to ACVR2B (e.g., human ACVR2B).
[0276] In some embodiments, the antibody or fragment provided herein comprises an amino acid sequence having a content of at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, and so on, compared to the amino acid sequence of SEQ ID NO: 9.The antibody or fragment thereof has at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the VH domain and / or has at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 10, and retains (e.g., substantially retains, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) binding to ACVR2B (e.g., human ACVR2B).
[0277] In some embodiments, the antibody or fragment provided herein comprises a VH domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 11 and / or a VL domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 12, and retains (e.g., substantially retains, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) the binding of the antibody or fragment thereof to ACVR2B (e.g., human ACVR2B).
[0278] In some embodiments, the antibody or fragment provided herein comprises a VH domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 13 and / or a VL domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 14, and retains (e.g., substantially retains, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) binding of the antibody or fragment thereof to ACVR2B (e.g., human ACVR2B).
[0279] In some embodiments, the antibody or fragment provided herein comprises the amino acid sequence of SEQ ID NO: 15.The antibody or fragment thereof has a VH domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 16, and retains (e.g., substantially retains, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 98%, or at least 99%) binding to ACVR2B (e.g., human ACVR2B).
[0280] In some embodiments, the antibody or fragment provided herein comprises a VH domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 17 and / or a VL domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 18, and retains (e.g., substantially retains, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) the binding of the antibody or fragment thereof to ACVR2B (e.g., human ACVR2B).
[0281] In some embodiments, the antibody or fragment provided herein comprises a VH domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 19 and / or a VL domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 20, and retains (e.g., substantially retains, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) binding of the antibody or fragment thereof to ACVR2B (e.g., human ACVR2B).
[0282] In some embodiments, the antibody or fragment provided herein comprises a VH domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 21 and / or a VL domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 22, and retains (e.g., substantially retains, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) the binding of the antibody or fragment thereof to ACVR2B (e.g., human ACVR2B).
[0283] In some embodiments, the antibody or fragment provided herein comprises a VH domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 23 and / or a VL domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 24, and retains (e.g., substantially retains, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) the binding of the antibody or fragment thereof to ACVR2B (e.g., human ACVR2B).
[0284] In some embodiments, the antibody or fragment provided herein comprises a VH domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 25 and / or a VL domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 26, and retains (e.g., baseEssentially maintaining, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) the binding of the antibody or its fragment to ACVR2B (e.g., human ACVR2B).
[0285] In some embodiments, the antibody or fragment provided herein comprises a VH domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 27 and / or a VL domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 28, and retains (e.g., substantially retains, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) binding of the antibody or fragment thereof to ACVR2B (e.g., human ACVR2B).
[0286] In some embodiments, the antibody or fragment provided herein comprises a VH domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 29 and / or a VL domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 30, and retains (e.g., substantially retains, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) binding of the antibody or fragment thereof to ACVR2B (e.g., human ACVR2B).
[0287] In some embodiments, the antibody or fragment provided herein comprises a VH domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 31 and / or having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, or at least 94% sequence identity with the amino acid sequence of SEQ ID NO: 32.The antibody or fragment thereof has at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the VL domain and retains (e.g., substantially retains, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) binding to ACVR2B (e.g., human ACVR2B).
[0288] In some embodiments, the antibody or fragment provided herein comprises a VH domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 33 and / or a VL domain having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 34, and retains (e.g., substantially retains, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) the binding of the antibody or fragment thereof to ACVR2B (e.g., human ACVR2B).
[0289] In some embodiments, functional epitopes can be mapped, for example, by combining alanine scans, to identify the amino acids in the ACVR2B protein necessary for interaction with the anti-ACVR2B antibodies provided herein. In some embodiments, the conformation and crystal structure of the anti-ACVR2B antibody bound to ACVR2B can be used to identify the epitope. In some embodiments, this disclosure provides antibodies that specifically bind to the same epitope as any anti-ACVR2B antibody provided herein. For example, in some embodiments, the antibody or antigen-binding fragment provided herein binds to the same epitope as an anti-ACVR2B antibody comprising a VH containing the amino acid sequence of SEQ ID NO: 1 and a VL containing the amino acid sequence of SEQ ID NO: 2. In some embodiments, the antibody or antigen-binding fragment provided herein binds to the same epitope as an anti-ACVR2B antibody comprising a VH containing the amino acid sequence of SEQ ID NO: 3 and a VL containing the amino acid sequence of SEQ ID NO: 4. In some embodiments, the antibody or antigen-binding fragment provided herein binds to the same epitope as the anti-ACVR2B antibody, which comprises VH containing the amino acid sequence of SEQ ID NO: 5 and VH containing the amino acid sequence of SEQ ID NO: 6.The antibody or antigen-binding fragment provided herein binds to the same epitope as the anti-ACVR2B antibody, which comprises a VH containing the amino acid sequence of SEQ ID NO: 7 and a VL containing the amino acid sequence of SEQ ID NO: 8. In some embodiments, the antibody or antigen-binding fragment provided herein binds to the same epitope as the anti-ACVR2B antibody, which comprises a VH containing the amino acid sequence of SEQ ID NO: 9 and a VL containing the amino acid sequence of SEQ ID NO: 10. In some embodiments, the antibody or antigen-binding fragment provided herein binds to the same epitope as the anti-ACVR2B antibody, which comprises a VH containing the amino acid sequence of SEQ ID NO: 11 and a VL containing the amino acid sequence of SEQ ID NO: 12. In some embodiments, the antibody or antigen-binding fragment provided herein binds to the same epitope as an anti-ACVR2B antibody, which comprises a VH containing the amino acid sequence of SEQ ID NO: 13 and a VL containing the amino acid sequence of SEQ ID NO: 14. In some embodiments, the antibody or antigen-binding fragment provided herein binds to the same epitope as an anti-ACVR2B antibody, which comprises a VH containing the amino acid sequence of SEQ ID NO: 15 and a VL containing the amino acid sequence of SEQ ID NO: 16. In some embodiments, the antibody or antigen-binding fragment provided herein binds to the same epitope as an anti-ACVR2B antibody, which comprises a VH containing the amino acid sequence of SEQ ID NO: 17 and a VL containing the amino acid sequence of SEQ ID NO: 18. In some embodiments, the antibody or antigen-binding fragment provided herein binds to the same epitope as an anti-ACVR2B antibody, which comprises a VH containing the amino acid sequence of SEQ ID NO: 19 and a VL containing the amino acid sequence of SEQ ID NO: 20. In some embodiments, the antibody or antigen-binding fragment provided herein binds to the same epitope as an anti-ACVR2B antibody, which comprises a VH containing the amino acid sequence of SEQ ID NO: 21 and a VL containing the amino acid sequence of SEQ ID NO: 22. In some embodiments, the antibody or antigen-binding fragment provided herein binds to the same epitope as an anti-ACVR2B antibody, which comprises a VH containing the amino acid sequence of SEQ ID NO: 23 and a VL containing the amino acid sequence of SEQ ID NO: 24. In some embodiments, the antibody or antigen-binding fragment provided herein binds to the same epitope as an anti-ACVR2B antibody.The anti-ACVR2B antibody contains the same epitope as the anti-ACVR2B antibody, comprising a VH containing the amino acid sequence of SEQ ID NO: 25 and a VL containing the amino acid sequence of SEQ ID NO: 26. In some embodiments, the antibody or antigen-binding fragment provided herein binds to the same epitope as the anti-ACVR2B antibody, comprising a VH containing the amino acid sequence of SEQ ID NO: 27 and a VL containing the amino acid sequence of SEQ ID NO: 28. In some embodiments, the antibody or antigen-binding fragment provided herein binds to the same epitope as the anti-ACVR2B antibody, comprising a VH containing the amino acid sequence of SEQ ID NO: 29 and a VL containing the amino acid sequence of SEQ ID NO: 30. In some embodiments, the antibody or antigen-binding fragment provided herein binds to the same epitope as the anti-ACVR2B antibody, comprising a VH containing the amino acid sequence of SEQ ID NO: 31 and a VL containing the amino acid sequence of SEQ ID NO: 32. In some embodiments, the antibody or antigen-binding fragment provided herein binds to the same epitope as an anti-ACVR2B antibody, which comprises a VH containing the amino acid sequence of SEQ ID NO: 33 and a VL containing the amino acid sequence of SEQ ID NO: 34.
[0290] In some embodiments, an anti-ACVR2B antibody or an antigen-binding fragment thereof is provided herein that competitively and specifically binds to ACVR2B with any of the anti-ACVR2B antibodies described herein. In some embodiments, the antibody or antigen-binding fragment provided herein competitively and specifically binds to ACVR2B with an anti-ACVR2B antibody, which comprises a VH containing the amino acid sequence of SEQ ID NO: 1 and a VL containing the amino acid sequence of SEQ ID NO: 2. In some embodiments, the antibody or antigen-binding fragment provided herein competitively and specifically binds to ACVR2B with an anti-ACVR2B antibody comprising a VH containing the amino acid sequence of SEQ ID NO: 3 and a VL containing the amino acid sequence of SEQ ID NO: 4. In some embodiments, the antibody or antigen-binding fragment provided herein competitively and specifically binds to ACVR2B with an anti-ACVR2B antibody comprising a VH containing the amino acid sequence of SEQ ID NO: 5 and a VL containing the amino acid sequence of SEQ ID NO: 6. In some embodiments...In some embodiments, the antibody or antigen-binding fragment provided herein competitively and specifically binds to ACVR2B with an anti-ACVR2B antibody comprising a VH containing the amino acid sequence of SEQ ID NO: 7 and a VL containing the amino acid sequence of SEQ ID NO: 8. In some embodiments, the antibody or antigen-binding fragment provided herein competitively and specifically binds to ACVR2B with an anti-ACVR2B antibody comprising a VH containing the amino acid sequence of SEQ ID NO: 9 and a VL containing the amino acid sequence of SEQ ID NO: 10. In some embodiments, the antibody or antigen-binding fragment provided herein competitively and specifically binds to ACVR2B with an anti-ACVR2B antibody comprising a VH containing the amino acid sequence of SEQ ID NO: 11 and a VL containing the amino acid sequence of SEQ ID NO: 12. In some embodiments, the antibody or antigen-binding fragment provided herein competitively and specifically binds to ACVR2B with an anti-ACVR2B antibody comprising a VH containing the amino acid sequence of SEQ ID NO: 13 and a VL containing the amino acid sequence of SEQ ID NO: 14. In some embodiments, the antibody or antigen-binding fragment provided herein competitively and specifically binds to ACVR2B with an anti-ACVR2B antibody comprising a VH containing the amino acid sequence of SEQ ID NO: 15 and a VL containing the amino acid sequence of SEQ ID NO: 16. In some embodiments, the antibody or antigen-binding fragment provided herein competitively and specifically binds to ACVR2B with an anti-ACVR2B antibody comprising a VH containing the amino acid sequence of SEQ ID NO: 17 and a VL containing the amino acid sequence of SEQ ID NO: 18. In some embodiments, the antibody or antigen-binding fragment provided herein competitively and specifically binds to ACVR2B with an anti-ACVR2B antibody comprising a VH containing the amino acid sequence of SEQ ID NO: 19 and a VL containing the amino acid sequence of SEQ ID NO: 20. In some embodiments, the antibody or antigen-binding fragment provided herein competitively and specifically binds to ACVR2B with an anti-ACVR2B antibody comprising a VH containing the amino acid sequence of SEQ ID NO: 21 and a VL containing the amino acid sequence of SEQ ID NO: 22. In some embodiments, the antibody or antigen-binding fragment provided herein competitively and specifically binds to ACVR2B with an anti-ACVR2B antibody comprising the amino acid sequence of SEQ ID NO: 23.The antibody or antigen-binding fragment provided herein competitively and specifically binds to ACVR2B with an anti-ACVR2B antibody comprising a VH containing the amino acid sequence of SEQ ID NO: 25 and a VL containing the amino acid sequence of SEQ ID NO: 26. In some embodiments, the antibody or antigen-binding fragment provided herein competitively and specifically binds to ACVR2B with an anti-ACVR2B antibody comprising a VH containing the amino acid sequence of SEQ ID NO: 27 and a VL containing the amino acid sequence of SEQ ID NO: 28. In some embodiments, the antibody or antigen-binding fragment provided herein competitively and specifically binds to ACVR2B with an anti-ACVR2B antibody comprising a VH containing the amino acid sequence of SEQ ID NO: 29 and a VL containing the amino acid sequence of SEQ ID NO: 30. In some embodiments, the antibody or antigen-binding fragment provided herein competitively and specifically binds to ACVR2B with an anti-ACVR2B antibody comprising a VH containing the amino acid sequence of SEQ ID NO: 31 and a VL containing the amino acid sequence of SEQ ID NO: 32. In some embodiments, the antibody or antigen-binding fragment provided herein competitively and specifically binds to ACVR2B with an anti-ACVR2B antibody comprising a VH containing the amino acid sequence of SEQ ID NO: 33 and a VL containing the amino acid sequence of SEQ ID NO: 34. Specification 46 / 108 pages 54 CN 121909215 A
[0291] In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 239. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a light chain containing the amino acid sequence of SEQ ID NO: 240. In some embodiments, the anti-ACVR2B antibody or antigen-binding fragment provided herein comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 239 and a light chain containing the amino acid sequence of SEQ ID NO: 240.
[0292] In some embodiments, the antibody or antigen-binding fragment provided herein is IgG. In some embodiments, the antibody or antigen-binding fragment provided herein is IgG1. In some embodiments, the antibody is a human antibody. In some embodiments, the antibody or antigen-binding fragment provided herein contains one or more mutations in the Fc region to reduce or eliminate the antibody.Cell-dependent cell-mediated cytotoxicity (ADCC) and / or complement-dependent cytotoxicity (CDC) effects. In some embodiments, the antibody or antigen-binding fragments provided herein contain one or both mutations of L239A and L240A in the Fc region. In some embodiments, the antibody or antigen-binding fragments provided herein contain mutations of L239A and L240A in the Fc region. In some embodiments, the antibody or antigen-binding fragments provided herein contain one or both mutations of L234A and L235A in the Fc region to reduce effector functions such as ADCC or CDC. In some embodiments, the antibody or antigen-binding fragments provided herein contain mutations of L234A and L235A in the Fc region. (Lund J et al., J Immunol. 147: 2657–2662 (1991)).
[0293] In some embodiments, the ACVR2B binding protein comprising any of the anti-ACVR2B antibodies described above is provided herein. In some embodiments, the ACVR2B binding protein is a monoclonal antibody, including mouse antibodies, chimeric antibodies, humanized antibodies, or human antibodies. In some embodiments, the anti-ACVR2B antibody is an antibody fragment (e.g., scFv). In some embodiments, the ACVR2B binding protein is a fusion protein comprising the anti-ACVR2B antibody provided herein. In other embodiments, the ACVR2B binding protein is a multispecific antibody comprising the anti-ACVR2B antibody provided herein. Other exemplary ACVR2B binding molecules are described in more detail in the following sections.
[0294] In some embodiments, the anti-ACVR2B antibody or antigen-binding protein according to any of the above embodiments may be incorporated, alone or in combination, with any feature as described in sections 5.2.2 through 5.2.6 below.
[0295] 5.2.2. Antibody Fragments
[0296] As used herein, the term “antibody” also includes various antibody fragments thereof. The antibodies provided herein include, but are not limited to, immunoglobulin molecules and immunologically active portions of immunoglobulin molecules. The immunoglobulin molecules provided herein can be any class of immunoglobulin molecules (e.g., IgG, IgE, IgM, IgD, and IgA) or any subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2). In some embodiments, the antibody is an IgG antibody. In some embodiments, the IgG antibody is an IgG1 antibody. In some embodiments, the IgG antibody is an IgG2 antibody, an IgG3 antibody, or an IgG4 antibody.
[0297] Variants and derivatives of the antibody include antibody functional fragments that retain the ability to bind to an antigen. Exemplary functional fragments include Fab fragments (e.g., those containing an antigen-binding domain and comprising a light chain and a portion of a heavy chain bridged by disulfide bonds).Fab' (e.g., an antibody fragment containing a single antigen-binding domain comprising a Fab and an additional portion of the heavy chain via a hinge region); F(ab')2 (e.g., two Fab' molecules linked by interchain disulfide bonds in the hinge region of the heavy chain; the Fab' molecules may target the same or different epitopes); bispecific Fab (e.g., a Fab molecule having two antigen-binding domains, each of which may target a different epitope); a single chain containing a variable region, also known as scFv (e.g., a variable antigen-binding determinant region of a single light and heavy chain of an antibody linked together by, for example, 10 to 25 amino acids); disulfide-linked Fv or dsFv (e.g., a variable antigen-binding determinant region of a single light and heavy chain of an antibody linked together by disulfide bonds); camelified VH (e.g., a variable antigen-binding determinant region of a single heavy chain of an antibody, wherein some amino acids at the VH interface are those found in naturally occurring camel antibody heavy chains); bispecific scFv Specification 47 / 108 pages 55 CN 121909215 A (e.g., an scFv or dsFv molecule having two antigen-binding domains, wherein each antigen-binding domain may target a different epitope); biantibodies (e.g., a dimerized scFv formed when the VH domain of a first scFv is assembled with the VL domain of a second scFv and the VL domain of the first scFv is assembled with the VH domain of the second scFv; the two antigen-binding regions of the biantibody may target the same or different epitopes); triantibodies (e.g., a trimerized scFv formed in a manner similar to a biantibody, but wherein three antigen-binding domains are generated in a single complex; the three antigen-binding domains may target the same or different epitopes); and tetraantibodies (e.g., a tetramerized scFv formed in a manner similar to a biantibody, but wherein four antigen-binding domains are generated in a single complex; the four antigen-binding domains may target the same or different epitopes).
[0298] Various techniques have been developed to generate antibody fragments. Traditionally, these fragments are obtained through the proteolytic digestion of intact antibodies (see, for example, Morimoto et al., 1992, J. Biochem. Biophys. Methods 24: 107–17; and Brennan et al., 1985, Science 229: 81–83). However, these fragments can now be produced directly from recombinant host cells. For example, Fab, Fv, and scFv antibody fragments can all be expressed and secreted from E. coli or yeast cells, thus allowing for the easy production of large quantities of these fragments. The antibody fragments can be isolated from the aforementioned antibody phage libraries. Alternatively, the Fab'-SH fragment can be directly recovered from E. coli and chemically conjugated to form the F(ab')2 fragment.(Carter et al., 1992, Bio / Technology 10: 163-67). According to another method, the F(ab')2 fragment can be isolated directly from recombinant host cell cultures. Fab and F(ab')2 fragments containing salvage receptor-binding epitope residues with increased in vivo half-lives are described, for example, in U.S. Patent No. 5,869,046. Other techniques for generating antibody fragments will be apparent to those skilled in the art. In some embodiments, the antibody is a single-chain Fv fragment (scFv) (see, for example, WO 93 / 16185; U.S. Patent Nos. 5,571,894 and 5,587,458). Fv and scFv have intact binding sites without constant regions; therefore, they are adapted to reduce nonspecific binding during in vivo use. scFv fusion proteins can be constructed to produce fusions of effector proteins at the amino or carboxyl termini of the scFv (see, for example, Borrebaeck et al., above). Antibody fragments can also be “linear antibodies,” for example, as described in the references cited above. Such linear antibodies can be monospecific or multispecific, such as bispecific.
[0299] 5.2.3. Antibody Variants
[0300] Modifications to the antibodies bound to ACVR2B described herein are considered. For example, it may be desirable to optimize the binding affinity and / or other biological properties of the antibody, including but not limited to specificity, thermal stability, expression level, effector function, glycosylation, reduced immunogenicity, or solubility. Therefore, it is contemplated that variants of the antibodies bound to ACVR2B described herein can be prepared and included in this disclosure. In some embodiments, an antibody variant is an antibody having an amino acid sequence variation compared to the original antibody, for example, substitution, deletion, or insertion of one or more amino acids as described above. For example, the variation can be a substitution, deletion, or insertion of one or more codons encoding the antibody or polypeptide, resulting in a change in the amino acid sequence compared to the original antibody or polypeptide (e.g., conserved substitution). Sites of interest for substitution mutagenesis include CDR, FR, and / or constant regions. For example, antibody variants can be prepared by introducing appropriate nucleotide changes into the encoding DNA and / or by synthesizing the desired antibody or peptide. Those skilled in the art will understand that amino acid changes may alter the post-translational processes of the antibody.
[0301] Modifications of the antibodies bound to ACVR2B as described herein are contemplated. For example, it may be desirable to optimize the binding affinity and / or other biological properties of the antibody, including but not limited to specificity, thermal stability, expression level, effector function, glycosylation, reduced immunogenicity, or solubility. Therefore, it is contemplated that variants of the antibodies bound to ACVR2B as described herein can be prepared and are included in this disclosure. In some embodiments, the antibody variant is one with amino acid sequence variations compared to the original antibody.Antibodies, for example, substitutions, deletions, or insertions of one or more amino acids as described above. For example, a mutation can be a substitution, deletion, or insertion of one or more codons encoding an antibody or polypeptide that results in a change in the amino acid sequence compared to the original antibody or polypeptide (e.g., a conserved substitution). Sites of interest for substitution mutagenesis include CDRs, FRs, and / or constant regions. For example, antibody variants can be prepared by introducing appropriate nucleotide changes into the encoding DNA and / or by synthesizing the desired antibody or polypeptide, as described on page 56 of specification 48 / 108 (CN 121909215 A). Those skilled in the art will understand that amino acid changes can alter the post-translational processes of antibodies.
[0302] Chemical Modification
[0303] In some embodiments, the antibodies provided herein are chemically modified, for example by covalent linkage of any type of molecule to the antibody. Antibody derivatives may include antibodies that have been chemically modified, such modifications being made, for example, by glycosylation, acetylation, polyethylene glycolation, phosphorylation, amidation, derivatization by known protecting / blocking groups, proteolytic cleavage, linkage to cellular ligands or other proteins, or conjugation to one or more immunoglobulin domains (e.g., Fc or a portion of Fc). Any of these chemical modifications can be performed using known techniques, including but not limited to specific chemical cleavage, acetylation, formulation, metabolic synthesis of tunicamycin, etc. Additionally, antibodies may contain one or more non-classical amino acids.
[0304] In some embodiments, the antibodies provided herein are modified to increase or decrease the degree to which the antibody is glycosylated. The addition or deletion of glycosylation sites can be conveniently achieved by altering the amino acid sequence to create or remove one or more glycosylation sites.
[0305] When the antibodies provided herein are fused to the Fc region, the carbohydrates linked to them can be modified. Naturally occurring antibodies produced by mammalian cells typically contain branched biantennary oligosaccharides, which are typically linked to the Asn297 of the CH2 domain of the Fc region via N-linking. See, for example, Wright et al., TIBTECH 15: 26-32 (1997). Oligosaccharides can include various carbohydrates such as mannose, N-acetylglucosamine (GlcNAc), galactose and sialic acid, and fucose linked to GlcNAc in the “stem” of the biantennary oligosaccharide structure. In some embodiments, the oligosaccharides in the binding molecules provided herein can be modified to produce variants with certain improved properties.
[0306] In other embodiments, when the antibody provided herein is fused to the Fc region, the antibody variant provided herein may have a carbohydrate structure lacking fucose linked (directly or indirectly) to said Fc region. For example, the amount of fucose in such an antibody may be 1% to 80%, 1% to 65%, 5% to 65%, or 20% to 40%. The amount of fucose is determined by the followingThe method for determining this is as follows: The average amount of fucose at Asn297 within the sugar chain is calculated relative to the sum of all sugar structures (e.g., complex, hybrid, and high-mannose structures) linked to Asn297, as measured by MALDI-TOF mass spectrometry, as described, for example, in WO 2008 / 077546. Asn297 refers to the asparagine residue located approximately at position 297 (EU number of the Fc region residue) in the Fc region; however, Asn297 can also be located approximately ±3 amino acids upstream or downstream of position 297, i.e., between position 294 and position 300, due to minor sequence variations in the antibody. Such fucoidylated variants can have improved ADCC function. See, for example, US Patent Publications US 2003 / 0157108 and US 2004 / 0093621. Examples of publications relating to “defucosylated” or “fucose-deficient” antibody variants include: US 2003 / 0157108; WO 2000 / 61739; WO 2001 / 29246; US 2003 / 0115614; US 2002 / 0164328; US 2004 / 0093621; US 2004 / 0132140; US 2004 / 0110704; US 2004 / 0110282; US 2004 / 0109865; WO 2003 / 085119; WO 2003 / 084570; WO 2005 / 035586; WO 2005 / 035778; WO2005 / 053742; WO2002 / 031140; Okazaki et al. J. Mol. Biol. 336: 1239-1249 (2004); Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004). Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells lacking protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249: 533-545 (1986); US Patent Application No. US 2003 / 0157108; and WO 2004 / 056312), and knockout cell lines, such as α-1,6-fucosyltransferase gene FUT8 knockout CHO cells (see, for example, Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004); Kanda, Y. et al. Biotechnol. Bioeng., 94(4): 680-688 (2006); and WO2003 / 085107).
[0307] Binding molecules containing the antibodies provided herein also provide bimeric oligosaccharides, for example, wherein the biantennary oligosaccharide linked to the Fc region is bimeric by GlcNAc. Such variants may have reduced fucosylation and / or improved ADCC function. Examples of such variants are described, for example, in WO 2003 / 011878 (Jean-Mairet et al.); U.S. Patent No. 6,602,684 (Umana et al.); and US 2005 / 0123546 (Umana et al.). Variants are also provided in which the Fc-linked oligosaccharide has at least one galactose residue. Such variants may have improved CDC function. Such variants are described, for example, in WO 1997 / 30087; WO 1998 / 58964; and WO 1999 / 22764.
[0308] In molecules comprising the antibody of the present invention and the Fc region, one or more amino acid modifications may be introduced into the Fc region to produce Fc region variants. Fc region variants may comprise a human Fc region sequence (e.g., human IgG1, IgG2, IgG3, or IgG4 Fc region) containing amino acid modifications (e.g., substitutions) at one or more amino acid positions.
[0309] In some embodiments, this application contemplates variants having some, but not all, effector functions, making them desirable candidates for applications where the in vivo half-life of the binding molecule is important but certain effector functions (such as complement and ADCC) are unnecessary or detrimental. In vitro and / or in vivo cytotoxicity assays may be performed to confirm a reduction / depletion of CDC and / or ADCC activity. For example, Fc receptor (FcR) binding assays may be performed to ensure that the binding molecule lacks FcγR binding (and therefore may lack ADCC activity), but retains FcRn binding capacity. Non-limiting examples of in vitro assays for evaluating the ADCC activity of molecules of interest are described in U.S. Patent No. 5,500,362 (see, for example, Hellstrom, I. et al., Proc. Nat'l Acad. Sci. USA 83: 7059–7063 (1986)) and Hellstrom, I. et al., Proc. Nat'l Acad. Sci. USA 82: 1499–1502 (1985); 5,821,337 (see, for example, Bruggemann, M. et al., J. Exp. Med. 166: 1351–1361 (1987)). Alternatively, non-radioactive assays may be used (see, for example, the ACTI™ non-radioactive cytotoxicity assay for flow cytometry (Cell Technology, Inc. Mountain View, CA); and CytoTox 96® non-radioactive assay).Cytotoxicity assays (Promega, Madison, WI). Effector cells that can be used for such assays include peripheral blood mononuclear cells (PBMCs) and natural killer (NK) cells. Alternatively or additionally, the ADCC activity of the molecule of interest can be assessed in vivo, for example in animal models, as disclosed in Clynes et al., Proc. Nat'l Acad. Sci. USA 95: 652-656 (1998). C1q binding assays can also be performed to confirm that the antibody does not bind C1q and therefore lacks CDC activity. See, for example, C1q and C3c binding ELISAs in WO 2006 / 029879 and WO 2005 / 100402. To assess complement activation, CDC assays can be performed (see, for example, Gazzano-Santoro et al., J. Immunol. Methods 202: 163 (1996); Cragg, MS et al., Blood 101: 1045–1052 (2003); and Cragg, MS and MJ Glennie, Blood 103: 2738–2743 (2004)). FcRn binding and in vivo clearance / half-life assays can also be performed using methods known in the art (see, for example, Petkova, SB et al., Int'l. Immunol. 18(12): 1759–1769 (2006)).
[0310] Binding molecules with reduced effector function include those with substitutions of one or more of the Fc region residues 238, 265, 269, 270, 297, 327, and 329 (US Patent No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more of the amino acid positions 265, 269, 270, 297, and 327, including the so-called “DANA” Fc mutant where residues 265 and 297 are substituted for alanine (US Patent No. 7,332,581).
[0311] In some embodiments, the antibody or antigen-binding fragments provided herein include one or both mutations of L239A and L240A in the Fc region to reduce effector function such as ADCC or CDC. In some embodiments, the antibody or antigen-binding fragments provided herein include mutations of L239A and L240A in the Fc region.
[0312] In some embodiments, the antibody or antigen-binding fragments provided herein include one or both mutations of L234A and L235A in the Fc region to reduce effector functions such as ADCC or CDC. In some embodiments, the antibody or antigen-binding fragments provided herein include mutations of L234A and L235A in the Fc region. (Lund)J et al., J Immunol. 147: 2657–2662 (1991)). Specification 50 / 108 pages 58 CN 121909215 A
[0313] describes certain variants with improved or reduced binding to FcR. (See, for example, U.S. Patent No. 6,737,056; WO 2004 / 056312, and Shields et al., J. Biol. Chem. 9(2): 6591–6604 (2001)).
[0314] In some embodiments, the variants comprise an Fc region with one or more amino acid substitutions that improve ADCC, such as substitutions at positions 298, 333 and / or 334 of the Fc region (EU numbers of the residues). In some embodiments, alterations are made in the Fc region that produce altered (i.e., improved or reduced) C1q binding and / or complement-dependent cytotoxicity (CDC), as described, for example, in U.S. Patent No. 6,194,551, WO 99 / 51642 and Idusogie et al., J. Immunol. 164: 4178–4184 (2000).
[0315] Binding molecules with increased half-life and improved binding to the neonatal Fc receptor (FcRn) responsible for transferring maternal IgG to the fetus (Guyer et al., J. Immunol. 117: 587 (1976) and Kim et al., J. Immunol. 24: 249 (1994)) are described in US2005 / 0014934A1 (Hinton et al.). Those molecules contain an Fc region having one or more substitutions that improve the binding of the Fc region to FcRn. Such Fc variants include those having substitutions at one or more of the following Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424, or 434, for example, the substitution of Fc region residue 434 (U.S. Patent No. 7,371,826). For other examples of Fc region variants, see also Duncan and Winter, Nature 322: 738-40 (1988); U.S. Patent No. 5,648,260; U.S. Patent No. 5,624,821; and WO 94 / 29351.
[0316] In some embodiments, it may be desirable to produce cysteine-engineered antibodies, wherein one or more residues of the antibody are replaced by cysteine residues. In some embodiments, the substituted residues are located at accessible sites on the antibody. By usingCysteine residues are substituted, thereby positioning reactive thiol groups at accessible sites on the antibody and allowing them to be used to conjugate the antibody to other parts, such as pharmaceutical parts or linker-pharmaceutical parts, to produce immunoconjugates, as further described herein.
[0317] Substitution, Deletion, or Insertion
[0318] Mutations can be substitutions, deletions, or insertions of one or more codons encoding an antibody or polypeptide that result in a change in the amino acid sequence compared to the original antibody or polypeptide. Sites of interest for substitution mutagenesis include CDR and FR.
[0319] Amino acid substitution can be the result of replacing one amino acid with another amino acid having similar structure and / or chemical properties (such as replacing leucine with serine, for example, a conserved amino acid substitution). Mutations can be introduced into the nucleotide sequence encoding the molecules provided herein using standard techniques known to those skilled in the art, including, for example, site-directed mutagenesis leading to amino acid substitution and PCR-mediated mutagenesis. Insertions or deletions can optionally be in the range of about 1 to 5 amino acids. In some embodiments, substitution, deletion, or insertion includes substitutions of fewer than 25 amino acids, fewer than 20 amino acids, fewer than 15 amino acids, fewer than 10 amino acids, fewer than 5 amino acids, fewer than 4 amino acids, fewer than 3 amino acids, or fewer than 2 amino acids relative to the original molecule. In a specific embodiment, substitution is a conserved amino acid substitution performed at one or more predicted non-essential amino acid residues. Permissible variations can be determined by systematically inserting, deleting, or substituting amino acids in the sequence and testing the activity exhibited by the parent antibody in the resulting variant.
[0320] Amino acid sequence insertion includes amino-terminal and / or carboxyl-terminal fusions ranging in length from one residue to a polypeptide containing multiple residues, and intra-sequence insertions of a single amino acid residue or multiple amino acid residues. Examples of terminal insertions include antibodies having an N-terminal methionine residue.
[0321] Antibodies generated by conserved amino acid substitution are included in this disclosure. In conserved amino acid substitution, an amino acid residue is replaced by an amino acid residue having a side chain with a similar charge. As described above, families of amino acid residues with similarly charged side chains, as defined in this art (page 51 / 108, CN 121909215 A), are included. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), amino acids with uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), amino acids with nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), amino acids with β-branched side chains (e.g., threonine, valine, isoleucine), and amino acids with aromatic side chains.The side chain amino acids (e.g., tyrosine, phenylalanine, tryptophan, histidine). Alternatively, mutations can be randomly introduced along all or part of the coding sequence, such as through saturation mutagenesis, and the resulting mutants can be screened for biological activity to identify mutants that retain activity. After mutagenesis, the encoded protein can be expressed, and the protein's activity can be determined. Conserved substitutions can be made (e.g., within amino acid groups having similar properties and / or side chains) to maintain the property or not significantly alter it. Exemplary substitutions are shown in Table 2 below.
[0322]
[0323] Amino acids can be grouped according to the similarity of the characteristics of their side chains (see, for example, Lehninger, Biochemistry 73-75 (2nd edition, 1975)): (1) Nonpolar: Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M); (2) Uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q); (3) Acidic: Asp (D), Glu (E); and (4) Basic: Lys (K), Arg (R), His (H). Alternatively, naturally occurring residues can be grouped into several groups based on common side-chain properties: (1) hydrophobic: leucine, Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues affecting chain orientation: Gly, Pro; and (6) aromatic: Trp, Tyr, Phe. For example, any cysteine residue that does not participate in maintaining the correct conformation of the antibody can also be replaced, for example, with another amino acid (such as alanine or serine) to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Non-conservative substitution would require exchanging members of one of these categories for another.
[0324] One type of substitution variant involves substituting one or more hypervariable residues of the parent antibody (e.g., humanized or human antibody). Typically, the resulting variants selected for further research will have modifications (e.g., improvements) in certain biological properties (e.g., increased affinity, decreased immunogenicity) relative to the parent antibody, and / or will substantially retain some of the biological properties of the parent antibody. Exemplary substitution variants are affinity-matured antibodies, which can be conveniently generated, for example, using phage display-based affinity maturation techniques (such as those described herein). In short, one or more CDR residues are mutated, and the variant antibody is displayed on a phage and screened for specific biological activities (e.g., binding affinity). Specification 52 / 108 pages 60 CN 121909215 A
[0325] Alterations (e.g., substitutions) can be made in the CDR, for example, to improve antibody affinity. Such alterations can be made in CDR “hotspots” (i.e., residues encoded by codons that undergo mutations at a high frequency during somatic maturation) (see, for example, Chowdhury, Methods Mol. Biol. 207: 179–196 (2008)) and / or SDR (a-CDR), where the binding affinity of the resulting variant antibody or fragment thereof is tested. Affinity maturation by constructing and reselecting from a secondary library has been described, for example, in Hoogenboom et al., Methods in Molecular Biology 178: 1–37 (edited by O'Brien et al., Human Press, Totowa, NJ, (2001)). In some embodiments of affinity maturation, diversity is introduced into the variable gene selected for maturation using any of a variety of methods (e.g., error-prone PCR, strand shuffling, or oligonucleotide directed mutagenesis). A secondary library is then created. This library is then screened to identify any antibody variant with the desired affinity. Another approach to introducing diversity involves methods targeting CDRs, where several CDR residues (e.g., four to six residues at a time) are randomized. CDR residues involved in antigen binding can be specifically identified, for example, using alanine scan mutagenesis or modeling. A more detailed description of affinity maturation is provided below.
[0326] In some embodiments, substitutions, insertions, or deletions may occur within one or more CDRs, as long as such changes do not substantially reduce the antibody's ability to bind to the antigen. For example, conserved changes (e.g., conserved substitutions as provided herein) that do not substantially reduce binding affinity can be made in CDRs. In some embodiments of the variant antibody sequences provided herein, each CDR is unchanged or contains no more than one, two, or three amino acid substitutions.
[0327] A useful method for identifying residues or regions of an antibody that can be targeted for mutagenesis is known as "alanine scan mutagenesis," as described in Cunningham and Wells, Science, 244: 1081-1085 (1989). In this method, a residue or group of target residues (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) is identified and substituted with a neutral or negatively charged amino acid (e.g., alanine or polyalanine) to determine whether the antibody-antigen interaction is affected. Additional substitutions can be introduced at amino acid positions that exhibit functional sensitivity to the initial substitution. Alternatively or additionally, the crystal structure of the antigen-antibody complex is used to identify the contact points between the antibody and antigen.The base and adjacent residues can be targeted or eliminated as candidates for substitution. Variants can be screened to determine whether they contain the desired properties.
[0328] Amino acid sequence insertions include amino-terminal and / or carboxyl-terminal fusions ranging in length from one residue to peptides containing one hundred or more residues, as well as intra-sequence insertions of a single amino acid residue or multiple amino acid residues. Examples of terminal insertions include antibodies having an N-terminal methionine residue. Other insertion variants of antibody molecules include fusions of the N-terminus or C-terminus of the antibody with an enzyme (e.g., for ADEPT) or peptide that increases the serum half-life of the antibody.
[0329] Mutation can be performed using methods known in the art, such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis (see, for example, Carter, Biochem J. 237: 1–7 (1986); and Zoller et al., Nucl. Acids Res. 10: 6487–500 (1982)), cassette mutagenesis (see, for example, Wells et al., Gene 34: 315–23 (1985)) or other known techniques can be performed on cloned DNA to produce antibody variant DNA.
[0330] 5.2.4. In vitro affinity maturation
[0331] In some embodiments, antibody variants with improved properties (such as affinity, stability, or expression level) compared to the parent antibody can be prepared by in vitro affinity maturation. As with the natural prototype, in vitro affinity maturation is based on the principles of mutation and selection. The antibody library is displayed on the surface of an organism (e.g., bacteriophage, bacteria, yeast, or mammalian cells) or associated with its encoding mRNA or DNA (e.g., covalently or non-covalently). Affinity selection of displayed antibodies allows for the separation of organisms or complexes carrying genetic information encoding antibodies. Two or three rounds of mutation and selection using display methods (such as phage display) typically produce antibody fragments with low nanomolar affinities. Affinity-matured antibodies can have nanomolar or even picomolar affinities to target antigens. Specification 53 / 108 pages 61 CN 121909215 A
[0332] Phage display is a widely used method for displaying and selecting antibodies. Antibodies are displayed as fusions with bacterial phage capsid proteins on the surface of Fd or M13 bacterial phages. Selection involves exposing antibodies to antigens to allow phage-displayed antibodies to bind to their targets; this process is called “panning”. Phages that have bound to antigens are recovered and used to infect bacteria to produce phages for another round of selection. For reviews, see, for example, Hoogenboom, Methods. Mol. Biol. 178: 1–37 (2002); and Bradbury and Marks, J.Immunol. Methods 290: 29-49 (2004).
[0333] In some embodiments, a mammalian display system may be used.
[0334] Diversity may also be introduced into the CDRs of an antibody library either in a targeted manner or by random introduction. The former approach includes targeting all CDRs of the antibody sequentially by high or low levels of mutagenesis, or targeting somatic hypermutation hotspots (see, for example, Ho et al., J. Biol. Chem. 280: 607-17 (2005)) or residues suspected of affecting affinity based on experimental or structural reasons. Diversity may also be introduced by replacing naturally diverse regions with DNA shuffling or similar techniques (see, for example, Lu et al., J. Biol. Chem. 278: 43496-507 (2003); U.S. Patent Nos. 5,565,332 and 6,989,250). Alternative techniques for targeting hypervariable loops extending into framework region residues (see, for example, Bond et al., J. Mol. Biol. 348: 699-709 (2005)) employ loop deletions and insertions in the CDR or use hybridization-based diversification (see, for example, U.S. Patent Publication No. 2004 / 0005709). Further methods for generating diversification in the CDR are disclosed, for example, in U.S. Patent No. 7,985,840. Other methods that can be used to generate antibody libraries and / or mature antibody affinity are disclosed, for example, in U.S. Patent Nos. 8,685,897 and 8,603,930 and U.S. Publications Nos. 2014 / 0170705, 2014 / 0094392, 2012 / 0028301, 2011 / 0183855, and 2009 / 0075378, each of which is incorporated herein by reference.
[0335] Library screening can be accomplished by various techniques known in the art. For example, antibodies can be immobilized on solid supports, columns, needles, or cellulose / poly(vinylidene fluoride) membranes / other filters for expression on host cells attached to an adsorption plate or for cell sorting, or conjugated to biotin for capture with streptavidin-coated beads or for any other method of panning and displaying libraries.
[0336] For reviews of in vitro affinity maturation methods, see, for example, Hoogenboom, Nature Biotechnology 23: 1105-16 (2005); Quiroz and Sinclair, Revista Ingeneria Biomedia 4: 39-51 (2010); and references therein.
[0337] 5.2.5. Antibody Modification
[0338] Covalent modification of antibodies is included within the scope of this disclosure. Covalent modification includes modifying the target amino acid residues of the antibody.The group reacts with an organic derivatizing agent capable of reacting with selected side chains or N-terminal or C-terminal residues of the antibody. Other modifications include deamidation of glutamine acyl and asparagine acyl residues to their corresponding glutamine acyl and asparagine acyl residues, respectively; hydroxylation of proline and lysine; phosphorylation of the hydroxyl groups of serine or threonine residues; methylation of the α-amino groups of the lysine, arginine, and histidine side chains (see, for example, Creighton, Proteins: Structure and Molecular Properties 79–86 (1983)); acetylation of the N-terminal amine; and amidation of any C-terminal carboxyl group.
[0339] Other types of covalent modifications included within the scope of this disclosure include altering the native glycosylation pattern of the antibody or peptide as described above (see, for example, Beck et al., Curr. Pharm. Biotechnol. 9: 482-501 (2008); and Walsh, Drug Discov. Today 15: 773-80 (2010)), and linking the antibody to one of a variety of non-protein polymers (e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyethylene) in a manner set forth, for example, in the following documents: U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; or 4,179,337. The antibodies of this disclosure that bind to ACVR2B can also be genetically fused or conjugated to one or more immunoglobulin constant regions or portions thereof (e.g., Fc) to prolong half-life and / or confer known Fc-mediated effector functions.
[0340] The antibodies of this disclosure that bind to ACVR2B can also be modified to form chimeric molecules comprising the antibody bound to ACVR2B, which is fused with another heterologous polypeptide or amino acid sequence (e.g., epitope tag) (see, for example, Terpe, Appl. Microbiol. Biotechnol. 60: 523-33 (2003)) or the Fc region of an IgG molecule (see, for example, Aruffo, Antibody Fusion Proteins 221-42 (edited by Chamow and Ashkenazi, 1999)).
[0341] Fusion proteins comprising the antibody of this disclosure that binds to ACVR2B and a heterologous polypeptide are also provided herein. In some embodiments, heterologous peptides fused to or chemically conjugated with antibody genes can be used to target antibodies to cells expressing ACVR2B on their cell surface.
[0342] This document also provides sets of antibodies that bind to the ACVR2B antigen. In specific embodiments, the antibody sets have different association rates, different dissociation rates, different affinities for the ACVR2B antigen, and / or different specificities for the ACVR2B antigen. In some embodiments, the set comprises or consists of about 10 to about 1000 or more antibodies. The antibody sets can be used, for example, in 96-well or 384-well plates for assays such as ELISA.
[0343] 5.2.6. Other binding molecules containing antibodies
[0344] In another aspect, this document provides binding molecules that contain the anti-ACVR2B antibodies provided herein. In some embodiments, the antibodies against ACVR2B provided herein are part of other binding molecules. Exemplary binding molecules of this disclosure are described herein.
[0345] Fusion proteins
[0346] In various embodiments, the antibodies provided herein can be fused or chemically conjugated to the gene of another agent (e.g., a protein-based entity). The antibody can be chemically conjugated to the agent or otherwise non-covalently conjugated to the agent. The agent may be a peptide or antibody (or a fragment thereof).
[0347] Accordingly, in some embodiments, antibodies and their uses are provided herein, which are recombinantly fused or chemically conjugated (covalently or non-covalently conjugated) to a heterologous protein or polypeptide (or a fragment thereof, for example, about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100, about 150, about 200, about 250, about 300, about 350, about 400, about 450 or about 500 amino acids or more than 500 amino acids) to produce a fusion protein. In particular, fusion proteins are provided herein that comprise an antigen-binding fragment (e.g., CDR1, CDR2 and / or CDR3) of the antibody provided herein and a heterologous protein, polypeptide or peptide.
[0348] Furthermore, the antibodies provided herein can be fused with labeled or “tag” sequences, such as peptides, to facilitate purification. In specific embodiments, the labeled or tagged amino acid sequences are hexahistine peptides, hemagglutinin (“HA”) tags, and “FLAG” tags.
[0349] Methods for fusing or conjugating portions (including peptides) to antibodies are known (see, for example, Arnon et al., Monoclonal Antibodies for Immunotargeting of Drugs in Cancer Therapy, in Monoclonal Antibodies and Cancer Therapy 243-56 (edited by Reisfeld et al., 1985); Hellstrom et al., Antibodies for DrugDelivery, in Controlled Drug Delivery 623-53 (edited by Robinson et al., 2nd edition, 1987); Thorpe, Antibody Carriers of Cytotoxic Agents in Cancer Therapy: A Review, in Monoclonal Antibodies: Biological and Clinical Applications 475-506 (edited by Pinchera et al., 1985); Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody in Cancer Therapy, in Monoclonal Antibodies for Cancer Detection and Therapy 303-16 (edited by Baldwin et al., 1985); Thorpe et al., Immunol. Rev. 62: 119-58 (1982); US Patent No. 5, Specification 55 / 108 pages 63 CN 121909215 A No. 336,603; No. 5,622,929; No. 5,359,046; No. 5,349,053; No. 5,447,851; No. 5,723,125; No. 5,783,181; No. 5,908,626; No. 5,844,095; and No. 5,112,946; EP 307,434; EP 367,166; EP 394,827; PCT Publications WO 91 / 06570, WO 96 / 04388, WO 96 / 22024, WO 97 / 34631 and WO 99 / 04813; Ashkenazi et al., Proc. Natl. Acad. Sci. USA, 88: 10535-39 (1991); Traunecker et al., Nature, 331: 84-86 (1988); Zheng et al., J. Immunol. 154: 5590-600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89: 11337-41 (1992).
[0350] Fusion proteins can be generated, for example, through gene shuffling, motif shuffling, exon shuffling, and / or codon shuffling (collectively).This is generated by the “DNA shuffling” technique. DNA shuffling can be used to alter the activity of antibodies as presented herein, including, for example, antibodies with higher affinity and lower dissociation rates (see, for example, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458; Patten et al., Curr. Opinion Biotechnol. 8: 724–33 (1997); Harayama, Trends Biotechnol. 16(2): 76–82 (1998); Hansson et al., J. Mol. Biol. 287: 265–76 (1999); and Lorenzo and Blasco, Biotechniques 24(2): 308–13 (1998)). Antibodies or encoded antibodies can be altered by random mutagenesis prior to recombination using error-prone PCR, random nucleotide insertion, or other methods. Polynucleotides encoding the antibodies provided herein can be recombined with one or more components, motifs, segments, parts, domains, fragments, etc., of one or more heterologous molecules.
[0351] In some embodiments, the antibody provided herein is conjugated with a second antibody to form an antibody heteroconjugate.
[0352] In various embodiments, the antibody is genetically fused with a drug. Gene fusion can be accomplished by placing a linker (e.g., a polypeptide) between the antibody and the drug. The linker can be a flexible linker.
[0353] In various embodiments, the antibody is genetically conjugated with a therapeutic molecule, wherein a hinge region links the antibody to the therapeutic molecule.
[0354] Methods for preparing the various fusion proteins provided herein are also provided herein. The various methods described in Section 5.4 can also be used to prepare the fusion proteins provided herein.
[0355] In a particular embodiment, the fusion proteins provided herein are recombinantly expressed. Recombinant expression of the fusion proteins provided herein may require the construction of an expression vector containing a polynucleotide encoding the protein or a fragment thereof. Once a polynucleotide encoding the protein or a fragment thereof provided herein has been obtained, a vector for producing the molecule can be generated using recombinant DNA techniques well known in the art. Therefore, methods for preparing proteins by expressing polynucleotides containing encoding nucleotide sequences are described herein. Methods well known to those skilled in the art can be used to construct expression vectors containing encoding sequences and appropriate transcription and translation control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo gene recombination. Also provided are reproducible vectors containing nucleotide sequences operatively linked to a promoter, which encode fusion proteins or fragments thereof or CDRs provided herein.
[0356] Expression vectors can be transferred to host cells using conventional techniques, and then the transfected cells can be cultured using conventional techniques to produce the fusion proteins provided herein. Therefore, host cells containing a polynucleotide operatively linked to a heterologous promoter encoding the fusion proteins or fragments thereof provided herein are also provided herein.
[0357] A variety of host expression vector systems can be used to express the fusion proteins provided herein. Such host expression systems represent media by which the coding sequence of interest can be generated and subsequently purified, and also represent cells that can express the fusion proteins provided herein in situ when transformed or transfected with the appropriate nucleotide coding sequence. These include, but are not limited to, microorganisms, such as bacteria transformed with recombinant bacterial phage DNA, plasmid DNA, or coliform DNA containing the coding sequence (e.g., *Escherichia coli* and *Bacillus subtilis*). Yeast transformed with a recombinant yeast expression vector containing a coding sequence (e.g., *Saccharomyces*, *Pichia*); insect cell systems infected with a recombinant viral expression vector containing a coding sequence (e.g., baculovirus); plant cell systems infected with a recombinant viral expression vector (e.g., cauliflower mosaic virus, CaMV, tobacco mosaic virus, TMV) or transformed with a recombinant plasmid expression vector containing a coding sequence (e.g., Ti plasmid); or mammalian cell systems with a recombinant expression construct (e.g., COS, CHO, BHK, 293, NSO, and 3T3 cells) containing a promoter derived from a mammalian cell genome (e.g., metallothionein promoter) or a promoter derived from a mammalian virus (e.g., adenovirus late promoter; vaccinia virus 7.5K promoter). Bacterial cells (such as *Escherichia coli*) or eukaryotic cells (especially eukaryotic cells used for expressing complete recombinant antibody molecules) can be used to express recombinant fusion proteins. For example, with vectors (such as major intermediate from human cytomegalovirus). Mammalian cells (such as Chinese hamster ovary cells (CHO)) that combine early gene promoter elements are efficient expression systems for antibodies or variants thereof. In specific embodiments, the expression of the nucleotide sequence encoding the fusion protein provided herein is regulated by a constitutive promoter, an inducible promoter, or a tissue-specific promoter.
[0358] In bacterial systems, a number of expression vectors can be advantageously selected depending on the intended use of the fusion protein being expressed. For example, when producing large quantities of such a fusion protein, a vector that directs the expression of a high level of easily purified fusion protein product may be desired in order to produce a pharmaceutical composition of the fusion protein. Such vectors include, but are not limited to, E. coli expression vectors.Examples of fusion proteins include pUR278 (Ruther et al., EMBO 12: 1791 (1983)), where the coding sequence can be ligated separately into a vector within the reading frame along with the lacZ coding region to produce a fusion protein; pIN vectors (Inouye and Inouye, Nucleic Acids Res. 13: 3101–3109 (1985); Van Heeke and Schuster, J. Biol. Chem. 24: 5503–5509 (1989)); and so on. pGEX vectors can also be used to express exogenous polypeptides as fusion proteins with glutathione 5-transferase (GST). Generally, these fusion proteins are soluble and can be readily purified from lysed cells by adsorption and binding to matrix glutathione agarose beads, followed by elution in the presence of free glutathione. The pGEX vector is designed to include a thrombin or factor Xa protease cleavage site, allowing the cloned target gene product to be released from the GST portion.
[0359] In mammalian host cells, many virus-based expression systems can be used. When adenovirus is used as an expression vector, the coding sequence of interest can be ligated to an adenoviral transcription / translation control complex (e.g., a late promoter and a triple leader sequence). The chimeric gene can then be inserted into the adenoviral genome via in vitro or in vivo recombination. Insertion into non-essential regions of the viral genome (e.g., regions E1 or E3) will produce a recombinant virus that is viable and capable of expressing the fusion protein in an infected host (e.g., see Logan and Shenk, Proc. Natl. Acad. Sci. USA 8 1: 355-359 (1984)). Specific start signals may also be necessary for the efficient translation of the inserted coding sequence. These signals include the ATG start codon and adjacent sequences. Furthermore, the start codon must be in phase with the reading frame of the desired coding sequence to ensure the translation of the entire insert. These exogenous translation control signals and start codons can be from a variety of sources, both natural and synthetic. Expression efficiency can be enhanced by including appropriate transcriptional enhancer elements, transcription terminators, etc. (see, for example, Bittner et al., Methods in Enzymol. 153: 51–544 (1987)).
[0360] Furthermore, host cell lines can be selected to regulate the expression of the inserted sequence or to modify and process the gene product in a desired specific manner. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products can be important for protein function. Different host cells possess characteristic and specific mechanisms for post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be selected to ensure proper modification and processing of the expressed exogenous protein.Processing. For this purpose, eukaryotic host cells with appropriate cellular mechanisms for processing primary transcripts, glycosylation, and phosphorylation of gene products can be used. Such mammalian host cells include, but are not limited to, CHO cells, VERY cells, BHK cells, HeLa cells, COS cells, MDCK cells, 293 cells, 3T3 cells, W138 cells, BT483 cells, Hs578T cells, HTB2 cells, BT2O and T47D cells, NSO cells (a mouse myeloma cell line that does not endogenously produce any immunoglobulin chains), CRL7O3O cells, and HsS78Bst cells.
[0361] For long-term, high-yield production of recombinant proteins, stable expression can be utilized. For example, cell lines that stably express fusion proteins can be engineered. Instead of using expression vectors containing viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoters, enhancers, sequences, transcription terminators, polyadenylation sites, etc.) and selection markers. After introducing the exogenous DNA, engineered cells can be grown in enrichment medium for 1 to 2 days and then transferred to selection medium. The selection markers in the recombinant plasmid confer resistance to selection and allow cells to stably integrate the plasmid into their chromosomes and grow to form focal points, which can then be cloned and amplified into cell lines. This method can be advantageously used to engineer cell lines expressing fusion proteins. Such engineered cell lines can be particularly used for screening and evaluating compositions that interact directly or indirectly with binding molecules.
[0362] Many selection systems can be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11: 223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska and Szybalski, Proc. Natl. Acad. Sci. USA 48: 202 (1992)) and adenine phosphoribosyltransferase (Lowy et al., Cell 22: 8-17 (1980)) genes, which can be used for tk cells, hgprt cells or aprt cells, respectively. Furthermore, antimetabolite resistance can serve as a basis for selection on the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77: 357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); and gpt, which confers resistance to mycophenolic acid (Mulligan and Berg, Proc. Natl. Acad. Sci. USA 78:2072).(1981)); neo, which confers resistance to aminoglycoside G-418 (Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32: 573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62: 191-217 (1993); May, TIB TECH 11 (5):155-215 (1993)); and hygro, which confers resistance to hygromycin (Santerre et al., Gene 30: 147 (1984)). The desired recombinant clone can be selected using methods commonly known in the field of recombinant DNA technology, and such methods are described, for example, in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds.), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et al., J. Mol. Biol. 150:1 (1981), which are incorporated herein by reference in their entirety.
[0363] The expression level of the fusion protein can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol. 3 (Academic Press, New York, 1987)). When the marker in the vector system expressing the fusion protein is amplifiable, an increase in the level of inhibitor present in the host cell culture will increase the copy number of the marker gene. Since the amplified region is associated with the fusion protein gene,Therefore, the production of fusion proteins will also increase (Crouse et al., Mol. Cell. Biol. 3: 257 (1983)).
[0364] Host cells can be co-transfected with a variety of expression vectors provided herein. The vectors may contain the same selection markers that enable the corresponding encoded polypeptides to be expressed equally. Alternatively, a single vector encoding and capable of expressing multiple polypeptides may be used. The coding sequence may comprise cDNA or genomic DNA.
[0365] Once the fusion protein provided herein has been generated by recombinant expression, it can be purified by any method known in the art for purifying polypeptides (e.g., immunoglobulin molecules), such as by chromatography (e.g., ion exchange chromatography, affinity chromatography (particularly by affinity for specific antigens after protein A), fractionation column chromatography, and κ-selective affinity chromatography), centrifugation, differential solubility, or by any other standard technique for purifying proteins. Furthermore, the fusion protein molecules provided herein may be fused with heterologous polypeptide sequences described herein or originally known in the art to facilitate purification.
[0366] Immunoconjugates
[0367] In some embodiments, this disclosure also provides immunoconjugates comprising any of the anti-ACVR2B antibodies described herein conjugated to one or more cytotoxic agents, such as chemotherapeutic agents or drugs, growth inhibitors, toxins (e.g., protein toxins, bacterial, fungal, plant or animal-derived enzyme-active toxins, or fragments thereof) or radioisotopes.
[0368] In some embodiments, the immunoconjugate is an antibody-drug conjugate (ADC), wherein the antibody is conjugated to one or more drugs, including but not limited to maytansinoid (see U.S. Patent Nos. 5,208,020, 5,416,064 and European Patent EP 0 425 235 B1); auristatin, such as the monomethyl auristatin drug portions DE and DF (MMAE and MMAF) (see U.S. Patent Nos. 5,635,483, 5,780,588 and 7,498,298); dolastatin; chachiin or derivatives thereof (see U.S. Patent Nos. 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710). Nos. 5,773,001 and 5,877,296; Hinman et al., Cancer Res. 53: 3336–3342 (1993); and Lode et al., CancerRes. 58: 2925–2928 (1998)); anthracyclines, such as doxorubicin or doxorubicin (see Kratz et al., Current Med. Chem. 13: 477–523 (2006); Jeffrey et al., Bioorganic & Med. Chem. Letters 16: 358–362 (2006); Torgov et al., Bioconj. Chem. 16: 717–721 (2005); Nagy et al., Proc. Natl. Acad. Sci. USA 97: 829–834 (2000); Dubowchik et al., Bioorg. & Med. Chem. Letters 12: 1529–1532 (2002); King et al., J. Med. Chem. 45: 4336– 4343 (2002); and U.S. Patent No. 6,630,579); methotrexate; vindesine; taxanes, such as docetaxel, paclitaxel, larotaxel, tesetaxel, and ortataxel; trichothecene; and CC1065.
[0369] In some embodiments, the immunoconjugate comprises an antibody as described herein, which is conjugated to an enzymatically active toxin or a fragment thereof, including but not limited to diphtheria toxin A chain, a non-binding active fragment of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, absinthecin A chain, sarcin, arcinia fordii protein, dianthin protein, pokeweed protein (PAPI, PAPII and PAP-S), momordica charantia inhibitor, jatropha toxin, croton toxin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenolmycin, enoxamycin and trichothecene.
[0370] In some embodiments, the immunoconjugate comprises an antibody as described herein, which is conjugated with a radioactive atom to form a radioconjugate. A variety of radioisotopes can be used to generate the radioconjugate. Examples include radioisotopes of At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212, and Lu. When the radioconjugate is used to detect…At the same time, it may contain radioactive atoms for scintillation studies, such as tc99m or I123, or spin labels for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI), such as iodine-123, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese, or iron. Specification 59 / 108 pages 67 CN 121909215 A
[0371] A variety of bifunctional protein conjugates can be used to prepare conjugates of antibodies and cytotoxic agents, such as N-succinimide-3-(2-pyridyl dithio)propionate (SPDP), succinimide-4-(N-maleimide methyl)cyclohexane-1-carboxylic acid ester (SMCC), iminothiacyclopentane (IT), bifunctional derivatives of imine esters (such as dimethyl diimide adipate HCl), active esters (such as disuccinimide octanoate), aldehydes (such as glutaraldehyde), diazid compounds (such as bis(p-azidobenzoyl)hexamethylenediamine), and dinitrogen salt derivatives (such as bis- (p-diazonium benzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and difluorinated compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, ricin immunotoxin can be prepared as described in Vitetta et al., Science 238: 1098 (1987). Carbon-14 labeled 1-isothiocyanobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for the conjugation of radioactive nucleotides to antibodies. See WO94 / 11026.
[0372] The linker can be a “cuttable linker” that facilitates the release of the conjugated agent into the cell, but non-cuttable linkers are also covered herein. The linkers used in the conjugates disclosed herein include, but are not limited to, acid-labile linkers (e.g., hydrazone linkers), disulfide-containing linkers, peptidase-sensitive linkers (e.g., peptide linkers containing amino acids such as valine and / or citrulline (e.g., citrulline-valine or phenylalanine-lysine), light-labile linkers, dimethyl linkers, thioether linkers, or hydrophilic linkers designed to evade multidrug transporter-mediated resistance.
[0373] The immunoconjugates or ADCs described herein encompass, but are not limited to, such conjugates prepared with crosslinking agent reagents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfonyl-EMCS, sulfonyl-GMBS, sulfonyl-KMUS, sulfonyl-MBS, sulfonyl-SIAB, sulfonyl-SMCC, and sulfonyl-SMPB, as well as SVSB (succinimide-(4-vinyl sulfone)benzoate), which are commercially available (e.g., from Pierce).(Available commercially from Biotechnology, Inc., Rockford, IL., USA).
[0374] In other embodiments, the antibodies provided herein are conjugated or recombined with, for example, diagnostic molecules. Such diagnosis and detection can be accomplished, for example, by conjugating antibodies to detectable substances, including but not limited to various enzymes such as, but not limited to, horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; prosthetic groups such as, but not limited to, streptavidin / biotin or avidin / biotin; fluorescent materials such as, but not limited to, umbelliferone, luciferin, luciferin isothiocyanate, rhodamine, dichlorotriazineaminoluciferin, dansyl chloride, or phycoerythrin; luminescent materials such as, but not limited to, luminol; bioluminescent materials such as, but not limited to, luciferase, luciferin, or jellyfish luminescent protein; and chemiluminescent materials such as radioisotopes emitting 225Ac γ, radioisotopes emitting Auger effects, radioisotopes emitting β rays, radioisotopes emitting α rays, or radioisotopes emitting positrons.
[0375] 5.3. Polynucleotides
[0376] In some embodiments, this disclosure provides polynucleotides encoding antibodies of the present invention that bind to ACVR2B and fusion proteins comprising the antibodies described herein that bind to ACVR2B. The polynucleotides of this disclosure may be in the form of RNA or DNA. DNA includes cDNA, genomic DNA, and synthetic DNA; and may be double-stranded or single-stranded, and if single-stranded, may be a coding strand or a non-coding (antisense) strand. In some embodiments, the polynucleotide is in the form of cDNA. In some embodiments, the polynucleotide is a synthetic polynucleotide.
[0377] This disclosure also relates to variants of the polynucleotides described herein, wherein the variants encode fragments, analogs, and / or derivatives of, for example, the antibodies of this disclosure that bind to ACVR2B. In some embodiments, this disclosure provides a polynucleotide comprising a polynucleotide having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, and in some embodiments at least about 96%, 97%, 98%, or 99% identical nucleotide sequences to the polynucleotide encoding the antibody binding ACVR2B of this disclosure. As used herein, the phrase “polynucleotide having a nucleotide sequence that is at least, for example, 95% identical to a reference nucleotide sequence” is...
Claims
1. An antibody or antigen-binding fragment thereof that binds to ACVR2B, wherein the antibody or antigen-binding fragment has a greater affinity for ACVR2B than for ACVR2A, and wherein optionally the antibody or antigen-binding fragment comprises: (i) HCDR1, HCDR2 and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 1 and LCDR1, LCDR2 and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO:
2. (ii) HCDR1, HCDR2 and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 3 and LCDR1, LCDR2 and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO:
4. (iii) HCDR1, HCDR2 and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 5 and LCDR1, LCDR2 and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO:
6. (iv) HCDR1, HCDR2 and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 7 and LCDR1, LCDR2 and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO:
8. (v) HCDR1, HCDR2 and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 9 and LCDR1, LCDR2 and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO:
10. (vi) HCDR1, HCDR2 and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 11 and LCDR1, LCDR2 and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO:
12. (vii) HCDR1, HCDR2 and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 13 and LCDR1, LCDR2 and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO:
14. (viii) HCDR1, HCDR2 and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 15 and LCDR1, LCDR2 and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO:
16. (ix) HCDR1, HCDR2 and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 17 and LCDR1, LCDR2 and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO:
18. (x) HCDR1, HCDR2 and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 19 and LCDR1, LCDR2 and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO:
20. (xi) HCDR1, HCDR2 and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 21 and LCDR1, LCDR2 and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO:
22. (xii) HCDR1, HCDR2 and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 23 and LCDR1, LCDR2 and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO:
24. (xiii) HCDR1, HCDR2 and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 25 and LCDR1, LCDR2 and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO:
26. (xiv) HCDR1, HCDR2 and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 27 and LCDR1, LCDR2 and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO:
28. (xv) HCDR1, HCDR2 and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 29 and LCDR1, LCDR2 and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO:
30. (xvi) HCDR1, HCDR2, and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 31, and LCDR1, LCDR2, and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO: 32; or (xvii) HCDR1, HCDR2 and HCDR3 as shown in VH containing the amino acid sequence of SEQ ID NO: 33 and LCDR1, LCDR2 and LCDR3 as shown in VL containing the amino acid sequence of SEQ ID NO:
34.
2. The antibody or antigen-binding fragment according to claim 1, wherein... (i) The HCDR1 contains the amino acid sequence of SEQ ID NO: 35, the HCDR2 contains the amino acid sequence of SEQ ID NO: 36, the HCDR3 contains the amino acid sequence of SEQ ID NO: 37, the LCDR1 contains the amino acid sequence of SEQ ID NO: 38, the LCDR2 contains the amino acid sequence of SEQ ID NO: 39, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 40; (ii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 41, the HCDR2 contains the amino acid sequence of SEQ ID NO: 42, the HCDR3 contains the amino acid sequence of SEQ ID NO: 43, the LCDR1 contains the amino acid sequence of SEQ ID NO: 44, the LCDR2 contains the amino acid sequence of SEQ ID NO: 45, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 46; (iii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 47, the HCDR2 contains the amino acid sequence of SEQ ID NO: 48, the HCDR3 contains the amino acid sequence of SEQ ID NO: 49, the LCDR1 contains the amino acid sequence of SEQ ID NO: 50, the LCDR2 contains the amino acid sequence of SEQ ID NO: 51, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 52; (iv) The HCDR1 contains the amino acid sequence of SEQ ID NO: 53, the HCDR2 contains the amino acid sequence of SEQ ID NO: 54, the HCDR3 contains the amino acid sequence of SEQ ID NO: 55, the LCDR1 contains the amino acid sequence of SEQ ID NO: 56, the LCDR2 contains the amino acid sequence of SEQ ID NO: 57, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 58; (v) The HCDR1 contains the amino acid sequence of SEQ ID NO: 59, the HCDR2 contains the amino acid sequence of SEQ ID NO: 60, the HCDR3 contains the amino acid sequence of SEQ ID NO: 61, the LCDR1 contains the amino acid sequence of SEQ ID NO: 62, the LCDR2 contains the amino acid sequence of SEQ ID NO: 63, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 64; (vi) The HCDR1 contains the amino acid sequence of SEQ ID NO: 65, the HCDR2 contains the amino acid sequence of SEQ ID NO: 66, the HCDR3 contains the amino acid sequence of SEQ ID NO: 67, the LCDR1 contains the amino acid sequence of SEQ ID NO: 68, the LCDR2 contains the amino acid sequence of SEQ ID NO: 69, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 70; (vii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 71, the HCDR2 contains the amino acid sequence of SEQ ID NO: 72, the HCDR3 contains the amino acid sequence of SEQ ID NO: 73, the LCDR1 contains the amino acid sequence of SEQ ID NO: 74, the LCDR2 contains the amino acid sequence of SEQ ID NO: 75, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 76; (viii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 77, the HCDR2 contains the amino acid sequence of SEQ ID NO: 78, the HCDR3 contains the amino acid sequence of SEQ ID NO: 79, the LCDR1 contains the amino acid sequence of SEQ ID NO: 80, the LCDR2 contains the amino acid sequence of SEQ ID NO: 81, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 82; (ix) The HCDR1 contains the amino acid sequence of SEQ ID NO: 83, the HCDR2 contains the amino acid sequence of SEQ ID NO: 84, the HCDR3 contains the amino acid sequence of SEQ ID NO: 85, the LCDR1 contains the amino acid sequence of SEQ ID NO: 86, the LCDR2 contains the amino acid sequence of SEQ ID NO: 87, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 88; (x) The HCDR1 contains the amino acid sequence of SEQ ID NO: 89, the HCDR2 contains the amino acid sequence of SEQ ID NO: 90, the HCDR3 contains the amino acid sequence of SEQ ID NO: 91, the LCDR1 contains the amino acid sequence of SEQ ID NO: 92, the LCDR2 contains the amino acid sequence of SEQ ID NO: 93, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 94; (xi) The HCDR1 contains the amino acid sequence of SEQ ID NO: 95, the HCDR2 contains the amino acid sequence of SEQ ID NO: 96, the HCDR3 contains the amino acid sequence of SEQ ID NO: 97, the LCDR1 contains the amino acid sequence of SEQ ID NO: 98, the LCDR2 contains the amino acid sequence of SEQ ID NO: 99, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 100; (xii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 101, the HCDR2 contains the amino acid sequence of SEQ ID NO: 102, the HCDR3 contains the amino acid sequence of SEQ ID NO: 103, the LCDR1 contains the amino acid sequence of SEQ ID NO: 104, the LCDR2 contains the amino acid sequence of SEQ ID NO: 105, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 106; (xiii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 107, the HCDR2 contains the amino acid sequence of SEQ ID NO: 108, the HCDR3 contains the amino acid sequence of SEQ ID NO: 109, the LCDR1 contains the amino acid sequence of SEQ ID NO: 110, the LCDR2 contains the amino acid sequence of SEQ ID NO: 111, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 112; (xiv) The HCDR1 contains the amino acid sequence of SEQ ID NO: 113, the HCDR2 contains the amino acid sequence of SEQ ID NO: 114, the HCDR3 contains the amino acid sequence of SEQ ID NO: 115, the LCDR1 contains the amino acid sequence of SEQ ID NO: 116, the LCDR2 contains the amino acid sequence of SEQ ID NO: 117, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 118; (xv) The HCDR1 contains the amino acid sequence of SEQ ID NO: 119, the HCDR2 contains the amino acid sequence of SEQ ID NO: 120, the HCDR3 contains the amino acid sequence of SEQ ID NO: 121, the LCDR1 contains the amino acid sequence of SEQ ID NO: 122, the LCDR2 contains the amino acid sequence of SEQ ID NO: 123, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 124; (xvi) The HCDR1 contains the amino acid sequence of SEQ ID NO: 125, the HCDR2 contains the amino acid sequence of SEQ ID NO: 126, the HCDR3 contains the amino acid sequence of SEQ ID NO: 127, the LCDR1 contains the amino acid sequence of SEQ ID NO: 128, the LCDR2 contains the amino acid sequence of SEQ ID NO: 129, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 130; or (xvii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 131, the HCDR2 contains the amino acid sequence of SEQ ID NO: 132, the HCDR3 contains the amino acid sequence of SEQ ID NO: 133, the LCDR1 contains the amino acid sequence of SEQ ID NO: 134, the LCDR2 contains the amino acid sequence of SEQ ID NO: 135, and the LCDR3 contains the amino acid sequence of SEQ ID NO:
136.
3. The antibody or antigen-binding fragment according to claim 1, wherein... (i) The HCDR1 contains the amino acid sequence of SEQ ID NO: 137, the HCDR2 contains the amino acid sequence of SEQ ID NO: 138, the HCDR3 contains the amino acid sequence of SEQ ID NO: 139, the LCDR1 contains the amino acid sequence of SEQ ID NO: 140, the LCDR2 contains the amino acid sequence of SEQ ID NO: 141, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 142; (ii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 143, the HCDR2 contains the amino acid sequence of SEQ ID NO: 144, the HCDR3 contains the amino acid sequence of SEQ ID NO: 145, the LCDR1 contains the amino acid sequence of SEQ ID NO: 146, the LCDR2 contains the amino acid sequence of SEQ ID NO: 147, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 148; (iii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 149, the HCDR2 contains the amino acid sequence of SEQ ID NO: 150, the HCDR3 contains the amino acid sequence of SEQ ID NO: 151, the LCDR1 contains the amino acid sequence of SEQ ID NO: 152, the LCDR2 contains the amino acid sequence of SEQ ID NO: 153, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 154; (iv) The HCDR1 contains the amino acid sequence of SEQ ID NO: 155, the HCDR2 contains the amino acid sequence of SEQ ID NO: 156, the HCDR3 contains the amino acid sequence of SEQ ID NO: 157, the LCDR1 contains the amino acid sequence of SEQ ID NO: 158, the LCDR2 contains the amino acid sequence of SEQ ID NO: 159, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 160; (v) The HCDR1 contains the amino acid sequence of SEQ ID NO: 161, the HCDR2 contains the amino acid sequence of SEQ ID NO: 162, the HCDR3 contains the amino acid sequence of SEQ ID NO: 163, the LCDR1 contains the amino acid sequence of SEQ ID NO: 164, the LCDR2 contains the amino acid sequence of SEQ ID NO: 165, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 166; (vi) The HCDR1 contains the amino acid sequence of SEQ ID NO: 167, the HCDR2 contains the amino acid sequence of SEQ ID NO: 168, the HCDR3 contains the amino acid sequence of SEQ ID NO: 169, the LCDR1 contains the amino acid sequence of SEQ ID NO: 170, the LCDR2 contains the amino acid sequence of SEQ ID NO: 171, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 172; (vii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 173, the HCDR2 contains the amino acid sequence of SEQ ID NO: 174, the HCDR3 contains the amino acid sequence of SEQ ID NO: 175, the LCDR1 contains the amino acid sequence of SEQ ID NO: 176, the LCDR2 contains the amino acid sequence of SEQ ID NO: 177, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 178; (viii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 179, the HCDR2 contains the amino acid sequence of SEQ ID NO: 180, the HCDR3 contains the amino acid sequence of SEQ ID NO: 181, the LCDR1 contains the amino acid sequence of SEQ ID NO: 182, the LCDR2 contains the amino acid sequence of SEQ ID NO: 183, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 184; (ix) The HCDR1 contains the amino acid sequence of SEQ ID NO: 185, the HCDR2 contains the amino acid sequence of SEQ ID NO: 186, the HCDR3 contains the amino acid sequence of SEQ ID NO: 187, the LCDR1 contains the amino acid sequence of SEQ ID NO: 188, the LCDR2 contains the amino acid sequence of SEQ ID NO: 189, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 190; (x) The HCDR1 contains the amino acid sequence of SEQ ID NO: 191, the HCDR2 contains the amino acid sequence of SEQ ID NO: 192, the HCDR3 contains the amino acid sequence of SEQ ID NO: 193, the LCDR1 contains the amino acid sequence of SEQ ID NO: 194, the LCDR2 contains the amino acid sequence of SEQ ID NO: 195, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 196; (xi) The HCDR1 contains the amino acid sequence of SEQ ID NO: 197, the HCDR2 contains the amino acid sequence of SEQ ID NO: 198, the HCDR3 contains the amino acid sequence of SEQ ID NO: 199, the LCDR1 contains the amino acid sequence of SEQ ID NO: 200, the LCDR2 contains the amino acid sequence of SEQ ID NO: 201, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 202; (xii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 203, the HCDR2 contains the amino acid sequence of SEQ ID NO: 204, the HCDR3 contains the amino acid sequence of SEQ ID NO: 205, the LCDR1 contains the amino acid sequence of SEQ ID NO: 206, the LCDR2 contains the amino acid sequence of SEQ ID NO: 207, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 208; (xiii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 209, the HCDR2 contains the amino acid sequence of SEQ ID NO: 210, the HCDR3 contains the amino acid sequence of SEQ ID NO: 211, the LCDR1 contains the amino acid sequence of SEQ ID NO: 212, the LCDR2 contains the amino acid sequence of SEQ ID NO: 213, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 214; (xiv) The HCDR1 contains the amino acid sequence of SEQ ID NO: 215, the HCDR2 contains the amino acid sequence of SEQ ID NO: 216, the HCDR3 contains the amino acid sequence of SEQ ID NO: 217, the LCDR1 contains the amino acid sequence of SEQ ID NO: 218, the LCDR2 contains the amino acid sequence of SEQ ID NO: 219, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 220; (xv) The HCDR1 contains the amino acid sequence of SEQ ID NO: 221, the HCDR2 contains the amino acid sequence of SEQ ID NO: 222, the HCDR3 contains the amino acid sequence of SEQ ID NO: 223, the LCDR1 contains the amino acid sequence of SEQ ID NO: 224, the LCDR2 contains the amino acid sequence of SEQ ID NO: 225, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 226; (xvi) The HCDR1 contains the amino acid sequence of SEQ ID NO: 227, the HCDR2 contains the amino acid sequence of SEQ ID NO: 228, the HCDR3 contains the amino acid sequence of SEQ ID NO: 229, the LCDR1 contains the amino acid sequence of SEQ ID NO: 230, the LCDR2 contains the amino acid sequence of SEQ ID NO: 231, and the LCDR3 contains the amino acid sequence of SEQ ID NO: 232; (xvii) The HCDR1 contains the amino acid sequence of SEQ ID NO: 233, the HCDR2 contains the amino acid sequence of SEQ ID NO: 234, the HCDR3 contains the amino acid sequence of SEQ ID NO: 235, the LCDR1 contains the amino acid sequence of SEQ ID NO: 236, the LCDR2 contains the amino acid sequence of SEQ ID NO: 237, and the LCDR3 contains the amino acid sequence of SEQ ID NO:
238.
4. The antibody or antigen-binding fragment according to any one of claims 1 to 3, wherein the antibody or antigen-binding fragment comprises: (i) VH containing the amino acid sequence of SEQ ID NO: 1, and VL containing the amino acid sequence of SEQ ID NO: 2; (ii) VH containing the amino acid sequence of SEQ ID NO: 3, and VL containing the amino acid sequence of SEQ ID NO: 4; (iii) VH containing the amino acid sequence of SEQ ID NO: 5, and VL containing the amino acid sequence of SEQ ID NO: 6; (iv) VH containing the amino acid sequence of SEQ ID NO: 7, and VL containing the amino acid sequence of SEQ ID NO: 8; (v) VH containing the amino acid sequence of SEQ ID NO: 9, and VL containing the amino acid sequence of SEQ ID NO: 10; (vi) VH containing the amino acid sequence of SEQ ID NO: 11, and VL containing the amino acid sequence of SEQ ID NO: 12; (vii) VH containing the amino acid sequence of SEQ ID NO: 13, and VL containing the amino acid sequence of SEQ ID NO: 14; (viii) VH containing the amino acid sequence of SEQ ID NO: 15, and VL containing the amino acid sequence of SEQ ID NO: 16; (ix) VH containing the amino acid sequence of SEQ ID NO: 17, and VL containing the amino acid sequence of SEQ ID NO: 18; (x) VH containing the amino acid sequence of SEQ ID NO: 19, and VL containing the amino acid sequence of SEQ ID NO: 20; (xi) VH containing the amino acid sequence of SEQ ID NO: 21, and VL containing the amino acid sequence of SEQ ID NO: 22; (xii) VH containing the amino acid sequence of SEQ ID NO: 23, and VL containing the amino acid sequence of SEQ ID NO: 24; (xiii) VH containing the amino acid sequence of SEQ ID NO: 25, and VL containing the amino acid sequence of SEQ ID NO: 26; (xiv) VH containing the amino acid sequence of SEQ ID NO: 27, and VL containing the amino acid sequence of SEQ ID NO: 28; (xv) VH containing the amino acid sequence of SEQ ID NO: 29, and VL containing the amino acid sequence of SEQ ID NO: 30; (xvi) VH containing the amino acid sequence of SEQ ID NO: 31, and VL containing the amino acid sequence of SEQ ID NO: 32; or (xvii) VH containing the amino acid sequence of SEQ ID NO: 33, and VL containing the amino acid sequence of SEQ ID NO:
34.
5. The antibody or antigen-binding fragment according to any one of claims 1 to 4, wherein the antibody or antigen-binding fragment is IgG.
6. The antibody or antigen-binding fragment according to any one of claims 1 to 5, wherein the antibody or antigen-binding fragment is a human antibody.
7. The antibody or antigen-binding fragment according to any one of claims 1 to 6, wherein the antibody or antigen-binding fragment contains one or more mutations in the Fc region to reduce or eliminate antibody-dependent cell-mediated cytotoxicity (ADCC) and / or complement-dependent cytotoxicity (CDC) effects.
8. The antibody or antigen-binding fragment according to any one of claims 1 to 7, wherein the antibody or antigen-binding fragment comprises: (1) One or both mutations in L239A and L240A; or (2) One or both of L234A and L235A mutations.
9. The antibody or antigen-binding fragment according to any one of claims 1 to 8, wherein the antibody or antigen-binding fragment is genetically fused or chemically conjugated with the pharmaceutical agent.
10. A nucleic acid molecule encoding an antibody or antigen-binding fragment according to any one of claims 1 to 9.
11. A vector comprising the nucleic acid molecule according to claim 10.
12. A host cell, said host cell being transformed with the vector according to claim 11.
13. A composition comprising a therapeutically effective amount of an antibody or antigen-binding fragment according to any one of claims 1 to 9, a nucleic acid molecule according to claim 10, or a carrier according to claim 11, and a pharmaceutically acceptable excipient.
14. A method of treating a disease or ailment of a subject, the method comprising administering to the subject the composition according to claim 13.
15. The method of claim 14, wherein the disease or symptom is associated with ACVR2B.
16. The method of claim 14, wherein the disease or symptom is associated with the ACVR2B ligand.
17. The method of claim 14, wherein the disease or condition is associated with activator A, activator B, activator AB, GDF8, or GDF11.
18. The method according to any one of claims 14 to 17, wherein the disease or condition is a musculoskeletal disease or condition.
19. The method of claim 18, wherein the musculoskeletal disease or condition is selected from the group consisting of: muscle atrophy, spinal muscular atrophy, and cancer cachexia.
20. The method according to any one of claims 14 to 17, wherein the disease or condition is an age-related symptom selected from the group consisting of: sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, emphysema, osteoporosis, osteoarthritis, immunodeficiency, hypertension, dementia, Huntington's disease, Alzheimer's disease, cataracts, age-related macular degeneration, prostate cancer, stroke, shortened life expectancy, frailty, memory loss, wrinkles, impaired renal function, and age-related hearing loss.
21. The method according to any one of claims 14 to 17, wherein the disease or condition is a metabolic condition selected from the group consisting of: type II diabetes, metabolic syndrome, hyperglycemia, NASH, and obesity.
22. The method according to any one of claims 14 to 17, wherein the disease or condition is selected from the group consisting of: acute and / or chronic kidney disease or renal failure, liver fibrosis or cirrhosis, pulmonary fibrosis, pulmonary hypertension (PH), pulmonary arterial hypertension (PAH), renal fibrosis, Parkinson's disease, ALS, brain atrophy, dementia cachexia, and cancers that induce bone loss.
23. The method according to any one of claims 14 to 17, wherein the disease or symptom is a cancer selected from the group consisting of: rhabdomyosarcoma, ovarian cancer, breast cancer, esophageal cancer, head and neck cancer, lung cancer, melanoma, multiple myeloma, colorectal cancer, hepatocellular carcinoma, pancreatic cancer, endometrial cancer, and gastrointestinal cancer.
24. The method according to any one of claims 14 to 17, wherein the disease or condition is anemia.
25. The method according to any one of claims 14 to 17, wherein the method further comprises administering a second agent to the subject.
26. The method of claim 25, wherein the second agent is an ACVR2A antagonist, wherein optionally the ACVR2A antagonist is an ACVR2A antibody.
27. A method for inhibiting or antagonizing ACVR2B activity in cells, the method comprising contacting the cells with the composition according to claim 11.
28. A method for inhibiting or blocking the binding of an ACVR2B ligand to ACVR2B expressed on a cell, the method comprising contacting the cell with a composition according to claim 11, wherein optionally the ACVR2B ligand is activin A, activin B, activin AB, GDF8, or GDF11.
29. A method for inhibiting or blocking signal transduction induced by an ACVR2B ligand in cells, the method comprising contacting the cells with a composition according to claim 11, wherein optionally the ACVR2B ligand is activin A, activin B, activin AB, GDF8, or GDF11.
